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ABSTRACT 
 
Age-related skeletal muscle wasting, or sarcopenia, negatively impacts physical function and 
health. The mechanisms relating to sarcopenia are complex and unclear, but are thought to be 
underpinned by a blunted response of skeletal muscle to anabolic stimuli. Accordingly, Chapter 
2 explored how dose, timing, distribution and source of dietary protein intake differed between 
healthy young (23.6 ± 4.2 yrs) and community dwelling older (77.2 ± 6.8 yrs) individuals. We 
showed that, whilst the recommended dietary allowance for protein of 0.8 gkg-1day-1 was met 
by most individuals, total protein intake was lower and skewed across meals in old. The 
observation of suboptimal protein intakes in older individuals has important implications for 
skeletal muscle maintenance. Therefore, in Chapter 3 we investigated the muscle anabolic 
response in young lean (25.5 ± 4 yrs), old lean (71.7 ± 6 yrs) and obese old (69.1 ± 2 yrs) 
individuals to a suboptimal protein dose of 15 g. Whilst young lean and, to a lesser extent, old 
lean significantly increased postprandial myofibrillar protein synthesis (MyoPS), this response 
was blunted in obese old. Furthermore, MyoPS correlated positively with step count and 
negatively with leg fat mass in old. Based on the observed age-related decrease in MyoPS, 
Chapter 4 assessed the purported anabolic properties of the nutraceutical phosphatidic acid (PA) 
to increase MyoPS in healthy older individuals. Upon acute PA consumption, MyoPS was 
unexpectedly blunted in the late phase of resistance exercise recovery, and was accompanied 
by impaired intramuscular anabolic signaling. In conclusion, this thesis enhanced our 
understanding on the mechanisms underpinning sarcopenia by investigating protein intake and 
pattern in young and older individuals, demonstrating the detrimental effects of obesity and low 
physical activity on the muscle anabolic response to a suboptimal protein feed, and establishing 
the muscle anabolic effects upon acute PA consumption.  
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“Age has no reality except in the physical world. The essence of a human being is 
resistant to the passage of time. Our inner lives are eternal, which is to say that our 
spirits remain as youthful and vigorous as when we were in full bloom.” 
 
Gabriel García Márquez, novelist (1927 – 2014) 
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CHAPTER 1 
GENERAL INTRODUCTION 
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1.1 Musculoskeletal Ageing 
Skeletal muscle mass accounts for approximately 40% of total body mass and is indispensable 
for gait, posture, metabolic health and independent living (65, 183, 206). Furthermore, skeletal 
muscle mass is the primary storage site for amino acids (AA), which can be released and used 
as a fuel or substrate for other tissues (142). With a constant turnover rate of 1-2% per day, 
skeletal muscle mass is continuously built and broken down (40). This tightly regulated and 
complex process results in an overall skeletal muscle mass accretion throughout adolescence to 
peak in early adulthood, and decline from the 4th-5th decade of life onwards at an annual rate of 
~0.6% (111). The decrease in skeletal muscle mass is associated with myriad negative health 
outcomes, ranging from an increased susceptibility to fractures (101), insulin resistance (94), 
lower resting and basal metabolic rate (239), cardiovascular and metabolic disease (172) and, 
in severe cases, death (126). However, it is important to recognize that the gradual decline in 
skeletal muscle mass over time is interspersed with various acute health-related events such as 
immobilization and bed rest (during illness or hospitalization) (58, 85, 151). These acute events 
are thought to punctuate the ‘normal’ decline in muscle mass, accelerating the progression 
towards functional impairment and disability, beyond which, individuals are not able to perform 
activities of daily living without assistance (Figure 1.1) (24). 
Decreases in skeletal muscle mass are often accompanied by reductions in muscle strength. 
Disturbingly, age-related decline in strength occurs at significantly greater rate than muscle 
mass, with annual reductions commonly reported to range from 3-4% in males and 2.5-3% in 
females (47, 133). This disproportionate loss of muscle strength to muscle mass could be 
indicative of a loss of muscle quality. Therefore, maintaining or increasing skeletal muscle mass 
is key to prevent age-related declines in muscle strength (65, 89, 135) and preserve physical 
function. To date, we are yet to fully understand the mechanisms underpinning age-related 
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musculoskeletal deterioration. Gaining insight into the nature of these mechanisms is of 
paramount importance to develop new therapeutic interventions to prevent or even treat 
sarcopenia.  
 
 
Figure 1.1: Scenarios of age-associated decline in skeletal muscle mass. Each respective dotted 
grey line indicates the hypothetical chronological decline in muscle mass before or after an 
illness/injury if no other major disuse related events were to happen. The red line is the decline 
in muscle mass observed with periods of disuse. The solid black line represents the actual rate 
of decline. Redrawn from Witard et al. (2016) (227). 
 
1.1.1 The Ageing Demographic 
Worldwide, both more developed and least developed nations are growing older. Life-
expectancy in the U.K. at birth rose from 73.4 y in 1991 to 78.9 y in 2012. Individuals who 
were aged 65 in the year 2000 were likely to live another 12 y, whilst individuals aged 65 in 
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the year 2012 were expected to live for 16 more years (149). This increased longevity is mainly 
attributable to better health care and increased living standards (150), which in combination 
with the post-World War II ‘baby-boom’ has contributed to an ageing population (168). In the 
U.K., the number of people aged 75 y and over is expected to rise by nearly 90% by 2039, 
reaching 9.9 million individuals. Importantly, the fastest growing sub-population of older 
individuals are the centenarians, whose rise is projected to increase six-fold from 14,000 in the 
year 2014 to 83,000 in 2039 (149). 
Increased lifespan might, at first, appear to be a positive outcome. However, ageing 
demographics only tell one side of the story, as the gap between lifespan (i.e. number of years 
lived) and health-span (i.e. number of years live in good health) is expanding, which is reflected 
by a disproportionate number of older individuals using health services (150, 181). Therefore, 
healthy ageing should be prioritized over an increase in lifespan per se. It is clear that our 
society requires clear strategies to deal with the ever-expanding ageing population through 
better and more affordable healthcare. Influential governing bodies, such as the World Health 
Organisation (WHO), will undoubtedly play a pivotal role in fulfilling these shortcomings.   
 
1.1.2 Sarcopenia: Definitions, Prevalence and Healthcare Burden 
The term sarcopenia, derived from the Greek words “sarco” and “penia” meaning “flesh” and 
“poverty”, respectively, was first introduced by Irwin Rosenberg in 1989 to describe the age-
related skeletal muscle mass loss (165). The complex and multifactorial aetiology of sarcopenia 
has led to numerous definitions. In 1998, the relative skeletal muscle mass index (RSMI) was 
introduced. The RMSI is obtained by dividing appendicular skeletal muscle mass (kg) by height 
(m2). An individual is classed as sarcopenic if the obtained RSMI is two or more standard 
deviations below that of either a young male or female reference group (14). In 2002, Janssen 
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and colleagues expanded this definition by using total, instead of appendicular skeletal muscle 
mass, and by differentiating between Class 1 (RSMI one to two standard deviations below that 
of a reference group) and Class 2 (RSMI over two standard deviations below that of a reference 
group) sarcopenia (110). However, it wasn’t until 2010 that the European Working Group on 
Sarcopenia in Older People (EWGSOP) developed a widely accepted and more practical 
clinical definition of sarcopenia based on set diagnostic criteria. The EWGSOP consensus 
describes sarcopenia as “a syndrome that is characterised by a progressive and generalised 
loss of skeletal muscle mass and strength with a risk of adverse outcomes such as physical 
disability, poor quality of life and death” (51). Based on muscle mass, muscle strength and 
physical performance, three stages of sarcopenia were identified by the EWGSOP. Stage 1, 
termed ‘pre-sarcopenia’ is characterized by a decreased muscle mass only. Stage 2, ‘sarcopenia’ 
is low muscle mass accompanied by either decreased muscle strength or performance. Stage 3, 
‘severe sarcopenia’ is defined by a decrease in all three parameters (51). Furthermore, the 
EWGSOP attempted to clarify discrepancies between various definitions of sarcopenia by 
providing clear guidelines on measurement methods to assess each of the above diagnostic 
criteria. Skeletal muscle mass is typically quantified through computed tomography (CT), dual 
energy x-ray absorptiometry (DXA) or bioelectrical impedance or other anthropometrics (i.e. 
mid-arm circumference or skin-fold assessment). However, the latter is prone to erratic 
outcomes and is not recommended. Muscle strength should be determined using handgrip 
strength, knee flexion and/or extension power/strength, or peak expiratory flow. Finally, 
physical performance assessment is recommended using the Short Physical Performance 
Battery (SPPB) (96). However, limiting methods to assess muscle mass to modern, expensive 
and often exclusive machinery, poses a challenge to assess these diagnostic criteria in 
epidemiologic studies (108). 
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The prevalence of sarcopenia is difficult to determine with any accuracy as projections are often 
somewhat conflicting. Based on the specific population studied and definition of sarcopenia 
used, many studies have likely under- or over-estimated the actual prevalence of this condition. 
Generally, it is believed that the prevalence of sarcopenia ranges from 5-24% in persons aged 
under 80 y and increases to >50% in those aged 80 y and over (12, 14). With advancing age, 
the sarcopenic prevalence is thought to be higher in females due to lower initial levels of muscle 
mass and energy intake (110). Interestingly, sarcopenia is not exclusively limited to what one 
might consider to be ‘older’ individuals; with investigators observing sarcopenia even in 
middle-aged (45-54 yrs) community dwelling individuals (43). Considering the myriad 
negative health outcomes associated with sarcopenia, this condition places a significant strain 
on healthcare services and costs. Research investigating the socio-economic burden of 
sarcopenia is scarce. However, a study conducted in the U.S. in 2004 estimated the sarcopenic 
cost at $18.5 billion per annum (1.5% of healthcare expenditure) (112). These data were based 
on individuals who expressed a loss of muscle mass, and is therefore most likely to be an 
underestimation. More recently, a study attributed a 58.5 % and 34 % increase in hospitalisation 
costs in those aged under 65 y and over 65 y, respectively, to sarcopenia (181).  
 
1.1.3 Sarcopenic-Obesity: The Confluence of Two Epidemics 
Besides sarcopenia, obesity is one the greatest public health challenges of the 21st century (188). 
The prevalence of obesity has tripled in several countries in the last few decades according to 
the WHO European Region, and has risen globally to over 600 million adults (224). Obesity 
itself is associated with a plethora of negative health outcomes, such as cancer (214), 
cardiovascular disease (106), diabetes (84) and is thought to contribute to the progression of 
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sarcopenia (118). On the contrary, a loss of muscle mass might lead to insulin resistance and 
facilitate fat mass gain (166, 182). Therefore, these two seemingly independent conditions are 
likely inter-related and, in co-existence, are referred to as ‘sarcopenic-obesity’ (150). The 
concurrence of obesity and sarcopenia seemingly act as a ‘double-edged sword’, in which the 
rate of muscle loss and fat mass gain are exacerbated, thus amplifying the risk of frailty, 
metabolic disease and mortality (219). Therefore, priority should be given to the development 
of affordable treatments to counteract the deleterious health consequences of these two 
combined conditions.  
 
Sarcopenic-obesity is most commonly defined as having sarcopenia (according to the 
EWGSOP guidelines) in combination with being obese (body mass index  30 kgm2) (42, 51). 
Besides the above-mentioned problems associated with characterising sarcopenia, obesity, 
although considered a disease, has not been clearly defined. Furthermore, complexities such as 
the age-associated ‘obesity paradox’, in which excess adiposity is thought to offer protective 
effects against skeletal muscle loss and other related health conditions, obstruct the pathway to 
a clear definition (45, 97). Nonetheless, obesity has most commonly been defined as having a 
body mass index (BMI) 30 kgm2 (42). Based on this definition, it is estimated that 20% of 
the older population suffers from sarcopenic-obesity (12). The pathology of sarcopenic-obesity 
is complex and yet to be fully elucidated, mainly due to i) a vast range of implicated molecules 
and pathways (145, 195), ii) an overlap in the causes that might be involved in both conditions 
(184) and iii) age-related comorbidities that could act as confounding factors (48). Taken 
together, the global rise in sarcopenia, obesity, and sarcopenic-obesity, alongside the associated 
negative socio-economic impact, requires research to fill the hiatuses in our knowledge and 
understanding of how these conditions modulate skeletal muscle mass, strength and quality. 
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Furthermore, the search for effective non-pharmacological preventative and treatment 
countermeasures is essential. 
 
1.2 Translational Regulation of Muscle Protein Turnover 
Since the introduction of stable isotope amino acid tracer techniques, insights into the 
mechanisms regulating skeletal muscle mass have substantially improved (117). The 
continuous and complex interplay between muscle protein synthesis (MPS) and muscle protein 
breakdown (MPB) determine whether protein accretion or loss presides (159). In the 
postabsorptive state MPB exceeds MPS resulting in an overall negative net protein balance 
(NPB) and, ultimately, net muscle loss (17). Food ingestion, particularly protein-based 
nutrition, and skeletal muscle contraction (through physical activity/exercise) have the potential 
to promote net muscle protein accretion (19). Alterations in skeletal muscle mass are mainly 
caused by changes in MPS and, to a lesser extent, MPB (19, 155, 228). To date, the use of stable 
isotope tracers has provided us with invaluable information on how protein feeding and 
resistance exercise acutely alter MPS and MPB. Underlying these changes, are intramuscular 
signaling cascades that ultimately lead to increased or decreased translational efficiency. Over 
time changes in the net protein balance will lead to muscle mass accrual or loss (18, 155, 228).  
Developing novel methods to accurately measure these long-term changes in MPS and MPB 
remains an ongoing quest. Furthermore, unravelling the intramuscular mechanisms leading to 
alterations in skeletal muscle mass is of crucial importance to understand how anabolic stimuli, 
but also ageing, might influence the translational regulation of muscle protein turnover (52, 71, 
164). In healthy young individuals not undertaking strenuous exercise training, diurnal 
alterations in MPS and MPB result in a neutral NPB or proteostasis, in which skeletal muscle 
mass is stable. From an evolutionary perspective, the energy demanding process of MPS will 
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only occur during favourable conditions. Therefore, it is safe to assume that this process is 
under strict regulation. The evolutionary intact serine/threonine protein kinase mTOR 
(mechanistic target of rapamycin) plays a crucial role in this complex process and consists of 
two functional, but distinct multiprotein complexes; mTOR complex 1 (mTORC1) and mTOR 
complex 2 (mTORC2) (116). Both complexes are similar in that they both consist of the 
catalytic component mTOR and G protein -subunit like protein, but are different in that 
mTORC1 additionally consists of raptor (regulatory-associated protein of mTOR) and PRAS40 
(proline-rich Akt substrate 40 kDa), an insulin regulated mTORC1 inhibitor. Several signals, 
including those from growth factors, nutrients and mechanical stress, converge on mTORC1 to 
exert an influence on cellular growth. One of the most important activators of mTORC1 is Rheb 
(ras homolog enriched in brain). When in the GTP state, Rheb binds directly onto mTORC1 
activating the complex (131). However, tuberous sclerosis 2 (TSC2) initiates GTP hydrolysis 
and is therefore a Rheb, and consequently mTORC1 activation, inhibitor (196). Several factors 
can converge on the TSC1/2 complex to modulate its GAP activity and relieve its inhibitory 
effects on Rheb (113). 
 
Activation of mTORC1 leads to translation initiation, a process characterized by the binding of 
a ribosomal subunit to a messenger RNA strand (mRNA) starting its translation and formation 
of a polypeptide chain. The assembly of a ribosomal subunit at the mRNA strand requires the 
formation of the eukaryotic initiation factor complex, consisting of 3 eukaryotic initiation 
factors; eIF4E, eIF4G and eIF4a (132). The binding of eIF4E at the 5’ cap end attracts the two 
other eukaryotic initiation factors to form the eIF4F complex. However, when 4E-BP1 (eIF4E 
binding protein 1) is in a hypophosphorylated state, it binds eIF4E preventing the formation of 
the eukaryotic initiation complex (86). A well-described mechanism through which mTORC1 
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promotes translation initiation is through 4E-BP1 phosphorylation. When phosphorylated, 4E-
BP1 will dissociate from eIF4E, allowing the eukaryotic initiation complex to be formed and 
promote translation initiation (35). Another well-studied target of mTORC1 is the ribosomal 
protein S6 kinase 1 (p70S6K1). As a protein kinase, it phosphorylates several downstream 
proteins all of which are involved in cell growth (132). One of the mechanisms exerted by 
p70S6K1 is the promotion of mRNA translation initiation through increasing the helicase 
activity of the eukaryotic initiation complex. Besides altering helicase activity, p70S6K1 
activation can also increase translation elongation efficiency. When p70S6K1 becomes 
activated it phosphorylates eEF2k (eukaryotic elongation factor 2 kinase), which in turn 
becomes inactivated and hence alleviates its inhibitory effect on eEF2 (eukaryotic initiation 
factor 2) (218). Most commonly, p70S6K1 phosphorylation is measured at the Thr389 
mTORC1-specific site. Although additional phosphorylation is required for full p70S6K1 
activation, the Thr389 site correlates reasonably well to p70S6K1 activation and is hence often 
used in in vivo studies as a marker for translational efficiency (222).  
 
1.2.1 Exercise Contraction and Muscle Protein Turnover 
Both acute and chronic exercise acts as a potent modulator of muscle protein turnover (18). 
Studies investigating alterations in MPS and MPB during exercise contractile activity (i.e. mid-
exercise) are scarce due to difficulties in achieving and maintaining a stable isotopic steady-
state during conditions of exercise, or due to a lack of stable isotope incorporation into muscle 
tissue over such short periods of time (162). However, based on a study by Carraro and 
colleagues it is generally accepted that MPB rates are elevated and MPS rates attenuated during 
prolonged and vigorous exercise, resulting in an overall negative NPB (40). The majority of 
studies have investigated how exercise modulates muscle protein turnover in the recovery 
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period following exercise cessation. Generally, a 50-200% increase in MPS above basal rates 
has been reported over several hours after resistance exercise (RE) completion (18, 159). 
Without the intake of AA, the rise in myofibrillar protein synthesis upon RE  returns to baseline 
after approximately 4 h (125), whilst mixed MPS stays upregulated for up to 48 h (159).  A 
sigmoidal dose-response relationship has been observed in MPS stimulation upon RE exercise, 
reaching near maximal levels around 60-90% of 1 repetition maximum (29). Nevertheless, 
several RE-related factors such as load, volume and rest interval in-between exercising sets can 
influence the extent to which MPS is stimulated. A study by Burd and colleagues revealed that 
low-load RE was as effective as high-load RE in stimulating mixed and myofibrillar protein 
synthesis when performed to fatigue(33). Whereas McKendry et al have shown superior MPS 
rates in young men upon resting 5 min between RE sets compared with 1 min rest (134). Besides 
an upregulation in MPS, a concomitant increase in MPB rates of around ~30-50% are observed 
after RE completion (159). This post-exercise divergence in MPS and MPB responses are 
thought to improve overall NPB (159, 160). Assuming RE in the postabsorptive state would 
increase MPS rates to the extent that a positive NPB is achieved, would be premature. In order 
to achieve a positive NPB, amino acids (AA) are required as substrate to synergistically enhance 
MPS and further attenuate MPB rates (152). Importantly, one cannot necessarily extrapolate 
acute exercise-induced changes in MPS rates to quantitatively predict long-term skeletal muscle 
mass remodelling responses. Mitchell et al.  reported that acute changes in MPS to RE plus 
protein ingestion did not correlate with the change in muscle mass seen after a 16-week RE 
training protocol (139). How MPS rates are altered over the course of a RE training regimen 
needs to be further defined, but one hypothesis is that alterations in MPS at the onset of RE 
training may be directed towards repair of muscle damage (53). Furthermore, the MPS response 
to a bout of RE changes as one progresses to a more trained state. It is possible that responders 
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and non-responders exhibit similar changes in MPS to an acute, first bout of RE but might show 
a different muscle anabolic response at some point during the training period (194). Measuring 
the MPS response to a bout of RE in the middle and at the end of a training regimen in the 
above-mentioned study performed by Mitchell et al (139) would have provided us with more 
insight on how the muscle anabolic response would change over time, and might be more 
predictive of a subject’s ability to gain muscle mass. Although a potent anabolic stimulus, RE 
is only a small part of an individual’s daily routine or life. Other factors such as nutrition (129) 
and daily physical activity outside structured exercise settings might have a significant impact 
on muscle mass gain or loss over time, and might therefore dilute the acute benefits of RE (31). 
Therefore, it is important to measure MPS, and if possible MPB, over the period of several 
months to further elucidate how RE influences the ability to gain skeletal muscle mass.  
The recent revival of deuterium oxide (D2O) could potentially facilitate this quest, as it permits 
the assessment of MPS and MPB rates over chronic periods of time (weeks-to-months) under 
free-living conditions. Using D2O in conjunction with acute stable isotope tracer infusions 
could resolve longitudinal and more acute MPS responses to RE training (27, 53, 176).  
 
Mechanistically, RE has a profound impact on a number of proteins at a molecular level that 
regulate muscle protein turnover. Baar and Esser (7) were the first to observe how increases in 
skeletal muscle mass after a 6-week electrical stimulation protocol in rats positively correlated 
with acute changes in p70S6K1 phosphorylation. Since then, several studies have reported 
robust increases in p70S6K1 phosphorylation upon stimulation of MPS in animals (100, 220). 
One of the first pioneering in vivo studies validating the importance of mTORC1 on skeletal 
muscle growth was performed by Bodine et al (20). In this elegantly designed study, an 
mTORC1 inhibitor, rapamycin, prevented the occurrence of compensatory muscle hypertrophy 
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following synergist ablation in animals. When translating these observations into humans, 
similar results have been reported (60, 69). Administrating an acute dose of rapamycin (12mg) 
was able to block RE-induced increases in mTORC1 and MPS, confirming the critical role of 
mTORC1 in skeletal muscle plasticity (69). Furthermore, RE has been shown to downregulate 
eEF2, which, in a hypophosphorylated state, becomes active and improves ribosomal 
translocation along the mRNA strand (39), and upregulate protein kinase B (Akt) and 4E-BP1 
(36, 134). Taken together, an acute bout of RE robustly increases MPS rates and, to a lesser 
extent, MPB rates through molecular networks that improve mRNA translation and regulate 
cell size.  
 
1.2.2 The Role of Amino Acids 
Amino acids (AA) fulfil several important bodily functions, especially as constituents for 
proteins and polypeptides. Of the 20 amino acids, 11 are endogenously synthesised, whilst the 
other 9 cannot by synthesised and are required through dietary consumption. These AA groups 
are respectively termed non-essential (NEAA) and essential amino acids (EAA). Protein 
nutrition is a potent stimulus for skeletal muscle accretion through stimulation of MPS and, to 
a lesser extent, attenuation of MPB (59). Of the AA, the EAA are thought to be predominantly 
responsible for feeding-induced alterations in MPS and MPB, with little-to-no stimulatory 
effect found for NEAA (179, 180, 201). A major muscle anabolic role has been attributed to 
the branched chain amino acid, leucine. In 1999, oral leucine supplementation was shown, for 
the first time, to stimulate MPS in rats (3). These observations have since been translated into 
in vivo mammalian and human studies, showing a similar capacity for leucine-induced 
stimulation of MPS (5, 73). In an elegantly designed study by Churchward-Venne and 
colleagues (46) the addition of leucine (3g) to low-dose protein ingestion (6.25g of whey) was 
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able to elicit a comparable MPS response to that observed with high-dose high-quality protein 
(25g of whey). Although many protein sources are capable of increasing postprandial MPS 
rates, the extent to which they do is largely dependent on the AA profile of the protein source 
ingested, the digestion and absorption kinetics, and the timing of protein intake in relation to 
exercise (23, 90, 202). Based on the absorption and digestive kinetics, proteins have been 
broadly classed as “fast” or “slow” proteins. Fast proteins, such as whey and soy, cause a rapid 
but transient rise in plasma AA, whilst slow proteins, such as casein, are more slowly released 
into circulation, causing a pattern of aminoacidemia that is lower but more sustained than so-
called fast proteins. These different protein digestion and absorption kinetics modulate MPS 
each in different ways, with fast proteins causing a more pronounced rise in MPS rates than 
slow proteins (23, 193). Generally, MPS rates respond quite rapidly to an increased plasma AA 
availability, rising up to ~2-3 fold from basal levels at between 90-120 min post-feeding, 
returning to basal levels thereafter, even in conditions where plasma hyperaminoacidemia 
persist, a phenomenon referred to as the “muscle full” effect where MPS is thought to become 
refractory to the continued appearance of AA’s (137). Amino acids in se stimulate insulin 
secretion causing hyperinsulinemia. The exact role of AA-induced insulin release on MPS and 
MPB is much debated. Generally, it is accepted that a rise in insulin, up to a certain level and 
in the absence of sufficient AA’s, will stimulate MPS rates by upregulating the insulin receptor 
substrate (IRS)-Akt-mTORC1 pathway, and may play an important anti-proteolytic role when 
insulin levels are further elevated (92, 157). 
 
As outlined above, molecular regulation of MPS and cell size is mainly modulated by mTORC1 
activity, which can be modified by protein nutrition (through constituent EAA’s). Although our 
understanding of how AA modulate mTORC1 activity is not entirely clear, we do know that 
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AA are a crucial signal for mTORC1 activity, since growth factors are incapable of efficiently 
activating mTORC1 when AA are lacking (113). Put simply, AA promote the formation of the 
active RAG GTPase complex, causing mTORC1 to bind to this complex at the lysosome where 
it becomes activated (113). However, the first step in sensing AA availability for mTORC1 
signaling is currently unknown. Recently, evidence has emerged supporting the importance of 
AA transporters in the sensing of AA levels and the subsequent activation of intracellular 
signaling cascades. Specific amino acid transporters could act as nutrient sensors and 
subsequently initiate cellular signals, or the binding of AA to the nutrient sensor is enough to 
evoke intracellular signaling events (107). Increased mTORC1 phosphorylation through AA 
provision is further linked to the phosphorylation of downstream factors p70S6K and 4EBP1, 
resulting in increased protein translation efficiency (4, 82). In summary, protein/AA provision 
in healthy young individuals increases MPS and attenuates MPB, through phosphorylation of 
mTORC1-mediated signaling pathway and enhanced capacity for mRNA translation efficiency 
and ribosome biogenesis. 
 
1.3 Age-Related Alterations in Muscle Protein Turnover 
As highlighted above, skeletal muscle mass declines from the 4th to 5th decade of life at a rate 
of 0.6 % per annum (111). Intuitively, sarcopenia must be driven by alterations in muscle 
protein turnover that contribute to an overall net protein loss (24). In contrast to proteostasis in 
healthy young individuals, imbalances in muscle protein turnover in older individuals lead to 
greater periods of net protein loss, which are thought to primarily underpin the progression of 
sarcopenia (24). Initially, Trappe et al (203) attributed age-related skeletal muscle loss to an 
increase in basal-state rates of MPB . However, this study measured 3-methylhistidine (3-MH), 
a breakdown product from myosin and actin, as a surrogate marker for MPB in blood. This 
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experimental approach is liable to a few assumptions, such as accepting that the amount of 
methylated myosin and the amount of muscle sampled by the microdialysis is equal among 
young and old. Further to this work, Yarasheski et al (233) reported decreased basal-state rates 
of MPS in older individuals compared with the young. In line with these results, Balagopal and 
co-workers found a decline in mixed MPS and whole-body protein turnover from young to 
middle age (10), and Welle et al observed reduced myofibrillar MPS in older compared with 
younger individuals (221). Collectively, these studies infer that basal-state rates of MPS are 
reduced by 20-40 % and MPB rates elevated by 30 %. However, inferring the NPB from these 
values would result in a rate of skeletal muscle mass loss far exceeding the commonly reported 
0.6 % muscle loss per annum in older age. Since, studies have refuted the observed differences 
in postabsorptive MPS and MPB between young and older individuals, showing no differences 
in basal MPS and MPB (81, 213). Given the importance of protein-based nutrition and physical 
activity in the regulation of muscle protein turnover, researchers have turned their attention to 
understanding how ageing modifies skeletal muscle anabolic and anti-catabolic responses to 
these stimuli (24). 
 
1.3.1 Age-Related Impairments in Exercise-Induced Muscle Protein Turnover  
Despite recent advances in pharmaceutical interventions to enhance skeletal muscle mass, 
exercise is still the most potent stimulus for muscle protein accretion (124, 233). In young 
individuals, resistance exercise (RE) robustly increases MPS (134, 225) and, when repeated 
frequently over time, promotes muscle hypertrophy and strength increases (53). An important 
discovery is that the net anabolic response to RE is diminished in older age. A seminal study 
from Kumar et al (125) showed the MPS response to unilateral leg extension, across a range of 
intensities, was lower in older compared with younger individuals. Accompanying this blunted 
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MPS response to RE was a dampened p70S6K and 4E-BP1 signaling response (80). The 
phosphorylation status of these proteins was associated with MPS rates over 1-2 h post-exercise 
in young, but not older individuals (125). This sensitivity ‘shift’ in aged muscle might be 
alleviated by increasing exercise training volume. Specifically, follow-up work by Kumar et al 
(124) showed that doubling RE volume (i.e. from 3 to 6 sets of moderate-load training) restored 
a ‘youthful’ muscle anabolic response in older individuals, which was matched by a greater 
phosphorylation of p70S6K. The necessity in older individuals to double RE volume could be 
the results of a lower strength-related performance, i.e. older individuals lifted significantly less 
weight per unit muscle cross-sectional area, and, consequently, had to double RE volume to 
elicit a similar MPS response compared with younger individuals. An additional explanation 
could be found in  Henneman’s size principle where slow twitch fibres are primarily recruited 
during the onset of RE, whilst increasing muscular force/fatigue will lead to an upregulation in 
the recruitment of type II fibres (99). Doubling RE volume in older individuals at 40% of 1RM 
would have led to greater muscle fatigue and hence increased recruitment of Type II muscle 
fibres, resulting in elevated MPS rates. On the contrary, doubling RE volume at 40% 1RM in 
younger individuals did not significantly alter MPS, as skeletal muscle in younger individuals 
is more fatigue resistant, and, hence, would have  led to a lower recruitment of Type II fibres 
(208). Even though evidence supporting the age-related blunting in the anabolic response to 
acute exercise is compelling, others have been unable to reproduce these findings (68, 233). 
This might partially be due to the protein fraction isolated for MPS interrogation. The majority 
of studies that have assessed protein synthesis in a mixed protein fraction instead of an isolated 
myofibrillar fraction, have been unable to detect the presence of age-related anabolic resistance 
to feeding or exercise (189, 190, 212). Although myofibrillar proteins constitute 60 % of the 
mixed muscle protein pool, the residual 40% contains proteins with differing turnover rates that 
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could potentially alter/mask any differences in MPS between young and older individuals (28). 
Although limited, studies measuring myofibrillar protein fractional synthesis rates often do 
detect the evidence of age-related muscle anabolic resistance (8, 52, 95, 125). 
  
Furthermore, some of the alterations observed in muscle protein turnover in old age might be 
caused by sexual dimorphisms. Although, no differences in postabsorptive or postprandial MPS 
rates are commonly observed between young-to-middle aged males and females (66, 83, 177), 
sex has been reported to affect MPS in older individuals. A study by smith et al (178) measured 
basal and postprandial MPS in young and old men and women. Compared with young and old 
men and young women, basal MPS was elevated in older women. Upon infusion of combined 
glucose, insulin and AA, MPS increased in young and to a lesser extent in old men, but did not 
increase in old women. It might be argued that the lack of postprandial MPS in older women is 
a consequence of higher basal MPS rates, or due to the relatively small amount of protein 
provided; 21g and 13 g in males and females, respectively, spread over the course of three 
hours. Furthermore, older women had a significantly greater relative fat mass compared with 
older men. Hence, it is questionable if the observed changes in MPS are due to gender 
dimorphism or are the consequence of differences in body composition or relative amount of 
ingested protein. To date, it appears that body composition rather than gender per se, plays a 
greater role in influencing muscle protein turnover in old age. 
Resistance exercise training, is arguably the most effective measure to increase muscle mass 
and counteract the onset and progression of sarcopenia (78). In older individuals, the muscle 
remodelling response to RE training is somewhat impaired (93, 122). This might partially be 
due to deficits in cumulative MPS, lower ribosomal biogenesis, and inferior translational 
efficiency as measured by p70S6K phosphorylation (26). Nevertheless, RE training is an 
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effective method to increase muscle mass and strength (154) even in frail nonagenarians (78). 
Future studies should investigate the underlying mechanism for the blunted RE training-
induced MPS response in older individuals in order to modify physical activity 
recommendations for this population.   
 
1.3.2 Age-Related Impairments in Amino Acid-Induced Muscle Protein Turnover 
Protein-based nutrition (via constituent EAA’s), is a potent stimulator of MPS in younger 
individuals (200). As extracellular EAA availability is of primary importance to stimulate MPS 
(21), and AA delivery to skeletal muscle does not appear impaired in older individuals despite 
a higher first-pass capture of AA in splanchnic tissues (212), anabolic resistance can be directly 
attributed to a muscle-specific defect. Early research, in which AA were administered to older 
individuals, suggested elevated MPS rates compared with younger individuals. However, in the 
absence of a young control group it was impossible to compare the influence of age per se on 
postprandial MPS rates (211). One of the first studies to show a blunted response to food 
ingestion, specifically protein nutrition, was conducted by Dardevet et al (54). Young and old 
rat muscles were treated in vitro with different concentrations of leucine, with a weakened MPS 
response evident in older muscles. Subsequent to this study, Cuthbertson et al. (52) provided 
young and older individuals with graded doses of crystalline EAA and showed a decreased 
responsiveness of MPS in older individuals. Since these pioneering studies, several others have 
explored the relationship between protein provision and MPS rates in younger vs. older 
individuals, with the general consensus being that older individuals are less responsive to low-
moderate dose protein provision and may require larger protein-doses to overcome this muscle 
anabolic resistance (8, 95, 231). Recently, Moore et al. (143) provided strong evidence that the 
relative amount of protein required to maximally stimulate MPS is considerably greater in older 
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adults (0.4 gkg-1body mass-1) than in the young (0.24 gkg-1body mass-1). Put into context, for 
an average 75- to 80-kg older individual, this equates to 30 g of high-quality protein to 
maximally stimulate MPS. In support of these data, Wall et al. (216) have demonstrated that 
the MPS response to 20 g of casein protein ingestion is 16% lower in older than in young 
individuals. The precise mechanisms underlying this age-related anabolic resistance to protein 
provision are still unclear, but deficits in mTORC1-mediated signaling might partially explain 
this phenomenon. Specifically, p70S6K phosphorylation was reported to be less sensitive to in 
vitro stimulation by leucine in older compared with younger rat muscle, and was maximally 
stimulated only when higher leucine concentrations were used (54). In older humans, the 
relative protein content of mTOR, p70S6K and eIF2B was reported to be significantly lower 
compared with younger individuals and, when stimulated by EAA, phosphorylation of mTOR 
and p70S6K was significantly lower in older individuals (52).  
 
Research translating the concept of age-related muscle anabolic resistance to protein provision 
from acute experimental models to chronic long-term observational studies is scarce and yields 
conflicting results. Whilst some studies fail to report any beneficial effects on skeletal muscle 
mass or strength following long-term protein supplementation in older individuals (127, 209), 
others have reported positive outcomes on muscle function and acute postprandial MPS rates 
(41, 62, 198). Methodological differences, such as the specific older population studied and 
dose/source of ingested protein, most likely underlie these conflicting findings between the 
aforementioned studies. Supplementing large amounts of high quality proteins or EAA over 
longer periods of time will most likely yield in muscle mass gains (62). However, the feasibility 
of merely increasing protein intake in older individuals is questionable as their appetite is 
downregulated (161). Furthermore, executing long-term supplementation studies over several 
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months are expensive and very demanding for both researcher and participant, especially of 
stable isotope tracers are used for the precise determination of muscle protein kinetics.  
Experimenting with protein fortified foods might be the way forward. These foods would allow 
an increase in protein intake without a concomitant increase in total energy intake. Most studies 
investigating the effectiveness of protein supplementation have been undertaken in a Caucasian 
study population. However, cultural and ethnical differences affect food choice and 
consequently protein intake (175). Furthermore, failure to include an exercise regimen 
alongside a nutritional intervention will most likely result in a sub-optimal muscle anabolic 
stimulus (199). Addressing these methodological difficulties might shed light on the potential 
therapeutic benefits of high protein diets or protein supplementation in healthy and frail older 
individuals.  
 
In conclusion, the current consensus regarding changes in muscle protein turnover in older 
individuals that underlie sarcopenia iterates that both postabsorptive rates of MPS and MPB are 
unchanged with advancing age, and that any imbalance in NPB likely stems from a blunted 
MPS response to normally anabolic stimuli (i.e. exercise and protein nutrition). However, in 
stark contrast are the numerous studies that have been unable to detect the presence of muscle 
anabolic resistance to exercise and protein nutrition, alone or combined, in older individuals (5, 
70, 119, 152, 212). Methodological discrepancies between studies might underlie these 
inconsistent findings. For example, the period of tracer incorporation over which MPS is 
measured varies greatly between studies. This has important implications on the interpretation 
of MPS data in young and older individuals. When MPS is measured over longer periods (≥ 6 
h), it is likely that any peak transient MPS response is diluted by lower postprandial MPS rates 
during the later phase of protein ingestion. Given that MPS rates return back to basal 
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postabsorptive levels ~3 h post-protein ingestion, it is unlikely that muscle anabolic resistance 
will be detected in older individuals when MPS is measured over longer periods (174). 
However, it is important to realize that by measuring MPS, only one side of the story is told. 
Omitting MPB from the NPB equation makes it difficult to elucidate the effectiveness of an 
anabolic stimulus on skeletal muscle remodelling (176). Furthermore, age-related muscle 
anabolic resistance is unlikely to be observed when studies provide a robust enough anabolic 
stimulus to healthy older individuals with high levels of physical activity (174). For example, 
when older individuals ingest a very high protein dose in the context of an acute exercise setting, 
muscle anabolism is likely to be maximally stimulated. Considering the above information, 
anabolic resistance is most likely to be observed when older individuals are provided with a 
sub-optimal anabolic stimulus of physiological relevance to their habitual lifestyles (i.e. low-
moderate dose protein ingestion).  
 
1.4 Potential Mechanisms of Muscle Anabolic Resistance in Sarcopenia 
Age-associated loss of skeletal muscle mass, strength and function is undoubtedly an inevitable 
part of chronological ageing, and is even apparent in master athletes whose exercise/activity 
levels far exceed those observed in the general ageing population (98). The mechanisms that 
induce age-related muscle anabolic resistance to exercise and/or protein nutrition are yet to be 
fully understood, but are essential to understand in order to treat or prevent the progression of 
sarcopenia. Factors contributing to muscle anabolic resistance in sarcopenia are thought to 
include, myosteatosis (i.e. excess subcutaneous and intramuscular fat accumulation) (191) and 
elevated levels of systemic and local pro-inflammatory cytokines, including tumour necrosis 
factor  (TNF-), interleukin 6 (IL-6), c-reactive protein (CRP) and interleukin  (IL-) (167). 
In addition to obesity and inflammatory-mediated mechanisms, reductions in sex hormones 
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(110) and neuromuscular apoptosis (238) may contribute the progression of sarcopenia, 
although it is not entirely clear how these parameters negatively impact muscle protein turnover 
in the old. Importantly, physical inactivity and dietary protein malnourishment may play an 
important role in modulating the extent to which these factors drive sarcopenia. Ultimately, 
these myriad contributing elements are not mutually exclusive, but can aggravate one another, 
hasten age-related skeletal muscle deterioration, and result in disability, morbidity and death 
(64, 110, 126). Figure 1.2 provides an overview of the impact of anabolic resistance on the 
muscle anabolic response.  
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Figure 1.2: Representation of the relationship between the optimal protein intake and 
postprandial muscle protein synthesis. Optimal protein intake is the amount needed to 
maximally stimulate MPS as defined by Moore et al via breakpoint analysis (143). Factors that 
affect the optimal protein intake can shift the protein intake curve to the left (positive) or right 
(negative). Anabolic resistance is represented as an increased protein intake to elicit maximal 
postprandial muscle protein synthesis. Redrawn with permission from English and Paddon-
Jones (2010) (72). 
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1.4.1 Importance of Dietary Protein Dose and Source 
As outlined above, protein nutrition is essential for skeletal muscle maintenance and function 
(37). The current recommended daily allowance (RDA) for protein intake in adults is 0.8 gkg-
1day-1, which is believed to be adequate to fulfil bodily metabolic demands of this 
macronutrient. However, studies assessing dietary intake have reported an inability of older 
individuals to consume this amount of protein (15). This might be problematic as older 
individuals require a greater absolute and relative protein dose compared to younger individuals 
to maximally stimulate MPS (0.40 gkgbody mass-1 per meal in older individuals vs. 0.24 
gkgbody mass-1 in the young) (143, 231). Recently, Cardon-Thomas and co-workers (38) 
studied dietary protein intakes in a local cohort of Birmingham-based older individuals to 
understand if these individuals reached the required protein intake ‘threshold’ of 0.40 gkg-
1body mass-1 per meal set forth by Moore et al (143). Surprisingly, only 3, 42 and 68% of older 
individuals reached this threshold for protein intake at breakfast, lunch and dinner, respectively, 
even though total daily protein intakes were well in excess of the current RDA (38). Similarly, 
dietary protein consumption patterns in a Northern-American (15) and Dutch (197) individuals 
aged over 50 y and 75 y, respectively, revealed that the majority of protein was consumed 
during the evening meal. These results require researchers and health institutions to embrace a 
more pragmatic approach to dietary protein intakes in older individuals, possibly expressing 
protein intake on a meal-to-meal basis. Indeed, a case is being put forward by recent studies to 
increase dietary protein recommendations and promote equal protein distribution across meals 
in older individuals to enhance overall health outcomes (104, 141, 210).  
Besides dose and pattern of dietary protein intake, protein source has an important impact on 
the ability of younger and older individuals to stimulate MPS (232). The extent to which MPS 
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is stimulated upon protein intake is largely dependent on the AA profile, absorption and 
digestive properties of the protein source consumed (23). Protein sources that are rapidly 
digested and absorbed will robustly increase blood aminoacidemia/leucinemia and hence evoke 
elevations in MPS to a greater extent than those observed after the ingestion of slower digestive 
proteins with inferior AA or leucine profiles (21, 23). Based on this information, it is generally 
accepted that most animal-derived proteins instigate greater increases in MPS compared with 
plant-derived proteins (232). The suggestion that protein quality, besides protein quantity, is an 
important factor in regulating the extent to which MPS changes, led to the development of the 
Protein Digestibility-Corrected Amino Acid Score (PDCAAS). The PDCAAS gives common 
protein sources a score based on their absorption-digestion kinetics compared with a reference 
protein (i.e. egg, with a PDCAAS of 1.00).  Protein sources with a lower PDCAAS are hence 
considered to be of inferior quality compared with those given a higher score. However, more 
recently concerns regarding the PDCAAS have been raised, as the scoring system was based 
on faecal rather than ileal protein digestibility, and the inability of distinguishing protein 
sources that are superior to the reference protein (156). These shortcomings are some of the 
reasons why the Digestible Indispensable Amino Acid Score (DIAAS) has been introduced and 
has been suggested a better protein quality ranking system (1). The DIAAS uses a theoretical 
reference protein that covers all the requirements for the indispensable amino acids, and can be 
calculated by dividing the amount (in mg) of digestible dietary IAA (as determined by a dietary 
test) by the amount (in mg) of the same IAA in the reference protein. The DIAAS reflects the 
minimal required intake for each individual AA and allows protein sources to score higher than 
the theoretical reference protein (1). 
Meals in a typical Western diet are composed of both animal- and plant-derived proteins, with 
the majority of proteins originating from animals (90). These animal-derived protein sources 
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have the ability to robustly increase MPS, as they have a high leucine content and an AA profile 
that closely matches the bodily needs. The superiority of animal-derived proteins is, hence, 
generally reflected by a higher DIAAS (32). On the other hand, plant-based proteins often lack, 
or contain less of, one or more specific EAA, resulting in an inferior AA profile which 
consequently renders them inferior to most animal-derived proteins (207). Nevertheless, the 
total amount proteins derived from a mixed meal should provide all AA needed to fulfil bodily 
functions if consumed in large enough quantities. However, with advancing age, a decrease in 
appetite and chewing efficiency is often observed (138, 161), making it more difficult for older 
individuals to consume sufficient amounts of dietary proteins. Recommendations on dietary 
protein intake in older individuals should therefore be more pragmatic and promote guidelines 
ensuring a sufficient quantity of  high-quality proteins are consumed with every meal. 
 
1.4.2 The role of Inactivity and Disuse in Age-Related Muscle Anabolic Resistance 
Maintaining appropriate physical activity levels is pivotal for healthy musculoskeletal ageing. 
UK physical activity guidelines propose older individuals perform 150 min of moderate-
intensity physical activity per week. Furthermore, exercises to improve muscle strength should 
at least be performed twice weekly in combination with exercises to improve balance and 
prevent falls (91). Unfortunately, the current guidelines are somewhat vague and require 
refinement. Accurate assessment of physical activity levels and intensities in our ageing 
population is therefore of crucial importance. Unfortunately, physical activity is often assessed 
by means of retrospective questionnaires, activity diaries or interviews, and is hence prone to 
subjectivity and over- or under-reporting (128). With the introduction of accelerometry, these 
potential problems can be circumvented. Accelerometers have been used successfully as a valid 
and objective measurement tool to assess physical activity in a variety of different populations 
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(74). As accelerometry is fairly new and quite costly, only a small number of studies have 
utilised this tool in older individuals, reporting decreased physical activity levels with 
advancing age, leading into deleterious effects on muscle metabolism (130, 229). For example, 
merely reducing daily step-count in older individuals for 14 days induced muscle atrophy, 
blunted postprandial MPS rates and impaired insulin sensitivity (25). Besides decreased 
physical activity levels, older individuals often undergo protracted periods of disuse and 
immobilization due to hospitalization, falls or illness. These more drastic disuse events are 
associated, both in young and older individuals, with rapid muscle atrophy driven by alterations 
in muscle protein turnover (58, 63, 76, 120, 121). This was first demonstrated by Gibson et al 
(85), who reported a 30% reduction in postabsorptive MPS rates in a limb that had been 
immobilized for 6 weeks compared with the non-immobilized limb. Since then, a number of 
studies have demonstrated a decline in postabsorptive MPS rates (76) and a blunted MPS 
response to AA provision (87, 215, 217) in response to disuse/immobilization events. The 
precise mechanisms underlying disuse-induced alterations in muscle protein turnover are 
unknown, but could partially be attributed to impairments in AA transport capacity and 
intramuscular signaling (67). Interventions to minimize or counteract disuse-induced muscle 
atrophy have included additional protein provision (77) and RE (147). However, it appears that 
older individuals require aggressive, tailored RE training compared with younger individuals 
to restore disuse-induced skeletal muscle losses (186, 187). The role of MPB in “healthy” 
models of disuse is dissimilar to the role in “diseased” disuse events. The latter is marked by a 
significantly elevated inflammatory state that elicits a pronounced rise in MPB, whilst in the 
former, systemic levels of inflammation are not drastically elevated and MPB is thought to play 
a lesser role (144, 158, 170).  
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As physical activity is a potent stimulator of MPS, the majority of studies advise older 
individuals to refrain from vigorous activity/exercise prior to a stable isotope infusion visit. 
However, only one study sought to directly monitor physical activity levels via accelerometry 
in the days prior to an infusion trial (44). Given the fact that the muscle anabolic response to 
protein nutrition is enhanced for up to several hours after exercise cessation (34), it is of utmost 
importance to rigorously control physical activity levels prior to the assessment of MPS. 
Physical (in)activity is a potent regulator of MPS in young and older individuals. However, our 
knowledge on the complex interactions between age-related muscle loss and physical activity 
levels is still in its infancy, and is to be further elucidated to help the development of successful 
anti-sarcopenic strategies. 
 
1.4.3 The Role of Obesity and Inflammation in Age-related Muscle Anabolic Resistance 
Undoubtedly, preserving muscle quality is of utmost importance to maintain robust anabolic 
sensitivity with advancing age (50, 57). Defining muscle quality is dependent on the 
physiologic perspective and methodology used to characterize the tissue parameters and assess 
performance. Although this has led to myriad definitions, the term ‘muscle quality’ allows us 
to look beyond the constructs of age-related muscle loss and explore how different facets 
influence this aspect (50). An important factor thought to influence muscle quality is adipose 
tissue and intramyocellular lipid (IMCL) infiltration, collectively termed myosteatosis (136).  
Ageing is, in most cases, associated with a decrease in whole-body fat-free mass and 
concomitant increase in adipose tissue mass (13). This ‘shift’ in body composition has various 
negative health outcomes and has been associated with mobility limitations (55) and all-cause 
mortality (16). Nevertheless, some studies advocate the potential protective effects obesity 
might exert in old age, especially during the recovery from adverse health events (97). Studies 
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supporting this apparent “obesity paradox” (where excess adipose tissue may protect ageing 
muscles from the wasting process) have most likely defined obesity based on BMI; a poor 
discriminator of fat mass. In comparison, studies using more accurate methods to determine 
whole-body fat mass have failed to support the protective effects of obesity on skeletal muscle 
in old age (45). Besides whole-body and regional changes in fat and fat-free mass, increases in 
IMCL content are apparent as one ages, irrespective of changes in body mass (57). Increased 
IMCL content has been associated with an increased risk for insulin resistance in healthy and 
young and older individuals and Type II diabetics (2, 88). The mechanisms through which 
IMCL may induce insulin resistance might be dependent on the lipid oxidative capacity of the 
muscle cell (88) and impairments in the insulin receptor substrate 1 (IRS1)-phosphatidylinositol 
3-kinase (PI3K)-Akt pathway (153). More recently, lipid-induced insulin resistance has been 
suggested to be associated with muscle anabolic resistance to AA ingestion in healthy young 
individuals. Concomitantly with this impaired response to AA feeding, a suppression in the 
phosphorylation of 4E-BP1 was suggested as a possible explanatory mechanism (185). A study 
by Kouw et al. (123) demonstrated no difference in the postabsorptive and postprandial MPS 
rates in older normal-weight diabetic individuals. Collectively, these data indicate that 
myosteatosis, but not necessarily insulin resistance per se, may induce muscle anabolic 
resistance.  
Skeletal muscle adipose infiltration is exacerbated by obesity and is linked to increased 
concentrations of systemic inflammatory markers (148). This increase in inflammatory markers 
is partially caused by a dysregulation in the secretion of both pro-inflammatory or anti-
inflammatory ‘adipokines’ that will, over time, lead to chronic low-grade inflammation (11). 
Therefore, increased systemic concentrations of pro-inflammatory cytokines such as 
interleukin-6 and c-reactive protein are commonly found in obese individuals. This state of 
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chronic low-grade inflammation can result in insulin resistance, Type 2 diabetes and other 
metabolic diseases (205). Furthermore, low-grade inflammation has been shown to blunt the 
postprandial muscle anabolic response in old rats, providing evidence for the contribution of a 
low-grade inflammatory state towards sarcopenia (9). On the other hand, reducing low-grade 
inflammation through provision of non-steroidal anti-inflammatory drugs (NSAID; i.e. 
Ibuprofen) restored postprandial muscle anabolic sensitivity in old rats, allowing for greater 
muscle mass retention in these animals (163). In line with these results, Trappe and colleagues 
(204) observed greater increases in muscle volume and strength in older individuals upon 
consuming ibuprofen or acetaminophen in combination with resistance exercise. These results 
seem to support the idea that daily consumption of NSAID in older individuals will decrease 
systemic inflammation and consequentially support superior muscle remodelling. On the 
contrary, a study by Buffière et al showed no impairment in the mixed muscle FSR response to 
protein provision in older individuals suffering from low-grade inflammation (30). These 
conflicting findings could have been the consequence of a continuous, rather than bolus, 
administration of protein, which would likely result in a lower FSR response (223). This lower 
FSR response was probably further diluted by measuring MPS over a 5-hour period, as MPS 
peaks around 1h post protein ingestion (22). A study by Dideriksen et al. tried to overcome 
these problems by feeding their older subjects a bolus of whey protein and measuring MPS over 
a 3-hour period (61). Furthermore, a subgroup of older individuals with low-grade 
inflammation were treated with ibuprofen to investigate the effects of NSAID on the muscle 
anabolic response to protein feeding. Surprisingly, no differences between the control, placebo 
and ibuprofen group were found for postprandial MPS, indicating no beneficial effect of 
NSAID on the muscle anabolic response to protein feeding and exercise. To date, the long-term 
effects of NSAID consumption are somewhat unclear and warrant further examination. 
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Although research has highlighted the negative effects of obesity on muscle metabolic quality, 
investigations examining the complex interactions between ageing, physical activity, obesity 
and myosteatosis are lacking. Given the evidence outlined above, it is tempting to propose a 
model where obesity might be protective for muscle mass in old age up to a certain point, 
beyond which it becomes detrimental and elicits a precipitous decline in skeletal muscle mass 
and metabolic health. This hypothetical threshold for the protective effects of obesity on ageing 
skeletal muscle mass may be influenced by physical activity levels and myosteatosis, 
particularly IMCL infiltration. Exploring this hypothesis further could potentially shed light on 
these complex interactions that underpin age-related muscle anabolic resistance in sarcopenia 
and inform researchers on how best to tackle this problem.  
 
1.5 Nutrient Interventions to Alleviate Age-related Muscle Anabolic Resistance and 
Sarcopenia 
So far two main interventions to counteract sarcopenia have been discussed; exercise and 
protein nutrition. These two anabolic stimuli have been proven to alleviate and potentially 
treat/reverse sarcopenia. Nonetheless, attention has recently turned to uncovering novel 
therapeutic interventions with the potential to enhance the potency of exercise and protein-
based nutrition in aged skeletal muscle and, thus, abolish age-related muscle anabolic 
resistance. Specifically, others have tried to identify various other nutritional compounds that 
might beneficially influence metabolic health. Such potentially ergogenic nutrients have been 
termed ‘nutraceuticals’ and have potentially important health benefits for a variety of 
individuals, ranging from athletes (79), frail older individuals (114) and those suffering from 
chronic diseases (171). Due to the novelty of the term, there is no set definition for 
nutraceuticals. In a recent review article, we defined nutraceuticals as a nutrient-derived 
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compound “with added extra health benefits” (173). More recently, Deane et al. (56) termed 
nutraceuticals as “a compound that alone or in tandem with exercise, impacts major 
physiological end-points”. At present, many of these potentially ergogenic nutrients have no 
solid scientific underbuilt and require further investigation.  
 
1.5.1 Phosphatidic Acid: A Potential ‘Nutraceutical’? 
The never-ending quest for nutritional compounds that might potentially promote skeletal 
muscle protein accretion has led to the recent discovery of phosphatidic acid (PA) (230). PA is 
a phospholipid consisting of a glycerol backbone with two fatty acids and a phosphate attached 
to it. The fatty acids are connected to neighbouring C-atoms at position sn-1 and sn-2, whereas 
the phosphate group is attached to the sn-3 position of the C-atom. Whether the fatty acid is 
saturated or unsaturated determines the ability for PA to activate mTORC1 and potentially 
upregulate MPS. However, when one or both fatty acids are unsaturated PA is able to increase 
mTORC1 activity (234). Most forms of PA have a saturated fatty acid at the sn-1 position, 
rendering the structure of the fatty acid at the sn-2 position determinative of PA’s ability to 
stimulate mTORC1. Soy-derived PA contains a higher concentration of unsaturated fatty acids, 
and is therefore probably more potent in upregulating mTORC1 activity, as derived from 
p70S6K1 phosphorylation, compared with egg-derived PA (115). 
 
PA can be synthesised through three main pathways. The first major pathway is able to 
synthesise PA de novo via glycerol-3-phosphate (G3P), a by-product formed during glycolysis. 
When glucose is converted into fructose 1,6-biphosphate, it is cleaved into two units; 
glyceraldehyde-3-phosphate (not to be confused with G3P) and dihydroxyacetone phosphate 
(DHAP). The latter is catalysed by glycerol-3-phosphate dehydrogenase into G3P which is 
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subsequently acylated into lysophosphatidic acid (LPA) catalysed by glycerol-3-phosphate 
acyltransferase, and finally acylated by lysophosphatidic acid acyltransferase (LPAAT) into 
PA. It should be noted that this de novo PA production favours the production of PA species 
containing two saturated fatty acids. A second pathway forms PA from phosphatidylcholine 
(PC), a reaction catalysed by phospholipase D (PLD). PLD consists of two isoforms PLD1 and 
PLD2 and have been deemed important for mTORC1 activation as PLD inhibition by 1-butanol 
prevented any increase in mTORC1. However, recent research has condemned the use of 1-
butanol to inhibit PLD activity as it does not always successfully reduce PA accumulation and 
might result in independent deleterious events. With the more specific PLD inhibitor 5-fluoro-
2-indolyl des-chlorohalopemide (FIPI) advances in the field have been made and have shown 
a weak correlation between PLD activity and cellular PA concentration. Finally, PA can be 
formed through deacylation of triglycerides to diacylglycerol (DAG) and phosphorylation 
through diacylglycerol kinase (DGK) (Figure 1.3). 
PA, a major constituent of the cell membrane, plays a key role in regulating various metabolic 
processes in the cell. The endogenous or exogenous upregulation of PA concentration could 
therefore pose a viable solution in the battle against sarcopenia (173). 
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Figure 1.3: Proposed model of endogenous (mechanical load) and exogenous phosphatidic (supplementation) acid-induced activation of mTOR 
leading to increased muscle protein synthesis. Redrawn from Shad et al (2015) (173). 
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1.5.2 Exercise-Induced Endogenous Phosphatidic Acid 
As outlined above, RE is a potent stimulator for muscle hypertrophy, stimulating mTORC1 and 
downstream factors. Whilst the effects of exercise on mTORC1’s downstream factors are well-
defined, less is known on how exercise affects factors upstream of mTORC1. In an attempt to 
unravel these upstream factors, Fang and co-workers stimulated HEK293 cells and observed an 
increase in PA concentration (75). They suggested a direct binding of PA to the FK506-binding 
protein (FKBP12)-rapamycin-binding (FRB) domain on mTORC1, which would be in direct 
competition with rapamycin. This led them to attribute a key role for mechanical load induced 
PA production in the process of cell growth (103, 146, 237).  
However, the fundamental question of what mechanism was responsible for the mechanical 
load increased intracellular PA concentration was left unanswered. At first, hydrolysis of PC 
through PLD was believed to be the primary mechanism through which mechanical loading 
increased intracellular PA concentration. This notion was supported by a handful of studies 
successfully using 1-butanol to inhibit mechanical induced rises in mTORC1 activation and PA 
concentration. However, when the more specific PLD inhibitor FIPI was used, mechanical load 
induced increases in PA leading to mTOR phosphorylation could not be prevented. More 
recently, research has focussed on PA synthesising enzymes of the DGK family, as earlier 
research showed a 2-fold increase in DAG and PA in rats after electrical stimulation of the 
sciatic nerve (49), and an upregulation in DAG content when rat cardiac myocytes were 
mechanically stretched ex vivo (169). A crucial role for the DGK isoform was set aside, as this 
specific isoform had been shown to induce mTORC1 dependent phosphorylation of 
p70S6K1(6). The importance of the DGK isoform was later confirmed by You et al., who in 
an elegantly designed study showed an impaired response in mechanically induced PA 
concentration and mTORC1 signalling in DGK-/- mice (236). In summary, mechanical load 
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induced increases in intracellular PA are obtained through the conversion of DAG into PA and 
is catalysed by DGK. PA will then bind directly onto the FRB domain of mTORC1, enhancing 
its protein translation efficiency. 
 
1.5.3 Exogenous Phosphatidic Acid Provision 
Besides endogenous increases in PA concentration, PA can be administered exogenously 
through supplementation. Foods naturally rich in PA content are cabbage, tomato and cucumber 
(~0.55, 0.25 and 0.2 mgg wet weight-1). However, the way in which these foods are prepared 
might alter PA content, as for example boiling will lead to the inactivation of PA synthesising 
enzymes (192). Recently, PA has become commercially available as a supplement with claims 
as a potent stimulus for enhancing skeletal muscle mass. Beyond these claims, research is still 
required to fully elucidate the molecular pathways through which exogenous PA provision acts, 
and leads to muscle protein accretion. Cell culture and animal-based studies have proven to be 
an effective platform to begin unravelling these mechanistic pathways. Increasing PA 
availability in cell culture media of mouse wild-type C2C12 myoblasts (146) and feeding PA 
to rats was able to increase mTORC1-mediated p70S6K signaling, but did not alter Akt 
phosphorylation (140). Together, these results suggest an alternative pathway from insulin and 
growth factors through which exogenous PA provision stimulates mTORC1 phosphorylation. 
At first it was proposed that exogenous PA, similar to endogenous PA, competes with the 
mTOR inhibitor FK506 binding protein 38 (FKBP38) to bind the mTORC1 FRB domain. 
However, exogenous PA provision was not able to reverse FKBP38’s inhibitory effects and 
failed to increase mTORC1 stimulation when FKBP38 was knocked out (235). Alternatively, 
it has been proposed for PA to stimulate mTORC1 through the extracellular regulated kinase 
(ERK) pathway. In order for PA to exert its stimulatory effect through the ERK pathway, it 
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needs to be converted into LPA. Once converted, LPA will bind its receptor ‘endothelial 
differentiation gene’ (EDG2) and subsequently activate G-protein, Ras, mitogen-activated 
kinase (MEK1/2) and ERK. ERK activation then leads to the phosphorylation of TSC1/2, which 
in turn places Rheb in its GTP bound state, allowing it to bind and activate mTORC1 (173). 
Evidence supporting this pathway was provided by Winter et al (226) showing that MEK1/2 
inhibition negated PA and LPA induced ERK and p70S6K phosphorylation. Besides 
stimulating MPS, PA has been touted an inhibitor of MPB via attenuation of atrophy related 
genes (109). More recently, acute PA supplementation has been shown to increase MPS in 
rodent skeletal muscle compared to a placebo. However, when PA and whey protein were given 
together MPS was attenuated compared to either condition alone (140). Adding PA to whey 
protein might alter the pathways leading to mTORC1 activation and thus shift peak MPS (56). 
Taken together, more research, and especially human research, is needed to fully elucidate how 
PA supplementation might lead to enhanced MPS (Figure 1.3). 
 
1.5.4 Phosphatidic Acid and Human Skeletal Muscle Hypertrophy 
Ex vivo and animal studies have provided us with promising results regarding PA’s potency to 
increase MPS and, potentially, decrease MPB. Based on the premise that endogenous PA acts 
through an ERK-independent (direct binding onto the mTOR FRB domain) pathway, and 
exogenous PA through an ERK-dependent pathway, it is tempting to speculate that activation 
of both pathways through feeding and exercise might heighten mTORC1 
phosphorylation/activity leading to increased MPS. To date, evidence supporting this notion is 
scarce. The first study investigating the effects of an 8-week resistance training programme 
with or without daily ingestion of 750 mg soy-derived PA revealed a likely but non-significant 
benefit on increases in lean tissue mass, and strength improvements, assessed through 1 
 39 
repetition maximum (RM) bench press squat (102). Although the study slightly supports the 
use of PA supplementation to increase muscle mass and improve body composition, some 
limitations need to be addressed. These limitations include lack of control over the timing of 
PA ingestion, no supervised resistance exercise training, and a small sample population 
potentially masking any differences between the treatment or placebo group. A study by Joy et 
al addressed these limitations and subjected 28 persons to an 8-week supervised resistance 
training programme. Fourteen subjects consumed a daily dose of 750 mg soy-derived PA, either 
split up in 450 and 300 mg to, respectively, consume 30 min prior and immediately after 
resistance exercise. On non-exercising days participants were asked to consume 450 mg PA 
with breakfast and the remaining 300 mg with dinner. Participants in the PA group significantly 
increased their lean body mass, rectus femoris cross sectional area and leg press strength over 
the placebo group. Even though the evidence of the two studies discussed above seem to support 
a likely positive effect of PA supplementation on increasing skeletal muscle mass, more 
participants, and a longer supplementation and training period might have been necessary to 
detect the possible anabolic benefits of PA over a placebo treatment. The necessity of subjecting 
ample participants to an extensive RE training regimen has been reiterated in a study by Hubal 
et al., revealing a wide range of muscular responses in both men and women to 12 weeks of 
progressive dynamic RE training (105). More research is needed to establish what mechanisms 
potentially underlie the PA-derived anabolic effects before this novel ‘nutraceutical’ compound 
might be applied as a potential intervention to counteract sarcopenia. Research should further 
explore the metabolic pathways through which PA might act in human skeletal muscle, through 
application of stable isotope tracer and muscle biopsy techniques to accurately measure the 
acute effects of PA on muscle protein turnover. Furthermore, research should establish what 
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the optimal dose and dosing strategy would be for PA to elicit its maximal skeletal muscle 
anabolic potential. 
 
1.6 Specific Thesis Objectives 
Based on the current gaps in our understanding of i) how dose and intake pattern of daily dietary 
protein differ between young and older individuals and contribute towards sarcopenia, ii) the 
mechanisms of age-related muscle anabolic resistance in sarcopenia, and iii) burgeoning 
interest in potential therapeutic strategies to counteract these deleterious age-related 
musculoskeletal phenomena, the studies presented in this thesis aimed to enhance our 
understanding on the mechanisms of and potential countermeasures to age-related muscle 
anabolic resistance to protein nutrition and exercise. Chapter 2 describes a study in which we 
determined dietary protein intake and patterns of consumption in healthy young and 
community-dwelling older individuals living in the Birmingham area. Three-day weighed food 
diaries were analysed to quantify daily and meal-specific protein intake in both younger and 
older individuals. Furthermore, given the importance of protein source on the ensuing muscle 
protein turnover response, the main protein sources consumed at each meal were assessed. We 
hypothesised that daily- and meal-specific relative protein intakes would be higher in younger 
compared with older individuals. Furthermore, we hypothesised that younger individuals would 
reach the threshold for maximal MPS stimulation more often than older individuals. Chapter 
3 describes a study in which myofibrillar protein synthesis (MyoPS) rates were determined in 
the postabsorptive state and in response to moderate-dose protein provision in young lean, older 
lean and older obese individuals. Furthermore, physical activity, whole-body/muscle metabolic 
health and inflammatory characteristics of these cohorts were established to see if these 
parameters were associated with MyoPS rates. We hypothesised that postprandial MyoPS rates 
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would be impaired in old lean, but to a greater extent in old obese, compared with young lean 
individuals, and therefore associated with levels of physical activity, adiposity and 
inflammation. Chapter 4 describes a study in which the acute effects of oral phosphatidic acid 
ingestion on MyoPS rates and intramuscular signaling at rest and after exercise were determined 
in healthy older individuals. We hypothesised that phosphatidic acid ingestion alone would not 
stimulate MyoPS, but would modulate RE-induced intramuscular signaling and MyoPS rates 
in older individuals compared with a placebo treatment. Chapter 5 discusses the main findings 
of the studies described in the previous chapters and provides an overview of the main 
conclusions. Practical implications and recommendations for further research are provided. 
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2.1 Abstract 
Background: Sub-optimal dietary protein consumption may partially underlie age-related 
muscle loss (sarcopenia). Specifically, dose, timing, and distribution of dietary protein across 
the day might play an important role in regulating muscle anabolism in older individuals. 
Purpose: The aim of the present study was to characterise daily and meal-specific dose and 
source of protein intake in young and older individuals. Methods: 30 healthy young (23.6 ± 4.2 
yrs) and 40 healthy community dwelling older (77.2 ± 6.8 yrs) individuals were recruited. 
Dietary intake was recorded via the completion of 3-day weighed food diaries. Absolute and 
relative daily and meal-specific protein intakes were compared against the current 
recommended daily allowance (RDA) of 0.80gkg-1body mass-1, and the recently outlined 
threshold for maximal muscle protein synthesis stimulation (0.24 gkg-1 and 0.4 gkg-1 in young 
and old respectively). Results: Average daily dietary protein intake was higher in young 
compared with older (1.52 ± 0.5 vs. 1.14 ± 0.4 gkg-1day-1; P = 0.002), and correlated with total 
energy intake in young only (r2 = 0.32, P < 0.001). Ninety-eight percent and 83% of young and 
older, respectively, met the RDA for protein of 0.8 gkg-1day-1, whilst 18% of young and 10% 
of older reported 3 daily meals with a protein content 0.24 and 0.4 gkg-1, respectively. Protein 
intake was uneven with 55% of young and older consuming the largest amount of protein at 
dinner. Main ingested protein source only differed between young and older at lunch 
(poultry/eggs and bread, respectively). Conclusion: Although the protein RDA was met by the 
majority of individuals, total protein intake and distribution across meals was lower in the older 
compared with young individuals, with important implications for maintenance of skeletal 
muscle mass.  
 76 
2.2 Introduction 
Dietary protein provision is essential to maintain skeletal muscle mass and overall health (23, 
53). In young individuals, protein provision robustly stimulates muscle protein synthesis (MPS) 
and, to a lesser extent, decreases muscle protein breakdown (MPB), resulting in an overall net 
muscle protein accretion (7). Constituent essential amino acids (EAA) in protein, particularly 
leucine, drive net muscle protein accretion through potent stimulation of MPS, insulin secretion 
and upregulation of intramuscular signaling events that enhance mRNA translational efficiency 
(1). Taken together, it is clear that dietary protein nutrition is vital for maintenance of skeletal 
muscle mass.  
 
Age-associated loss of skeletal muscle mass, strength and performance (sarcopenia; (46)) may 
be underpinned primarily by a blunted MPS response to protein-based nutrition (18, 49) that is 
exacerbated by illness (45) and lifestyle factors, such as inactivity (12) and bed rest (6). The 
current recommended daily allowance (RDA) for protein suggests 0.8 gkg-1day-1 to be 
“adequate” and to meet the metabolic demand of this macronutrient. However, recent studies 
suggest protein intakes above the current RDA, in the range of 1.0-1.5 gkg-1day-1, are 
associated with myriad health benefits for older individuals (4, 57). In addition to daily dietary 
protein intake, distribution of protein intake throughout the day is suggested to have a profound 
impact on MPS stimulation and overall net protein balance. It has been demonstrated that older 
individuals generally consume dietary protein in an uneven manner, with the majority of protein 
consumed in the evening meal (16). On a meal-by-meal basis, older individuals require a 
considerably greater protein dose (0.4 gkg body mass-1) to maximally stimulate MPS compared 
with the young (0.24 gkg body mass-1) (38). Thus, a more evenly distributed pattern of protein 
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intake through the day would, in theory, provide a greater muscle anabolic stimulus (43), 
although experimental evidence to support this notion is equivocal (31, 35).  
 
Alongside the dose and pattern of consumption, the source of dietary protein is an important 
determinant of the acute MPS response in young and older individuals (61). Specifically, the 
AA profile, absorption and digestive properties of ingested protein may determine the extent of 
MPS stimulation (10). Proteins that elicit a rapid increase in blood aminoacidemia/leucinemia, 
generally stimulate MPS to a greater extent than proteins with slower digestive properties or an 
inferior AA/leucine profile (9, 10). Therefore, it is generally accepted that most animal-derived 
proteins evoke greater MPS stimulation compared with plant-derived proteins (51, 61). In a 
Western diet, protein consumption primarily originates from meat and dairy products (25). 
These protein dense products, in contrast to plant-derived proteins, have an AA profile that 
closely matches the bodily requirements, and are hence capable of robustly stimulating MPS 
(13, 56). As most mixed meals consist of both animal- and plant-derived proteins, all EAA 
should be provided if meals are consumed in large enough quantities. However, older 
individuals experience a loss of appetite and chewing efficiency (36, 44), making it challenging 
to consume sufficient meal protein. Furthermore, cultural and/or geographical differences 
influence dietary intake, making it difficult to compare findings across studies where different 
populations and/or age-groups are being investigated (50). Therefore, a more pragmatic 
approach is required in outlining protein intake guidelines for older individuals, that should be 
formulated on a meal-by-meal basis. 
 
To date, information on alterations in dietary protein intakes across the life-span is scarce, and 
this may be hampering the development of tailored dietary advice for older individuals. The 
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majority of studies investigating dietary habits of older individuals; i) omit a young control 
group, making direct comparisons across age within the same cultural population difficult, ii) 
use 24 h dietary recall questionnaires to assess food intake, which may give inaccurate 
representation of habitual diet (55), and iii) is country- or culture-specific (16, 30, 52). 
Therefore, the aim of the present study was to directly compare the habitual dietary intake of 
healthy young and community dwelling older individuals living in the UK, with a focus on 
dietary protein intake. Further to this, we assessed meal-specific protein intake and source of 
intake at breakfast, lunch, dinner and snacks. We hypothesised that overall daily and meal-
specific protein intakes would be greater in younger compared with older individuals, resulting 
in a higher proportion of younger individuals reaching the theoretical threshold for maximal 
MPS stimulation compared with their older counterparts. Furthermore, we hypothesised 
consumption of animal-derived protein to be more prominent in younger compared with older 
individuals.  
 
2.3 Methods 
2.3.1 Participants 
Healthy young and healthy community dwelling older individuals were recruited from the 
Birmingham area (West Midlands, UK) to participate in the present study. Participants were 
aged between 18-35 yrs, or  70 yrs, and were eligible if deemed healthy as assessed by the 
outcome of a general health questionnaire, living independent, and ambulatory. All participants 
were informed on the study procedures and provided written consent prior to study 
commencement. Ethical approval was obtained through the University of Birmingham 
Research Ethics Committee (#13-1475A). The study conformed to the latest guidelines set by 
the Declaration of Helsinki (7th edition).  
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2.3.2Dietary Intake Recording 
Participant height and body mass were assessed to the nearest 0.1 cm and 0.1 kg, respectively, 
using a digital scale and stadiometer. Participants were provided with a 3-day weighed food 
diary, to be completed over 2 week-days and 1 weekend-day. All participants received written 
and verbal instructions on how to accurately complete the weighed food diary, which required 
participants to provide information on time, cooking method, brand, and weighed amount of all 
foods and drinks consumed during the 3-day period. Participants were provided with a set of 
kitchen scales (Wuwangni, WeiHeng, Hong Kong) to accurately determine the weight of foods 
and drinks ingested. 
 
2.3.3 Nutritional Data Analyses 
Weighed food diaries were analysed using Dietplan 7 software (Forestfield Ltd, West Sussex, 
UK, V7.00.46). Daily total energy intake, macronutrient and micronutrient composition data 
were generated. Dietary protein values were calculated relative to participant total body mass 
(gkg-1) and also as a relative percentage of total energy intake. Daily relative protein intake 
was compared with the current RDA for protein consumption (0.8 gkg-1day-1), and with an 
alternative recommendation (1.0 gkg-1day-1) (4), to determine the percentage of participants 
that met these recommendations. Daily dietary intake was divided into 4 time points; T1, T2, 
T3, and T4, respectively corresponding to breakfast (6.00h – 10.00h), lunch (11.30h – 14.30h), 
dinner (17.30 – 22.00h), and snacks (remainder of the day). Average protein intake was 
calculated for each specific time point, as was main source of protein consumed. Per meal 
protein intakes were compared against the 0.24 gkg-1 and 0.40 gkg-1 threshold for maximal 
MPS stimulation in young and older individuals (38), respectively, to assess the proportion of 
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individuals that managed or failed to reach this threshold. The most commonly consumed 
protein sources at each time point were determined for each individual. This was accomplished 
by ranking all dietary foods consumed over the 3-day period according to the total amount of 
protein they provided. The top five protein sources per meal were consequently determined and 
presented as a percentage of total protein intake for the respective meal. 
 
2.3.4 Statistical Analysis 
Data were analysed using Graphpad Prism V7.0 (Graphpad Software, CA, USA). Within group 
differences for meal-specific protein intake were identified using a 1-way repeated measures 
ANOVA, between group differences for meal-specific protein intake were analysed using a 2-
way ANOVA. Differences between groups for total intakes were assessed using t-tests. 
Pearson’s correlations were calculated to determine relationships between protein intake and 
total energy intake (TEI). Sidak post hoc analyses were utilised to determine differences within 
and between group differences. A test of two proportions was used to determine differences in 
proportions between both groups. Significance was set at P < 0.05. All values are expressed as 
mean ± SD or SEM. 
 
2.4 Results 
2.4.1 Participant Characteristics 
Participant characteristics are presented in Table 2.1. In total, complete data for 70 participants, 
40 young and 30 older, was analysed. Data from males and females was pooled for analysis 
due to no observed differences in average dietary protein intake, sources of protein intake or 
distribution pattern between males and females in young and older cohorts. No differences were 
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found between height and weight. However, older individuals had a significantly higher BMI 
compared with the young (P = 0.042). 
 
Table 2.1. Participant characteristics 
 
 YOUNG OLD 
Sample size (N) 40 30 
Male/Female (N/N) 26/14 13/17 
Age (y) 23.6 ± 4.2  77.2 ± 6.8** 
Weight (kg) 70.7 ± 11.9 71.7 ± 12.2 
Height (cm) 173.2 ± 8.4 169.7 ± 8.3 
BMI (kgm-1) 23.4 ± 2.6 24.8 ± 2.9* 
 
* indicates a significant difference from young (* P < 0.05, **P < 0.01). Values are presented 
as means ± SD. 
 
2.4.2 Dietary Energy and Macronutrient Intake 
No differences were found between young and older individuals for daily total energy intake 
(TEI) or carbohydrate intake. Dietary fat intake (as a proportion of TEI) was significantly 
greater in older compared with young individuals (P = 0.006). Significant differences were 
observed for absolute and relative daily protein intake, which were 35% (P = 0.002) and 32% 
(P < 0.001) greater in young compared with older individuals. In the young, both absolute and 
relative daily protein intake significantly correlated with TEI (r2 = 0.32, P < 0.001 for both), 
whilst no correlation was found in older individuals. The current RDA for protein intake of 0.8 
gkg-1day-1 was met by 98% in young and 83% in older individuals (Figure 2.1). However, 
the alternative recommendation of 1.0 gkg-1day-1 (27) were met by 83% and 60% in young 
and older, respectively. Examining relative protein intake in young and old on a meal-by-meal 
basis against the proposed threshold for maximal MPS stimulation (38) (0.24 gkg-1 in young 
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and 0.40 gkg-1 in older), resulted in a 38%, 73% and 86% accomplishment in young, and 
12%, 28% and 58% accomplishment in older for T1, T2 and T3, respectively. This was 
indicative of a significantly higher proportion in young compared with older to meet this 
threshold at each time point (P < 0.001 for all). An overview of average daily energy and 
macronutrient intakes is provided in Table 2.2. 
 
Figure 2.1: Average daily protein intake in healthy young and healthy community dwelling 
older individuals, expressed relative to body mass. Dashed line indicates current recommended 
daily allowance for dietary protein allowance of 0.8 gkg-1day-1. * indicates significantly 
different from old, P < 0.05. Values are presented as individuals and means ± SEM. 
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Table 2.2. Average daily energy and macronutrient intakes in young and old 
 YOUNG OLD 
Total Energy Intake (kcal) 2223 ± 454 2212 ± 482 
Total Protein Intake (g) 109 ± 44 81 ± 25* 
Protein Intake (gkg-1) 1.52 ± 0.5 1.14 ± 0.4** 
Protein (% TEI) 19 ± 7 15 ± 3** 
Total CHO Intake (g) 241 ± 76 238 ± 66 
CHO intake (gkg-1) 3.56 ± 1.2 3.42 ± 1.2 
CHO (% TEI) 43 ± 8 44 ± 6 
Total Fat Intake (g) 86 ± 22 91 ± 24 
Fat Intake (gkg-1) 1.25 ± 0.3 1.30 ± 0.4 
Fat (% TEI) 33 ± 7 38 ± 7** 
Total alcohol intake (g) 17 ± 22 9 ± 8 
Alcohol (gkg-1) 0.25 ± 0.34 0.13 ± 0.12 
Alcohol (% TEI) 5 ± 6 3 ± 3 
 
TEI; total energy intake, CHO; carbohydrate. * indicates a significant difference from young 
(* P < 0.05, **P < 0.01). Values are presented as means ± SD. 
 
2.4.3 Dietary Protein Distribution 
Daily dietary protein intake was distributed unevenly across the day with 15, 29, 43, and 13% 
of protein in young and 20, 29, 41, and 10% of protein in older individuals being consumed at 
T1, T2, T3 and T4 respectively. In young, both absolute and relative protein intake were greater 
at T2 (P < 0.001 for both) and T3 (P < 0.001 for both) compared with T1, and were greater at 
T3 compared with T2 (absolute P = 0.01; relative P = 0.006). Furthermore, absolute and relative 
protein intake in the young were lower at T4 compared with T2 (P < 0.001 for both) and T3 (P 
< 0.001 for both). In older individuals, absolute and relative protein intake were greater at T3 
compared with T1 (P < 0.001 for both). Protein ingested at T4 in older individuals was 
significantly lower compared with T1 (P = 0.004), T2 (P < 0.001) and T3 (P < 0.001). 
Significant differences between young and older individuals were only observed at T2 for 
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relative protein intake (P = 0.049), and at T3 for absolute (P = 0.009) and relative (P = 0.023) 
protein consumption. Meal-specific protein intakes are presented in Figure 2.2. 
 
 
Figure 2.2: Meal-specific average protein intakes in healthy young and healthy community 
dwelling older individuals. Dashed lines represents threshold protein intakes of 0.24 gkg-1 and 
0.4 gkg-1, suggested for maximal stimulation of MPS in young and older, respectively (38). * 
indicates significantly different from T1, † indicates significantly different from T2,   indicates 
significantly different from T3, # indicates significantly different from young. Values are 
presented as means ± SD. Significance was set at P < 0.05.
T1 T2 T3 T4
0.0
0.2
0.4
0.6
0.8
1.0
P
ro
te
in
 in
ta
k
e
 (
g
×k
g
-1
×B
W
-1
)
YOUNG
OLD
#
#
*†
†
* *
* z†
*†
 85 
2.4.4 Patterns of Dietary Protein Intake 
The uneven daily protein distribution in both young and older resulted in 9 observed protein 
intake patterns (Figure 2.3). Approximately 93% and 90% in young and older, respectively, 
distributed their daily protein intake according to one of three most frequently observed intake 
patterns. In young, 55% and 28% of individuals consumed the largest portion of protein at T3 
and T2, respectively, resulting in following daily protein distributions; 16%, 26% 58% and 
19%, 48%, 33%. Similar findings were observed in older individuals with 60% and 20% of 
individuals consuming the largest proportion of protein at T3 and T2, respectively, resulting in 
daily protein distributions of 21%, 27%, 52% and 14%, 52%, 34%. 
 
2.4.5 Common Sources of Dietary Protein Intake 
Table 2.3 represents the 5 most commonly consumed protein sources at each meal for young 
and older individuals for each meal. At T1, young and older, primarily consumed animal-
derived proteins in the form of milk. At T2, young mainly consumed animal-derived proteins 
(poultry/eggs), whereas older individuals predominantly ingested plant-derived proteins 
(bread). No major differences were observed at T3, with animal-derived proteins being the 
commonly ingested protein source. Protein intake at T4 in young was mainly derived from 
protein supplements (liquid and solid-form), whereas milk was the predominant protein source 
in older individuals. 
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Table 2.3. Top 5 most commonly consumed protein sources during breakfast (T1), lunch (T2), dinner (T3) and snacks (T4) in young and old. 
YOUNG OLD 
T1 T2 T3 T4 T1 T2 T3 T4 
Milk 
(30%) 
Poultry/eggs 
(30%) 
Poultry/Eggs 
(41%) 
Protein 
supplement 
(22%) 
Milk 
(67%) 
Bread 
(30%) 
Poultry/Eggs 
(30%) 
Milk 
(70%) 
Bread 
(19%) 
Fish 
(22%) 
Red meat/Pork 
(32%) 
Milk 
(19%) 
Bread 
(13%) 
Fish 
(27%) 
Red Meat/Pork 
(30%) 
Chocolate 
(7%) 
Poultry/Eggs 
(11%) 
Bread 
(19%) 
Pizza 
(8%) 
Cake/Biscuits 
(19%) 
Yogurt 
(7%) 
Poultry/Eggs 
(17%) 
Fish 
(27%) 
Nuts 
(3%) 
Yogurt 
(8%) 
Red Meat/Pork 
(19%) 
Fish 
(5%) 
Oats/Cereal 
(5%) 
Oats/Cereal 
(7%) 
Vegetarian Meat 
Substitutes 
(7%) 
Vegetarian Meat 
Substitutes 
(3%) 
Prawns 
(3%) 
Cheese 
(5%) 
Vegetarian 
Meat 
Substitutes 
(3%) 
Yogurt 
(5%) 
Nuts 
(5%) 
Poultry 
(3%) 
Cheese 
(5%) 
Bread 
(3%) 
Cheese 
(3%) 
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2.4.5 Common Sources of Dietary Protein Intake 
Table 2.3 represents the 5 most commonly consumed protein sources at each meal for young 
and older individuals. At T1, young and older, primarily consumed animal-derived proteins in 
the form of milk. At T2, young mainly consumed animal-derived proteins (poultry/eggs), 
whereas older individuals predominantly ingested plant-derived proteins (bread). No major 
differences were observed at T3, with animal-derived proteins being the commonly ingested 
protein source. Protein intake at T4 in young was mainly derived from protein supplements 
(liquid and solid-form), whereas milk was the predominant protein source in older individuals.
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Figure 2.3. Percentage of healthy young and community dwelling older individuals in each category of protein intake. Patterns depicted above 
each bar represent the relationship between breakfast, lunch and dinner, respectively, in each category
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2.5 Discussion 
In the present study, dietary intake in young and older individuals was assessed over a 3-day 
period by means of weighed food diaries. Whilst no difference was found between groups for 
TEI, young consumed more protein on a daily basis than older individuals. Evaluation of dietary 
protein intake revealed that 98% and 83% of young and older individuals, respectively, met the 
protein RDA of 0.8 gkg-1day-1. However, the pattern of daily protein intake was uneven in 
young and older, and indicative of a sub-optimal protein distribution for maximal stimulation 
of MPS in older individuals at breakfast and lunch (i.e. ≤0.4 gkg-1). Protein sources consumed 
were similar between groups at all time points except for T2, at which young consumed larger 
amounts of animal-derived protein compared with older individuals.  
 
Adequate protein nutrition is key to maintaining skeletal muscle mass in older individuals (29). 
Our data demonstrate that both absolute and relative daily protein intake was higher in young 
compared with older individuals, with no difference in TEI. Previously, others have reported 
lower relative protein intakes in older compared with younger individuals (47). However, in 
this latter study information on TEI and other macronutrients was omitted, making it difficult 
to deduct whether older individuals might have compensated for the reduced protein intake 
through consumption of different macronutrients. Herein, we demonstrate that older individuals 
negate the energy deficit instigated by a decreased protein intake through increased fat intake. 
In addition, protein intake and TEI were positively correlated in young but not in older 
individuals. This might suggest that merely increasing TEI in older individuals would not be a 
viable strategy to augment protein consumption. Instead, prioritising changes in the dietary 
composition (i.e. substituting nutrients high in fat for protein-dense foods) could be a more 
practical approach to increase total protein intake in older individuals. To date, an adequate 
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protein consumption is defined as a protein intake that meets, or exceeds, the RDA of 0.8 gkg-
1day-1. In the present study 98% and 83% of younger and older individuals, respectively, met 
this guideline, and were therefore considered to have adequate protein intake. However, in 
recent years, mounting evidence has emerged advocating improved musculoskeletal 
adaptations with higher protein intakes (29). In light of these findings, we assessed daily relative 
protein intake to an alternative RDA of 1.0  gkg-1day-1 (27), and observed that 15% and 23% 
fewer younger and older individuals, respectively, met this alternative guideline. Put 
differently, 60% of older individuals met the alternative guideline for protein intake, clearly 
emphasizing the need for strategies to promote and encourage an increase in dietary protein 
intakes in a large proportion of older individuals. Increasing dietary protein intakes up to, or 
beyond, the suggested alternative RDA of 1.0 gkg-1day-1, might be a viable approach to 
attenuate the sarcopenic progression. 
 
The accurate assessment of dietary intake is key in the development of future dietary guidelines. 
In the present study, participants were provided with a set of weighing scales and asked to 
record the weight of all foods and drinks consumed over a three-day period. Although this 
method allowed for a meticulous assessment of dietary intake, some disadvantages need to be 
addressed (5). Individuals who are not used to cooking on a regular basis, and are hence not 
familiar with weighing out foods, might have found this a complex and time-consuming method 
to assess dietary intake. The demanding nature of recording the weight of all foods and drinks 
consumed might have impacted (un)intentionally one’s dietary behaviour (15, 41). Finally, the 
onerous task of keeping a weighed food diary, limits the period over which food intake can be 
assessed, as it needs to be balanced against the likelihood of poor compliance (41). Based on 
the Harris-Benedict equation modified for light physical activity, the younger and older 
 91 
individuals in the present study would have had a daily energy expenditure of approximately 
2520 and 1959 kcal, respectively (28). These values are in line with the energy intakes of 2223 
and 2212 kcal presently reported in young and older individuals, respectively. Furthermore, 
similar dietary intake values have been previously reported in a study by Cardon-Thomas (16) 
et al. and in a study by Tieland et al (52). Based on the above information, it is safe to assume 
dietary intake has been reported accurately in the present study. 
 
Beyond total daily protein intake, per-meal protein intake has a significant impact on acute 
muscle protein turnover and, thus, skeletal muscle mass gains (2, 35, 37). The idea that per-
meal protein intake in older individuals is an important determinant of muscle protein accretion 
is supported by a study revealing a positive association between leg lean mass and the number 
of meals ingested containing a protein dose of at least 30g (34). Whereas this latter study 
employed an absolute protein dose of 30g as cut-off point, we decided to utilise a threshold 
value based on a relative protein-dose for maximal MPS stimulation. This threshold value is 
expressed relative to body mass, and thus takes into account the possibility that heavier 
individuals might require a higher protein dose to meet the metabolic demand for this 
macronutrient. In the present study, protein threshold values were 0.24 and 0.4 gkg-1 for young 
and older individuals, respectively, as outlined by Moore et al. (38). The ability to meet, or 
exceed, this threshold 3 times on one of the measured days was only achieved by 18% of young 
and 10% of older individuals. Alarmingly, only four young and one older individual(s) met 
their respective threshold for maximal MPS stimulation with every main meal over the entire 
3-day measurement period. Comparing average protein intakes per meal revealed that older 
individuals attained their respective threshold at dinner (T3) only, whereas young individual 
reached their threshold at lunch (T2) and dinner (T3). These observations reiterate the need for 
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meal-specific guidelines in older individuals. Promoting a more even distribution of dietary 
protein across the day might be of importance to maintain an elevated anabolic response in 
older individuals. 
 
In the present study, daily protein consumption in younger and older individuals was uneven 
across the day, with the majority of protein consumed at T3. These data are consistent with 
recent observations in British (16), Dutch (52), and American (42, 43) cohorts of older 
individuals of varying health status. However, two longitudinal studies have challenged the 
superiority of an evenly distributed protein intake across the day, and have revealed no benefit 
of an even compared with uneven daily protein distribution in older individuals (3, 11). These 
conflicting results could be explained by the fact that meals in the evenly spread protein group 
were <0.4 gkg-1, and hence not fully saturated MPS. Furthermore, Kim et al. (33) recently 
investigated the effects of uneven vs. even protein distribution over 8 weeks in older individuals 
on muscle mass accretion, strength and function. Even though the per meal protein dose in the 
evenly spread condition in this study was sufficient to theoretically maximize MPS in older 
individuals, no differences were observed between groups in muscle mass, strength or function. 
These results aligned with earlier acute work from the same group, demonstrating no 
differences in the MPS response to even and uneven protein ingestion patterns (32). The authors 
argued that higher protein intakes might be required in the context of a mixed meal to further 
enhance the muscle anabolic response in older individuals and that an 8-week intervention 
period might not have been long enough to detect any significant changes between both the 
even and uneven protein intake group. Indeed, a study by Dillon and colleagues where older 
females were supplemented over a 12-week period with EAA did find increases of 1.7 kg in 
lean body mass (20). As sarcopenia is characterized by a loss of muscle mass over several years, 
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it is important to consume protein intake doses capable of saturating acute MPS responses with 
every meal throughout the life-span.  
 
The premise underpinning the superiority of an evenly spread protein consumption throughout 
the day is based on a cut-off, or threshold, value sufficient to elicit a maximal MPS stimulation 
(in this case 0.24 and 0.4 gkg-1 in young and older individuals). That this amount of protein 
would elicit a maximal muscle anabolic response is somewhat presumptuous, as postprandial 
muscle protein accretion may also be dictated by rates of MPB (8). Protein ingestion provides 
a stimulus that increases MPS and, to a lesser extent, decreases MPB (59). The anti-proteolytic 
effect upon protein ingestion is thought to be mediated by insulin secretion, of which a small 
amount may also contribute toward postprandial MPS rates (26). However, the role of 
postprandial insulin secretion in the regulation of muscle protein turnover may be impaired with 
ageing (24, 58). Therefore, one could assume that increasing protein consumption beyond the 
point of MPS saturation in older individuals might promote an insulinemic response that would 
attenuate MPB (19). To date, it is yet to be elucidated if protein intakes beyond the threshold 
of 0.4 gkg-1 in older individuals have the potential to instigate a greater positive net protein 
balance leading to long-term muscle mass accretion/maintenance. 
 
Not only are protein dose and timing of major importance to augment MPS, the specific protein 
source ingested will significantly influence the extent to which MPS is stimulated. High-quality 
proteins, able to robustly stimulate MPS, are defined by rapid absorption/digestion kinetics, and 
a high proportion of EAA and leucine (10, 21). Based on these characteristics, most animal-
derived proteins are considered a “high-quality” protein, whilst plant-based proteins are in most 
cases considered a “lower-quality” proteins (40). In addition, the proportion of AA required by 
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the human body corresponds more closely to the AA profile observed in animal-derived 
proteins, whilst plant-based proteins might contain insufficient amounts of certain AA to 
support bodily functioning (56). Identifying the most commonly consumed dietary protein 
sources in older and younger individuals could be an important step forward in the search for 
novel strategies to increase or maintain muscle mass with age. In the current study, most meals 
consisted of both animal- and plant-based protein sources, theoretically providing all the EAA 
needed (56). Furthermore, no differences were observed in the predominant protein sources 
consumed at T1 and T3 between young and older individuals. However, at T2, more plant-
based proteins (mainly in the form of bread) were consumed by older compared with younger 
individuals. Bread and most grain-based products can be considered low-quality proteins due 
to their low protein-digestibility-corrected amino acid score (48). Therefore, substituting these 
low-quality proteins for higher quality proteins might enhance skeletal muscle anabolism in 
older individuals. Protein sources contributing to snacks were generally animal-derived in both 
groups, with 70% originating from milk in older and 22% from whey protein supplements in 
younger individuals. Both these protein sources are considered high-quality proteins, and are 
able to robustly stimulate MPS in young and older individuals (14, 22). However, maximal 
stimulation of MPS requires greater protein intakes in older compared with young individuals 
(60). In light of this, and taking into account that the majority of milk products consumed as a 
snack in older individuals were additives to tea or coffee, it is unlikely for this dose to evoke a 
robust increase in MPS. In contrast, whey protein supplementation in younger individuals 
would have provided a high-quality protein dose of ~15-25g per serving, sufficient to fully 
saturate MPS (39). In summary, our results suggest that protein source only differed at lunch 
between young and older individuals. Therefore, it is most likely the reduced amount of protein 
consumed with each meal rather than the protein source that contributes to the observed age-
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related muscle loss. Future protein intake recommendations for older individuals should hence 
prioritise total per-meal protein rather than protein source. 
 
The notion that there may be sex-specific differences in dietary protein intake and pattern of 
consumption between young and older individuals was not reinforced by our findings. 
Previously, others have reported lower relative protein intakes in older compared with younger 
males, but no difference between young and older females (47). In contrast, our data showed 
similar dietary protein intakes, sources, and patterns of distribution between males and females 
in each cohort, hence why we chose to pool data from males and females for analysis. The 
reason for this discrepancy may relate to potential differences in participant physical activity 
and training status between studies. Although we did not assess physical activity or training 
status of cohorts in the present study, it is likely that a greater proportion of young were engaged 
in higher intensity activity/exercise compared with older individuals. This may explain the 
observation that 18% of younger individuals consumed supplemental protein (predominantly 
whey-based) on at least one of three measured days at T4, with the aim of supporting training-
induced muscle remodelling (17). Nonetheless, dietary protein intakes remained significantly 
greater in young compared with older individuals when supplemental protein was removed 
from dietary analysis (1.49 vs 1.14gkg-1day-1 in young and older, respectively, P = 0.002). 
 
In addition to the recommended increase in the absolute amount and distribution pattern of 
dietary protein intake, it is important to consider lifestyle strategies to maximise the muscle 
anabolic response to sub-optimal protein ingestion in older individuals, that may improve or 
maintain long term musculoskeletal health and function. In an acute setting, it has previously 
been demonstrated that 45 min of moderate-intensity treadmill walking enhanced the  muscle 
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protein synthetic response to a subsequent mixed protein-carbohydrate feed in older individuals 
(54). More recently, it was demonstrated that the combination of resistance training with protein 
supplementation was required to increase muscle mass in older individuals (53), which is 
supported by a recent meta-analysis by Cermak and colleagues (17). Taken together, these 
results indicate the potential benefits of adding resistance or endurance exercise to a nutritional 
intervention to maximise muscle accretion in older individuals. Embracing the synergism 
between protein nutrition and exercise offers the most potent means of maintaining 
musculoskeletal mass, strength and function in old age. 
 
In conclusion, protein intake in the majority of young and older individuals generally met or 
exceeded current protein recommendations, even though relative and absolute protein intakes 
were greater in the young. Whilst TEI did not differ between groups, a positive correlation with 
total protein intake was found in young but not older individuals. Protein distribution 
throughout the day was uneven in both groups, with the majority of protein consumed at dinner 
and lunch (T1<T2<T3). Although the predominant protein sources ingested at each main meal 
were generally similar, except for lunch, older individuals ate considerably less protein at lunch 
and dinner. Increasing and ensuring an even distribution of protein intake across meals might 
be an effective strategy to maximally stimulate MPS in older individuals and attenuate age-
related muscle loss. Future research should further elucidate if increasing protein intake to 
levels that exceed MPS saturation would result in an augmented net protein balance, and hence 
lead to better maintenance of muscle mass over time in older individuals. Furthermore, research 
should explore the potential additive effects of exercise (endurance and resistance) when 
combined with a nutritional intervention. 
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3.1 Abstract 
Background: Age-related muscle loss (sarcopenia) may be partly underpinned by a diminished 
muscle anabolic response to protein nutrition, the cause of which is unclear. Purpose: The study 
aim was to determine the influence of old age and obesity on myofibrillar protein synthesis 
(MyoPS). Methods: Ten old lean (OL: 71.7 ± 6 yrs), 7 old obese individuals (OO: 69.1 ± 2 yrs) 
were 18 young lean controls (YL: 25.5 ± 4 yrs) were recruited. Anthropometrics, insulin 
resistance systemic inflammation, habitual diet and physical activity were determined. Skeletal 
muscle biopsies were obtained prior-to and 4h after ingestion of 15g of milk protein during a 
primed-continuous infusion of L-[ring-13C6]-phenylalanine. Results: Whole-body and regional 
fat mass, insulin resistance and systemic inflammation were greater in OO compared with YL 
and OL. Relative fat-free mass and Type I and II fibre CSA was lower in OL and OO compared 
with YL (P < 0.01) and Type II fibre intramyocellular lipid coverage was significantly greater 
in OO compared with YL and OL (P < 0.01). Daily step-count was lower in OO compared with 
YL and OL (P < 0.01). Postprandial MyoPS rates increased above postabsorptive values by 
81% in YL and 37 % in OL, respectively (P < 0.01), with no increase in OO. Postprandial 
MyoPS correlated positively with step-count (r2 = 0.26, P = 0.036) and negatively with leg fat 
mass (r2 = 0.4, P < 0.01) in OO and OL. Conclusion: Age-related muscle ‘anabolic resistance’ 
to protein nutrition may be exacerbated in obese inactive individuals.  
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3.2 Introduction 
Age-related muscle loss (sarcopenia (37)) leads to functional impairment, increases the risk of 
falls/fractures and metabolic disease and is associated with mortality (21, 23, 29, 30). As the 
number of older individuals globally dramatically over the next 30 years, so too will the 
prevalence of sarcopenia, placing a significant strain on healthcare resources (16, 24). Skeletal 
muscle proteostasis is a tightly coupled interplay between muscle protein synthesis (MPS) and 
muscle protein breakdown (MPB). Although there is no detectable change in postabsorptive 
rates of MPS or MPB in old age (49), recent studies demonstrate that a diminished MPS 
response to protein/amino acid provision in the old may underlie the progression of sarcopenia 
(11, 25). This age-related muscle ‘anabolic resistance’ is more apparent in response to low-to-
moderate dose protein intake, commonly consumed in the diet of older individuals (33, 40, 46). 
The underlying mechanisms of age-related muscle anabolic resistance are unclear, but are 
essential to understand in order to develop targeted therapeutic strategies to improve age-related 
musculoskeletal health. 
 
Although the aetiology of sarcopenia is undoubtedly multifactorial, there is contention as to the 
role of chronological and biological ageing (i.e. inactivity, malnourishment, disease) in this 
process (35). It is well accepted that chronological ageing is accompanied by declining physical 
activity levels interspersed by protracted periods of disuse (i.e. during illness/hospitalization) 
(17, 39). This is noteworthy, as it has been demonstrated that bed rest (43), limb immobilization 
(18) and reduced daily activity (6) induce muscle anabolic resistance and atrophy in older 
individuals, whereas acute treadmill walking restores postprandial muscle anabolic 
responsiveness (47). Thus, physical activity represents an important locus of control in age-
related MPS. To date, very few studies have assessed physical activity levels in conjunction 
with MPS in older individuals and, as such, any association between the two is lacking. 
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Sarcopenia is often accompanied by a concomitant increase in adiposity (3) and intramuscular 
fat infiltration (myosteatosis) (19), the confluence of which exacerbates the progression towards 
frailty and metabolic disease (27). Recently, Murton and colleagues (34) demonstrated a 
blunted MPS response to amino acid administration in obese vs. normal-weight older males. 
Furthermore, high-fat feeding, lipid administration and ectopic fat deposition induce muscle 
anabolic resistance in rodents and humans (1, 5, 42, 44), although postprandial MPS rates are 
not impaired in non-obese Type II diabetics (12, 28). Collectively, these data suggest that 
obesity, but not insulin resistance per se, may impair MPS, potentially through compromised 
muscle quality or elevated levels of adipose-derived inflammatory cytokines (‘adipokines’) 
(38). Currently, the interactive effects of myosteatosis, insulin resistance and inflammation on 
age-related muscle anabolic resistance are unclear and warrants further investigation. 
 
Therefore, the aim of the present study was to comprehensively assess the physical activity, 
whole-body/muscle metabolic health and inflammatory characteristics of i) young lean (YL), 
ii) older lean (OL) and iii) older obese (OO) individuals to establish for the first time whether, 
and to what extent, these parameters were associated with MyoPS rates in the postabsorptive 
state and in response to moderate-dose protein provision. We hypothesized that postprandial 
MyoPS rates would be impaired in OL, but more so in OO compared with YL, and would 
therefore be closely associated with levels of physical activity, adiposity and inflammatory 
markers. 
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3.3 Materials and Methods 
3.3.1 Participants 
In the present study, 10 lean older (OL) and 10 obese older (OO) individuals were compared 
against 18 young lean individuals (YL) (characteristics are provided in Table 3.1). Participants 
completed a general health questionnaire and were excluded from study participation if they 
had Type II Diabetes, uncontrolled hypertension, neuromuscular/cardiovascular/metabolic 
disease, or if they were smokers, losing weight or taking non-steroidal anti-inflammatory drugs. 
Participants were informed of the purpose and methodology of the study prior to providing 
written consent. Ethical approval was obtained through the NHS Black Country Research 
Ethics Committee (13/WM/0429). The study conformed to standards set by the Declaration of 
Helsinki (7th edition). Three OO participants were omitted from the study due the detection of 
one or more exclusion criteria during preliminary assessments (n=2), and non-collection of 
muscle biopsy tissue (n=1). 
 
3.3.2 Experimental Design 
Following an initial screening visit, participants reported to the Clinical Research Facility 
(CRF) of the Queen Elizabeth Hospital, Birmingham, on three separate occasions. During the 
initial visit, participants were given a weighed food diary, pedometer and accelerometer to 
record habitual food intake and physical activity/intensity over a four-day period. Five days 
following this initial visit, participants returned to the CRF for assessments of body 
composition, resting metabolic rate (RMR) and fasting plasma glucose and HbA1-C. On the 
third visit, participants underwent an experimental trial, comprising of a stable amino acid 
isotope tracer infusion with serial muscle biopsies and blood samples to determine basal 
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postabsorptive and postprandial MyoPS rates, intracellular signaling and muscle fibre/IMCL 
properties.  
 
3.3.3 Preliminary Assessments 
Body composition: Participants reported to the CRF at 0800 h, following a 10 h overnight 
fast, where body mass was first determined in loose clothing and without shoes to the nearest 
0.1 kg on an electronic balance scale. Height was measured to the nearest 0.1 cm using a 
stadiometer. Whole-body and regional fat mass, fat-free mass and visceral adipose tissue (VAT) 
was determined using dual energy x-ray absorptiometry (DXA) scanning (GE iDXA, GE 
Healthcare, Chicago, IL, U.S.). VAT was obtained by identifying the android/gynoid region 
and the horizontal plane by the area between the pelvis and the rib cage, with its vertical limits 
being the inner abdominal muscle wall. VAT is computed by substracting subcutaneous fat 
from the total android fat mass in the android region. Briefly, participants were placed in a 
supine position on the DXA scanner with their feet at shoulder width, secured with tape to avoid 
any discomfort. DXA scan duration was 7 min and all images were analysed by a trained 
radiographer. Obesity was defined by Body Mass Index of ≥ 30 kgm-2. 
Resting metabolic rate: Participants rested in a supine position for 30 min whilst expired gases 
were collected via a ventilated plastic hood and analysed for O2 and CO2 concentrations using 
a Moxus metabolic cart (AEI Technologies, Naperville, IL, U.S.), equipped with 
electrochemical gas analysers (AME-TEK model S-3A/1 and CD-3A). Breath-by-breath 
measurements were analysed for VO2 and VCO2 and values averaged over 30 sec periods using 
Moxus software (version 2.8.02). During RMR measurement, participants were instructed to 
lay as still as possible, breath normally, not to speak and stay awake. RMR was predicted using 
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the Weir equation (RMR = (3.94 x VO2) + (1.11 x VCO2)) and was based upon a five-minute 
measurement period where VO2 measurements showed the lowest coefficient of variation (51). 
Fasting plasma blood glucose and HbA1-C: Following RMR assessment, a 10mL venous 
blood sample was obtained to measure fasting plasma glucose and HbA1-C concentrations. 
Participants were excluded from study participation if fasting plasma glucose and HbA1-C 
values exceeded 7 mmol/L and 48 mmol/mol, respectively, indicating high-risk or presence of 
Type II diabetes (2). 
Physical activity/intensity levels: Participants were fitted with a wrist-worn accelerometer with 
a triaxial sensor (GENEActiv, ActivInsights, U.K.) for four consecutive days, including at least 
one weekend day. Accelerometers were initialized to sample data at a 10 Hz frequency. Data 
were downloaded onto a laboratory computer, converted into 60 second epochs and analysed 
using the GENEActiv software (version 2.2, ActivInsights). Activities were split into 4 
categories based upon the following metabolic equivalent (MET) values; i) sedentary activity 
(<1.5 METs) ii) light activity (1.5 – 3.99 METs) iii) moderate activity (4.0 – 6.99 METs) and 
iv) vigorous activity (>7 METs) (15). Furthermore, participants recorded their daily step count 
over four consecutive days using a hip-worn pedometer (Vital Steps, Omron Healthcare UK 
Ltd., Milton Keynes, U.K.).  
Dietary intake: Habitual dietary intake was assessed over a 4-day period. Participants were 
given a food diary and digital balance scales to record and weigh out their dietary and fluid 
intake. Food diaries were analysed using Dietplan software (Dietplan 7, Forestfield software 
Ltd, U.K). 
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3.3.4 Experimental trial 
The evening prior to the experimental trial, participants consumed a standardised evening meal 
(787 kcal) composed of ~19% protein (~37.5 g), ~46% carbohydrate (~90.7 g) and ~35% fat 
(~30.8 g). After a ~10-12 h overnight fast and having refrained from any strenuous activity for 
the previous 48 h, participants reported to the CRF at 0730 h having driven or taken public 
transport to ensure that resting MyoPS rates were maintained. Upon arrival, a 21G cannula was 
inserted into an antecubital vein of both forearms. One cannula was used for serial blood 
sampling throughout the day, whilst the other was used to administer a primed continuous 
infusion of L-[ring-13C6] phenylalanine (prime dose 2 molkg-1; continuous infusion 0.05 
molkg-1min-1; Cambridge Isotope Laboratories, Andover, MA, USA), which was initiated 
after obtaining a fasted resting blood sample. Further blood samples were drawn at -160, -95, -
35, -5 min prior to consumption of a milk protein beverage (described below) and 20, 40, 60, 
90, 120, 180 and 240 min post-beverage consumption. A total of 10 mL of blood was sampled 
at each time point and arterialised by heating the forearm to ~60C. Blood samples were 
collected in serum separator and ethylenediaminetetraacetic acid (EDTA) treated vacutainers 
(BD, Oxford, U.K.), centrifuged at 3000 rpm for 10 min at 4C, and plasma and serum aliquots 
were stored at -80C until further analyses. At 150 min into the infusion a muscle biopsy was 
obtained from quadriceps vastus lateralis of a randomly selected leg under local anaesthesia 
(1% lidocaine) using the Bergrström technique. Muscle biopsy samples were freed from any 
visible blood, adipose and connective using ice-cold saline and snap-frozen in liquid nitrogen 
before being stored at -80C. A separate piece of muscle tissue (~20mg) was mounted in O.C.T 
compound (VWR Chemicals, Leuven, Belgium) and frozen in 2-methylbutane (Sigma-Aldrich) 
before being stored at -80C for immunohistochemical analyses. Immediately after biopsy 
obtainment, participants consumed 15 g of milk protein isolate (MyProtein, Cheshire, U.K.) 
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dissolved in 300 mL of water. The amino acid content of the milk protein isolate was (as 
percentage content) Ala, 3.0; Arg, 3.7; Asp, 7.4; Cys, 0.9; Gln, 9.1; Gly, 1.7; His, 2.3; Ile, 5.6; 
Leu, 9.8; Lys, 8.7; Met, 2.6; Phe, 4.7; Pro, 9.9; Ser, 5.3; Thr, 3.8; Trp, 1.7; Tyr, 4.6; and Val, 
6.0, providing 13.6g of amino acids in total. A small amount of L-[ring-13C6] phenylalanine 
tracer (28.2mg to enrich to 4%) was added to the drink to minimize changes in 13C6 
phenylalanine enrichment. Following drink consumption, participants rested in a supine 
position for the remainder of the trial. Approximately 240 min after drink consumption, a 
second biopsy was obtained ~3 cm proximal to the first biopsy and indicated the end of the 
experimental trial.  
 
3.3.5 Blood Analyses 
Blood analyte and hormone concentrations 
Fasting plasma glucose was analysed by enzymatic colorimetric assay (Glucose Oxidase kit, 
Instrumentation Laboratories, Cheshire, U.K.) using an ILAB 650 Clinical Chemistry Analyzer 
(Instrumentation Laboratory, Warrington, U.K.). Plasma HbA1-C concentration was analysed 
via a Tosoh G8 HPLC semi-automated analyser (Tosoh Bioscience, Pennsylvania, U.S.). Serum 
interleukin-6 (IL-6), C-reactive protein (CRP) and insulin concentrations were measured using 
commercially available enzyme-linked immunosorbent assay (ELISA) kits (IL-6: R&D 
systems Europe, Abingdon, U.K.; CRP: RayBiotech, Norcross, GA, U.S.; Insulin: IBL 
International, Hamburg, Germany) according to the manufacturer’s instructions.  
Plasma amino acid enrichment and concentrations 
Plasma [13C6] phenylalanine enrichment was determined by gas chromatography-mass 
spectrometry (GCMS; model 5973; Hewlett Packard, Palo Alto, CA, USA) by monitoring ions 
234/240. Briefly, 300 L of plasma was diluted 1:1 with acetic acid before being purified 
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through cation-exchange columns and dried down overnight under nitrogen. The purified amino 
acids were then converted to their N-tert-butyldimethyl-silyl-N-methyltrifluoracetamide 
(MTBSTFA) derivative. Simultaneously, leucine and phenylalanine concentrations were 
measured by GCMS using the internal standard method based on the known volume of plasma 
(300 μL) and internal standard (6 μL) added and the known amino acid concentration of the 
internal standard. The internal standards were U-[13C6] leucine (ions 302/308) and U-[13C9–
15N] phenylalanine (ions 336/346) added in a ratio of 100 μLml−1 of blood. 
 
3.3.6 Muscle Tissue Analyses 
Myofibrillar protein enrichment 
Approximately 30mg of muscle tissue was minced in 10μL/mg of homogenization buffer 
(50mM Tris-HCL, 1mM EDTA, 1mM EGTA, 10mM ß-glycerophosphate, 50mM sodium 
fluoride, 1 x protease inhibitor tablet, 0.5mM sodium orthovanadate, pH 7.5) on ice using small 
scissors and a Teflon pestle before being shaken for 10 min at 1500rpm at room temperature, 
and finally centrifuged at 11,000rpm at 4°C for 5 minutes. The supernatant containing the 
sarcoplasmic proteins was transferred to a 2 mL Eppendorf for intracellular signaling analysis 
(described below). A 500µL volume of doubly distilled water (ddH2O) was added to the pellet, 
which was vortexed and centrifuged at 4500rpm at 4°C for 5 min and the supernatant discarded. 
The myofibrillar fraction was separated from collagen by adding 1mL of 0.3M NaOH and 
heating for 30 min at 37°C. The sample was then spun at 13,000 rpm at 4°C for 20 min. This 
process was repeated twice and both resultant supernatants were transferred to a 4mL glass 
collection tube. Myofibrillar proteins were precipitated by adding 1mL of 1M PCA to the 
supernatant, which was vortexed and centrifuged at 3200 rpm at 4°C for 20 min. The pellet was 
then washed with 2mL of 70 % EtOH, centrifuges at 3200 rpm at 4°C for 20 min. The remaining 
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myofibrillar protein pellet was hydrolysed overnight at 110C in 0.1N HCL and 1mL of 
activated Dowex 50W-X8 100-200 resin (Bio-Rad laboratories INC, USA). Constituent amino 
acids in the myofibrillar fraction were purified on cation-exchange columns (Bio-Rad 
laboratories INC, USA). Amino acids in the myofibrillar fraction were then converted to their 
N-acetyl-n-propyl ester derivative and phenylalanine labeling determined by gas 
chromatography-combustion-isotope ratio mass spectrometry (GC-C-IRMS, Delta-plus XP, 
Thermofinnigan, Hemel Hempstead, UK). Ions 44/45 were monitored for unlabeled and labeled 
CO2, respectively.  
Fibre-type intramyocellular lipid 
Lyophilised bodipy (#D3922, Thermo Fisher, Leicestershire, U.K.) and Wheat Germ 
Agglutinin (WGA, Alexa Fluor 350, Thermo Fisher, Leicestershire, U.K.) were diluted in 
ethanol and ddH2O, respectively (1 mg/mL), and stored at -20C. Muscle cross sections were 
fixed for 60 min in 3.7% formaldehyde and washed 3 times in ddH2O. Muscle cross sections 
were then incubated for 5 min in 0.5% Triton X-100, and 2 h in myosin heavy chain type I 
antibody (M IgM; DHSB, Iowa, U.S [1:25 diluted in 5% normal goat serum and 1x PBS]) 
Subsequently, muscle cross sections were incubated for 30 min in goat anti mouse IgM 594 
(#A21044, Thermo Fisher, Leicestershire, U.K. [1:50 GAM IgM diluted in 1x PBS]), washed 
3 times 5 min in 1x PBS, incubated for 30 min in WGA stock solution (1:100 diluted in 1x 
PBS), washed as before, and incubated for 20 min in bodipy (1:50 stock solution diluted in 1x 
PBS). Coverslips (No1, VWR International, Leicestershire, U.K.) were mounted with 20l of 
mowiol; 6g glycerol, 2.4 g mowiol 4-88 and 0.026g 1,4 diazobicyclo-[2,2,2]-octane (DABCO) 
dissolved in 18 mL 0.2 mol/L Tris-buffer (pH 8.5) (Sigma-Aldrich, Dorset, U.K.). Images were 
taken with a Nikon Eclipse E600 (Nikon, Badhoevedorp, The Netherlands) at 40x zoom. Image 
Pro Suite version 5.1.2.59 was used to quantify fibre type, size and lipid droplet content.  
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Intramuscular signaling 
Western blotting was performed on the sarcoplasmic fraction obtained during isolation of the 
myofibrillar protein fraction (described above) with the protein concentration determined by a 
DC protein assay. Equal amounts of protein (30 μg) were boiled for 5 min in 1 x Laemmli 
sample buffer and separated on 7.5–10% gels by SDS-PAGE for 1 h. Following electrophoresis, 
proteins were transferred to a Protran nitrocellulose membrane (Whatman, Dassel, Germany) 
at 100 V for 1 h. Membranes were incubated overnight at 4C in following primary antibodies: 
phospho-S6K1 Thr389 (#9205), total 70 kDa S6 protein kinase (p70S6K1; #9202), phospho-
eukaryotic initiation factor 4E binding protein (4E-BP1) Thr37/46 (#9459), total 4E-BP1 
(#9452), phospho-eukaryotic elongation factor 2 (eEF2) Thr56 (#2331), total eEF2 (#2332), 
phospho-protein kinase B (Akt) Ser473 (#3787), total Akt (#9272) each purchased from Cell 
Signaling Technology [New England Biolabs (UK) Ltd, Hitchin, UK]. Membranes were then 
washed 3 times in TBST for 5 min, incubated for 60 min in their respective secondary antibody 
and washed 3 times 5 min again in TBST. Immobilon Western chemiluminescent HRP 
substrate (Merck Millipore, Watford, UK) was used to quantify protein content following IgG 
binding, visualized on a G:BOX Chemi XT4 imager using GeneSys capture software (Syngene, 
Cambridge, U.K.). A Chemi Genius Bioimaging Gel Doc System (Syngene) was used to image 
and quantify bands. 
 
3.3.7 Calculations 
The standard precursor-product method was used to calculate MyoPS rates from 13C6 
phenylalanine incorporation: 
FSR (%h-1) =  Eb / Ep x 1 / t x 100  
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Where  Eb in the above equation is the algebraic difference in the amount of bound 13C6 
phenylalanine between two biopsy samples, Ep is the precursor enrichment, and t is the time 
between muscle biopsies samples expressed in minutes. Mean plasma 13C6 phenylalanine 
enrichment from arterialised blood samples was used as the precursor enrichment. Pre-infusion 
plasma 13C6 phenylalanine enrichment was used as a proxy for basal muscle protein enrichment, 
an approach that has been previously validated in older individuals (8).  
 
3.3.8 Statistics 
Data analysis was performed using SPSS version 22 (IBM, Chicago, IL, USA) and Graphpad 
Prism (Graphpad software Inc. La Jolla, CA, USA). A Shapiro-Wilks was used to test the 
normality of the data. Subsequently, non-normally distributed variables were logarithmically 
transformed. Anthropometric, dietary, physical activity, metabolic health/inflammatory and 
muscle fibre characteristics were analysed using a one-way ANOVA. MyoPS rates and 
intracellular signaling data were analysed using a two-way, repeated measures ANOVA with 
one within (two levels; ‘basal’ and ‘postprandial’ state) and one between factor (three levels; 
group). Insulin, plasma amino acid and 13C6 phenylalanine enrichment were analysed using a 
two-way, repeated-measures ANOVA (time x group). Additionally, 13C6 phenylalanine 
enrichment were analysed using linear regression to assess the existence of any deviation in 
enrichment. Tukey’s HSD post hoc analysis was performed whenever a significant F ratio was 
found to isolate specific differences. Correlational analysis was performed using a tow-tailed 
Pearson Correlation Coefficient test. Significance for all analyses was set at P < 0.05. All values 
are presented as means  SD or SEM. 
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3.4 Results 
3.4.1 Anthropometric and Metabolic Health Characteristics 
Body mass, BMI, fat mass (relative and absolute) and visceral adipose tissue were significantly 
greater in OO compared with OL and YL (P < 0.05), with no differences between YL and OL. 
Fat-free mass (FFM), expressed relative to total body mass, was significantly lower in OO 
compared to YL and OL (P < 0.001 and P = 0.001, respectively). Leg FFM, expressed relative 
to total body mass, was lower in OO and OL compared with YL (P < 0.001 and P = 0.038, 
respectively) and was lower in OO compared with OL (P = 0.023). Plasma IL-6, CRP, glucose, 
serum insulin and HOMA-IR were significantly greater in OO compared with OL and YL (P < 
0.01). Resting metabolic rate (RMR) was significantly lower in OL compared with YL (P = 
0.015). Anthropometric and metabolic health characteristics are presented in Table 3.1. 
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Table 3.1. Anthropometric, body composition and metabolic health data. 
 YL OL OO 
Participants (M/F) 10/8 4/6 4/3 
Age (yrs) 25.5 ± 3.7 71.7 ± 6.2** 69.1 ± 2.6** 
Body mass (kg) 70.1 ± 12.9 64.5 ± 10.9 91.6 ± 15**†† 
BMI (kgm-2) 23.3 ± 2.4 22.7 ± 2.5 32.9 ± 4**†† 
Fat mass (% of body mass) 24.3 ± 6.5 28.3 ± 7.1 41 ± 2**†† 
Fat mass (kg) 16.8 ± 5.6 17.7 ± 4.4 36.7 ± 6.4**†† 
Leg fat mass (kg) 6.6 ± 2.5 5.8 ± 1.3 9.9 ± 2.1**†† 
Visceral adipose tissue (kg) 0.23 ± 0.15 0.58 ± 0.48 2.76 ± 1.44**†† 
Fat-free mass (kg) 49.7 ± 10 43 ± 9.6 50.3 ± 8.8 
Fat-free mass (% of body mass) 71 ± 6.3 66.5 ± 7.3 54.8 ± 2.1**†† 
Leg fat-free mass (kg) 16.7 ± 3.4 14 ± 3.6 17.1 ± 3.4 
Leg fat-free mass (% of body mass) 23.8 ± 2.14 21.6 ± 2.6* 18.6 ± 1.3**† 
HOMA-IR 2.28 ± 0.91 2.16 ± 0.98 6.10 ± 3.02**† 
Fasting plasma glucose (mmol/L) 5.3 ± 0.5 5.9 ± 0.5** 6.5 ± 0.3** 
Fasting serum Insulin (IU/mL) 9.7 ± 3.7 8.2 ± 3.5 21.1 ±**†† 
Plasma IL-6 (pg/mL) 0.43 ± 0.29 1.1 ± 0.51** 1.49 ± 0.71** 
Plasma CRP (mg/L) 0.37 ± 0.14 0.92 ± 0.34 2.34 ± 0.98**†† 
Plasma HbA1-C (mmol/mol) - 37.3 ± 3.9 38.3 ± 3.4 
RMR (kcal) 1681 ± 296 1276 ± 353* 1515 ± 449 
 
Values presented as mean ± SD.  BMI; Body Mass Index, IL-6; interleukin-6, CRP; C-reactive 
protein, RMR; Resting Metabolic Rate. * is significantly different from YL, † is significantly 
different from OL. * indicates P<0.05, ** P<0.01, † P<0.05, †† P<0.01.  
 
3.4.2 Physical Activity and Dietary Characteristics 
Average daily step-count was significantly lower in OO compared with OL and YL (P < 0.01). 
Relative and absolute time spent in ‘light’ intensity activity was significantly greater in OL com 
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pared with YL (P = 0.003), but not different from OO. Dietary protein intake was significantly 
lower in OO compared with YL (P = 0.009), but was not different from OL. No other 
differences in physical activity or dietary intake were found between groups. Physical activity 
and dietary characteristics are detailed in Table 3.2.  
 
Table 3.2. Activity and diet characteristics. 
 YL OL OO 
Daily step count 11870 ± 3905 11102 ± 3271 5399 ± 2079**†† 
Sedentary Activity (%) 70.8 ± 6.6 65.5 ± 13.8 74.9 ± 7.4 
Light Activity (%) 10.2 ± 2.1 15 ± 5.2* 11 ± 2.4 
Moderate Activity (%) 16.8 ± 5.2 18.4 ± 9.7 13.9 ± 5.9 
Vigorous Activity (%) 2.3 ± 2.8 0.8 ± 1.5 0.2 ± 0.1 
Sedentary Activity (min) 643 ± 56 594 ± 115 684 ± 104 
Light Activity (min) 93 ± 19 140 ± 50* 101 ± 24 
Moderate Activity (min) 153 ± 53 169 ± 89 126 ± 48 
Vigorous Activity (min) 21 ± 26 7 ± 14 2 ± 1 
Daily Energy Intake (kcal) 2162 ± 473 2091 ± 451 2412 ± 628 
Daily Protein (gkg-1) 1.51 ± 0.46 1.36 ± 0.37 0.95 ± 0.20** 
Daily CHO (gkg-1) 3.20 ± 1.22 3.38 ± 0.91 2.65 ± 1.25 
Daily Fat (gkg-1) 1.17 ± 0.33 1.29 ± 0.46 1.07 ± 0.40 
Daily Alcohol (gkg-1) 0.22 ± 0.22 0.22 ± 0.25 0.33 ± 0.25 
Daily Fibre (gkg-1) 0.30 ± 0.14 0.34 ± 0.10 0.24 ± 0.12 
 
Values presented as mean ± SD. * is significantly different from YL, † is significantly different 
from OL. * indicates P<0.05, ** P<0.01, † P<0.05, †† P<0.01. 
 
3.4.3 Muscle Fibre Characteristics and Lipid Content 
Type I and II muscle fibre cross-sectional area (CSA) was greater in YL compared with OO (P 
< 0.001) and OL (P < 0.001) and was significantly different between OO and OL (P < 0.001). 
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Type I fibre lipid droplet number was significantly greater in YL compared with OL (P < 0.001) 
and OO (P = 0.021), and was different between OL and OO (P < 0.001). Type II fibre lipid 
droplet number was significantly greater in YL and OO compared with OL (P < 0.001 for both) 
with no difference between YL and OO. When normalized to fibre CSA, Type I lipid droplet 
area was lower in OL compared to YL (P = 0.014) but not OO, whereas Type II lipid droplet 
area was significantly greater in OO compared with YL (P < 0.001) and OL (P = 0.042). Muscle 
fibre CSA and IMCL characteristics are presented in Table 3.3. Representative IMCL staining 
images are presented in Figure 3.1A-C. 
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Table 3.3. Muscle fibre and IMCL characteristics 
 
 
Values 
presented as mean ± SD. * is significantly different from YL, † is significantly different from OL, * indicates P<0.05, ** P<0.01, † P<0.05, †† 
P<0.01. 
 YL OL OO 
Type I fibre (%) 48 ± 16 49 ± 18 36 ± 15 
Type II fibre (%) 52 ± 16 51 ± 18 65 ± 16 
Type I area (m2) 4031 ± 1978 3009 ± 1251** 3421 ± 1528**†† 
Type I lipid droplet number 616 ± 458 412 ± 298** 533 ± 505*†† 
Type I lipid droplet area (m2) 287 ± 238 175 ± 159** 244 ± 267*†† 
Type I lipid droplet area (% fibre area) 7.7 ± 6 6.4 ± 6.3** 6.9 ± 6.5 
Type II area (m2) 4009 ± 1733 2170 ± 1243** 3390 ± 1199** †† 
Type II lipid droplet number 377 ± 399 242 ± 312** 415 ± 407†† 
Type II lipid droplet area (m2) 133 ± 157 76 ± 99** 201 ± 207** †† 
Type II lipid droplet area (% fibre area) 3.1 ± 2.8 3.2 ± 3.4 5.8 ± 5.4**†† 
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Figure 3.1: Intramyocellular lipid infiltration in YL (A), OL (B), and OO (C). The top panel 
represents the bodipy 493/503 stain. The second panel represents the wheat germ agglutinin 
alexa fluor 350 stain for the cell border. The third panel shows myosin heavy chain I stain. 
Bottom panel is a composite picture. Scale bars are 50m. 
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3.4.4 Plasma Amino Acid and Insulin Concentrations 
Plasma leucine and phenylalanine concentrations increased above basal fasted values after 
ingestion of 15 g of milk protein isolate (P < 0.001; Fig. 3.2A and 3.2B), peaking between 20-
40 min post-ingestion, with no difference between groups. Plasma leucine and phenylalanine 
concentrations had returned to basal fasted values by 180 and 90 min post-ingestion, 
respectively, with no difference between groups. Basal fasted serum insulin concentration was 
significantly elevated in OO compared with YL (P < 0.001) and OL (P < 0.001). Serum insulin 
levels increased above basal-fasted values at 20 min post-ingestion (P < 0.01 for all groups), 
returning to basal-fasted values by 60 min post-ingestion (Figure 3.2C). Absolute serum insulin 
values at 20 and 40 min post-protein ingestion were greater in OO compared with YL (P = 
0.004 and 0.016, respectively) and OL (P = 0.001 and 0.007, respectively). Plasma 13C6 
phenylalanine enrichment had increased above basal (-180 min) values 60 min after the 
initiation of the stable isotope tracer infusion (P < 0.001) and remained stable for the entire trial 
duration (Figure 3.2D). Linear regression analysis identified that the slopes of the plasma 13C6 
phenylalanine enrichment was not significantly different from zero, indicating the presence of 
an isotopic steady state (P = 0.3). 
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Figure 3.2: Plasma leucine concentration (A), phenylalanine concentration (B), serum insulin 
concentration (C) and plasma 13C6 phenylalanine enrichment (D) in experimental trials. At t = 
0, a 15g bolus of milk protein isolate was consumed. Values are means ± SEM. Significance 
was set at P < 0.05. ∗ is significantly greater than fasting values (-180 min), † is significantly 
greater in OO compared with other groups. 
 
3.4.5 Myofibrillar Protein Synthesis and Intramuscular Signaling 
Postabsorptive MyoPS rates did not differ between groups. Following ingestion of 15 g of milk 
protein isolate, MyoPS rates increased by 81 % in YL (0.049 ± 0.011 %h-1; P < 0.001) and 
38% in OL (0.042 ± 0.01 %h-1; P = 0.002), respectively, with no significant increase found 
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in OO (0.036 ± 0.006 %h-1; P = 0.11). Postprandial MyoPS rates were significantly greater in 
YL compared with OO (P = 0.02), but were not different between YL and OL (P = 0.21) or 
between OL and OO (P = 0.11; Figure 3.3A). Postprandial MyoPS, expressed as the delta 
change from postabsorptive rates, was significantly greater in YL compared with OL (P = 
0.032) and OO (P < 0.001), with no significant difference found between OL and OO (P = 
0.173; Figure 3.3B). Phosphorylation of p70S6KThr389, AktSer473, eEF2Thr56 and 4EBP1Thr37/46 
was not significantly different from basal fasted values at 4 h post-protein consumption, and 
was not different between groups at any time point (Figure 3.4 and 3.5). The lack of any 
significant differences in signaling between groups is most likely due to the biopsy sampling 
time-points, which were primarily chosen to assess MyoPS. 
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Figure 3.3: Myofibrillar fractional synthesis rate (FSR) in rested postabsorptive and 4 h 
postprandial state (A) following ingestion of 15 g of milk protein (dashed line at 0 min) with 
values are presented as means ± SEM. Postprandial change in myofibrillar FSR (B), showing 
the median (central horizontal line), 25th and 75th percentiles (box), minimum and maximum 
values (vertical lines) and mean (cross). Significance was set at P < 0.05. * indicates 
significantly greater than corresponding postabsorptive values, † indicates significantly greater 
than OO, ‡ indicates significantly greater than OL.  
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Figure 3.4: Intracellular signaling phosphorylation of p70S6KThr389 (A), eEF2Thr56 (B), AktSer473 
(C) and 4E-BP1Thr37/46 (D) in rested postabsorptive and postprandial state. Data are expressed 
relative to total protein. Values are presented as means ± SEM. Significance was set at P < 0.05. 
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Figure 3.5: Representative western blot images. 
 
3.4.6 Correlations 
The delta change in MyoPS from postabsorptive values correlated negatively with leg fat mass 
for OL and OO combined (r2 = 0.4, P = 0.006, Figure 3.6 A) and positively with average daily 
step count (r2 = 0.26, P = 0.036, Figure 3.6 B). HOMA-IR correlated positively with Type I 
fibre lipid droplet number (r2 = 0.41, P = 0.018), Type I fibre lipid droplet area (r2 = 0.47, P = 
0.009), leg fat mass (r2 = 0.4, P = 0.007) and average daily step count (r2 = 0.26, P = 0.036) for 
OL and OO combined. Although not significant, there was a trend for a negative correlation 
between the delta change in MyoPS and serum CRP (r2 = 0.23, P = 0.050).
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Figure 3.6: Correlations between the 4 h postprandial change in myofibrillar FSR and leg fat 
mass (A) and average daily step-count (B) in OL and OO combined.
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3.5 Discussion 
Age-related impairment in the muscle protein synthetic response to protein-based nutrition is 
thought to be the primary metabolic defect underpinning the progression of sarcopenia (40). To 
what extent this age-related muscle ‘anabolic resistance’ is a consequence of chronological 
and/or aspects of biological ageing is unknown. The present data demonstrate that rates of 
myofibrillar protein synthesis (MyoPS) are increased above postabsorptive values following 
moderate-dose milk protein ingestion in young lean (YL) and older lean (OL), but not older 
obese (OO) individuals. Although there was no difference in absolute postprandial MyoPS rates 
between YL and OL, the net postprandial rise in MyoPS (delta change from postabsorptive 
rates) was greater in YL compared with both OL and OO. Postprandial MyoPS rates (absolute 
and delta change from postabsorptive) were associated with leg fat mass and average daily step 
count in older individuals. Collectively, these data demonstrate muscle anabolic resistance is 
apparent in healthy old age, but is exacerbated in obese individuals with low physical activity. 
 
In the present study, we provided participants with an oral 15g bolus of milk protein isolate 
((0.3, 0.35 and 0.3gkg-1lean mass-1 for YL, OL and OO, respectively), based on evidence 
that age-related muscle anabolic resistance may be most apparent with low-to-moderate 
protein doses typically consumed in the diet (10, 40). This feeding strategy produced 
postprandial MyoPS responses that were ~81% and 38% greater than postabsorptive values 
in YL and OL, respectively. Although not statistically different, absolute postprandial MyoPS 
rates in were 13% lower in OL vs. YL. Furthermore, we observed that the net postprandial 
MyoPS response above postabsorptive values was significantly lower in OL vs. YL. We 
acknowledge that the differences in net postprandial MyoPS response between OL and YL 
we observe here may differ with higher-dose protein intake (≥30g) or in the context of a 
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mixed-macronutrient meal. In line with our findings, others have reported that ingestion of 
20g of casein protein increases muscle protein synthesis by ~75% and 21% in healthy lean 
young and older males, respectively, with absolute postprandial protein synthesis rates 
being ~16% lower in old vs. young (50).. Collectively, these findings provide evidence of age-
related muscle anabolic resistance to protein ingestion. We also observed that postprandial 
MyoPS rates increased by only ~9% above postabsorptive values in OO. Absolute 
postprandial and net change in postprandial MyoPS rates were not statistically lower in OO 
vs. OL, likely due to the relatively small sample size. However, Murton and colleagues (34) 
recently demonstrated an impaired postprandial MyoPS in obese vs. normal-weight older 
males. Furthermore, the associations between absolute and net postprandial MyoPS 
responses and leg fat mass/step count reported here, suggest that age-related muscle 
anabolic resistance is exacerbated in obese inactive older individuals.  
 
Age-related muscle loss is commonly accompanied by a concomitant increase in whole-body 
adiposity and ectopic fat deposition within skeletal muscle (4, 19), which has been associated 
with accelerated progression of sarcopenia and metabolic disease risk (31). It has been 
postulated that obesity-induced blunting of postprandial MyoPS might be due to IMCL 
accumulation (34), or adipose tissue-derived inflammatory cytokines (adipokines) (36). 
Alongside the negative association between the net postprandial MyoPS response and leg fat 
mass, we observed a trend for a similar negative association with fasting serum CRP, but were 
unable to demonstrate any association between with fibre-specific IMCL content, despite two-
fold higher Type II fibre IMCL in OO compared with OL and YL. This was somewhat 
surprising given previous reports of associations between IMCL and muscle anabolic resistance 
in old rodents (45). In our hands, Type I fibre IMCL content was equivalent between YL and 
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OO. However, Type I fibre IMCL content was negatively associated with insulin sensitivity for 
OL and OO, but not YL, reinforcing the notion that the capacity for IMCL oxidation would 
likely have been greater in YL compared with OL and OO. Thus, although we did not observe 
any association of fibre-type IMCL content with the postprandial change in MyoPS, the sub-
cellular location of IMCL and/or specific class of lipid intermediates (i.e. ceramides and 
diacylglycerol) may associate more closely with age-related anabolic resistance. 
 
Despite the near-completely diminished postprandial MyoPS response in OO, there was no 
significant differences in whole-body or regional lean mass compared with OL and YL. In fact, 
the lower RMR in OL vs. YL and OO may be explained by marginally lower whole-body lean 
mass. Surprisingly, muscle fibre cross-sectional area was preserved to a greater extent in OO 
than OL, although still reduced compared with YL. Similarly, others have reported greater lean 
mass in obese compared with normal-weight older and younger individuals (22, 34). These data 
refute the mechanistic role of muscle anabolic resistance in sarcopenia and support the existence 
of an age-associated ‘obesity paradox’, in which the presence of obesity may protect against 
sarcopenia (20). Collectively, these data beg the question; when (if at all) does obesity-induced 
muscle anabolic resistance manifest in an accelerated loss of skeletal muscle in older 
individuals? We postulate that the extra work performed during locomotion and daily living in 
OO might offer a certain degree of protection against sarcopenia up to a point, beyond which 
the decline in muscle mass may be precipitous. This hypothetical threshold point would, 
therefore, most likely be influenced by muscle quality (i.e. inter- and perhaps intra-muscular 
adiposity) rather than quantity. Furthermore, the greater insulin resistance in OO compared with 
OL implies that the quality of muscle tissue retained in old age, and not necessarily the quantity, 
may play a more relevant role in whole-body metabolic health. 
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Physical activity is an important locus of control in the regulation of age-related muscle protein 
turnover (6, 47). Herein, we demonstrate that YL and OL took 122 and 106% more daily steps 
compared with OO, respectively. Interestingly, absolute postprandial MyoPS and the extent to 
which postprandial MyoPS increased above basal values correlated significantly with average 
daily step-count in older individuals, which aligns with evidence that reduced physical 
inactivity elicits muscle anabolic resistance in older individuals (6). However, the net 
postprandial MyoPS response was still lower in OL compared with YL despite equivalent daily 
physical activity levels, suggesting that increasing average daily step count in OO to a level 
observed in OL may, at best, only partially restore postprandial MyoPS responses. Indeed, 
others have demonstrated that 45 min of moderate-intensity treadmill walking enhanced the 
muscle protein synthetic response to amino acid provision in older males (47). The addition of 
activity-matched OO and OL individuals would have allowed us to reconcile this important 
point, but was unfortunately beyond the scope of the present study. In addition to average daily 
step count, we assessed the relative time spent in different physical activity intensities. Despite 
the absence of any difference between groups in the relative time spent at different activity 
intensities, combined time spent in light plus moderate plus vigorous intensity activity revealed 
a deficit of 38 and 87 min for OO compared with YL and OL, respectively, which might 
explain the lower average daily step count in OO, assuming an average of 100 stepsmin-1 and 
slower preferred walking speed (26, 48). Taken together, our findings suggest that a minimum 
number of daily steps (or time spent active) might offer partial protection against age-related 
muscle anabolic resistance. However, this notion requires further attention in future work. 
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In the present study, arterialized venous blood samples were used as a surrogate measurement 
for the true precursor enrichment and were obtained by heating the forearm vein to ~60C (32). 
In contrast, sampling from a non-heated vein would yield lower enrichment values. Some 
studies advocate the use of venous plasma samples to determine precursor enrichment as the 
enrichment values are closer to those found in the intracellular pool, and might therefore give 
a better representation of the true precursor pool (7, 13, 14). However, a concern using venous 
blood samples during prolonged tracer infusions (several days for skeletal muscle) might cause 
tracer reappearance due to breakdown. This violates one of the main stable isotope tracer 
assumptions, i.e. tracer recycling (52).  Furthermore, baseline MyoPS was calculated using the 
single biopsy approach. To date this approach is widely used and has been validated for the 
measurement of MyoPS in both young and older individuals (8, 9). Isolating protein from 
plasma for baseline enrichments, coupled with a carbon-based tracer and GC-C-IRMS, serves 
as a reliable alternative to the two-biopsy method for the calculation of MyoPS, provided the 
tracer incorporation is long enough (9). If the tracer incorporation time would be too short, 
MyoPS would show inflated rates as changes in 1.009  13CPDB would occur (9). Taken together, 
the above information supports the use of arterialized venous blood sampling and the 1-biopsy 
approach to determine plasma 13C6 Phenylalanine enrichment and basal MyoPS rates, 
respectively. 
 
In conclusion, we have demonstrated that old age per se, reduces the net postprandial MyoPS 
response to moderate-dose protein ingestion, whilst obesity and inactivity exacerbate, and are 
associated with, this muscle anabolic resistance. Despite the negative association between leg 
fat mass and the net postprandial MyoPS response in older individuals, we were unable to 
demonstrate a similar association with fibre-type IMCL content. Interestingly, despite evidence 
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of muscle anabolic resistance in OO, absolute lean tissue mass was equivalent and muscle fibre 
area greater than OL, which questions the mechanistic role of muscle anabolic resistance in 
sarcopenia. As such, further work is required to delineate whether, and to what extent, obesity 
and inactivity exacerbates sarcopenia (i.e. protective or harmful?), particularly in the very old 
individuals (>80 y). There is also a need to understand whether the sub-cellular location of 
IMCL is associated with age-related muscle anabolic resistance. Although we did not directly 
address potential differences in MyoPS rates between older men and women, there was no 
discernible pattern of difference. Nonetheless, others have demonstrated sexual dimorphism in 
muscle protein synthesis in older individuals (41), and this issue warrants further clarification. 
Finally, our data suggest that physical activity may partially protect against muscle anabolic 
resistance in older individuals, although further work is required to determine whether chronic 
physical activity interventions can restore muscle protein anabolism in normal-weight and 
obese older individuals. 
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4.1 Abstract 
Background: Age-related muscle loss (sarcopenia) has myriad adverse health consequences, 
and may be driven by a diminished myofibrillar protein synthesis (MyoPS) response to anabolic 
stimuli (i.e. exercise and feeding). Phosphatidic acid (PA) has been reported to stimulate resting 
MyoPS in rodents, and enhance resistance training-induced muscle remodelling in young 
humans. Purpose: This study examined the acute effects of oral PA ingestion on resting and 
exercise-induced MyoPS rates and intracellular signaling in older healthy male individuals. 
Methods: Sixteen older males performed 6 sets of unilateral leg resistance exercise with their 
dominant leg at 75% of 1 repetition maximum, followed by oral ingestion of 1.5 g of soy-
derived PA (n = 8; 68.4 ± 1.8 yrs) or a rice-flour placebo (PL) (n = 8; 69.4 ± 3.6 yrs) ingested 
0 min (750 mg) and 60 min (750 mg) post-exercise. A primed-continuous infusion of L-[ring-
13C6]-phenylalanine with serial muscle biopsies was used to obtain MyoPS at rest and between 
0-150 and 150-300 min post-exercise. Intracellular anabolic signaling was determined at rest 
and 150 and 300 min post exercise cessation. Results: MyoPS in the rested leg did not 
significantly differ within and between groups at baseline, between 0-150 min and 150-300 
min, and over the aggregate period. A trend for a reduction MyoPS rates in the rested leg 
between 150-300 min in PA was observed (P = 0.053). Exercise increased MyoPS rates above 
basal values only between 150-300 min post-exercise in PL (P = 0.001), whilst no effects of 
exercise on MyoPS were observed in PA (P = 0.83). Phosphorylation of p70S6K and 4E-BP1 
was elevated above basal levels in the exercised leg at 300 min post-exercise for PL only (P = 
0.018 and P = 0.011, respectively), and was significantly greater than PA (P = 0.002 and P = 
0.01, respectively). Conclusions: Oral phosphatidic acid ingestion does not augment 
intramuscular signaling and the MyoPS response to resistance exercise in older males and might 
not be a viable treatment to counteract sarcopenia.  
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4.2 Introduction 
Sarcopenia, or age-related skeletal muscle loss, leads to myriad adverse health consequences, 
ranging from reductions in strength (39), impaired functional capacity (32), increased risk of 
fractures (25), metabolic disease (33) and is associated with premature mortality (36). Whilst 
the incidence of age-related muscle wasting has been observed in people as young as 45 y, its 
prevalence increases with advancing age (14). The healthcare costs associated with sarcopenia 
are extensive and, in the context of a rapidly expanding global ageing population, are expected 
to increase considerably in the coming decades (46).   
 
Skeletal muscle proteostasis is dependent on the equilibrium between muscle protein synthesis 
(MPS) and muscle protein breakdown (MPB). One of the most effective strategies to attenuate 
the progression of sarcopenia is resistance exercise (RE) training (20, 48, 53). In young 
individuals, RE robustly increases MPS rates by 2 to 3-fold (37), thereby enhancing overall net 
protein balance for muscle hypertrophy (8, 42). However, the acute MPS response to RE is 
blunted in older compared with younger individuals (7, 35), which may explain the impaired 
muscle remodelling response to prolonged training in old age (7, 23). The age-related blunting 
of the muscle anabolic response to RE may be underpinned by impairments in ribosomal 
biogenesis and/or translational efficiency in the mechanistic target of rapamycin complex 1 
(mTORC1) signaling pathway (7, 24, 35). Collectively, these data have galvanized the search 
for strategies to abolish the impaired muscle anabolic response to RE in the old, in order to 
maximize the therapeutic benefits of this non-pharmacological intervention.  
 
The lipid second messenger phosphatidic acid (PA), has been touted as an important factor in 
the regulation and activation of mTORC1 for MPS. Specifically, mechanical contraction 
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increases the activity of diacylglycerol kinase  to convert diacylglycerol into PA, which in turn 
binds mTORC1 directly at the FKB12 rapamycin binding (FRB) domain (19, 28), increasing 
its activity and ultimately leading to an enhanced protein translational efficiency (27). In 
addition to its endogenous synthesis, exogenous PA administration in cell culture and isolated 
animal muscles is converted to lysophosphatidic acid (1), thereby inactivating the tuberous 
sclerosis complex (TSC1/2) through the extracellular regulated kinase (ERK) pathway to 
bolster mTORC1-mediated signaling (51). Thus, mechanical load-induced PA and exogenous 
PA appear to converge on mTORC1 through distinct proximal pathways. As such, we have 
postulated that exogenous PA via oral administration, may modulate the intramuscular anabolic 
signaling and MPS response to RE in older individual (44). Indeed, studies in healthy young 
humans report additive benefits of oral PA supplementation on increases in strength and lean 
body mass during prolonged RE training compared with a placebo (26, 34). However, before 
PA can be applied as a potential means to modulate RE-induced muscle anabolic signaling and 
MPS in older individuals, there is a need to understand the specific intramuscular mechanisms 
through which this purported ‘nutraceutical’ compound acts (16).  
 
Therefore, the primary aim of the present study was to establish the acute effects of oral PA 
ingestion on rates of myofibrillar protein synthesis (MyoPS) and intramuscular signaling at rest 
and in the ‘early’ (0-150 min) and ‘late’ (150-300 min) phase of recovery from a bout of RE in 
older individuals. We hypothesised that PA ingestion alone would not stimulate MyoPS, but 
would modulate RE-induced intramuscular signaling and MyoPS rates in older individuals 
compared with a placebo.  
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4.3 Methods 
 
4.3.1 Participants 
Sixteen older males were recruited for the present study. All participants were recreationally 
active and deemed healthy based on their responses to a general health questionnaire. 
Participants suffering from uncontrolled hypertension, Type 2 diabetes or generalised 
neuromuscular or cardiovascular diseases were excluded from the study. Furthermore, smoking 
and consuming non-steroidal anti-inflammatory drugs or any medication that might interfere 
with muscle metabolism rendered the participant ineligible to participate. Prior to obtaining 
written consent, participants were informed of the purpose and methodology of the study. 
Ethical approval was obtained through the Solihull Research Ethics Committee (15/WM/0228). 
The study conformed to the latest guidelines set by the Declaration of Helsinki (7th edition). 
 
4.3.2 Experimental design 
Following an initial screening, participants visited the laboratories of the School of Sport, 
Exercise and Rehabilitation Sciences (SportExR) on two separate occasions. During the initial 
visit, anthropometric characteristics and isotonic leg strength were determined. Approximately 
one week after this initial visit, participants underwent an experimental trial to determine the 
muscle anabolic properties of supplemental PA. The experimental trial consisted of a stable 
isotope amino acid infusion combined with serial muscle biopsies to determine the MyoPS 
response to PA or placebo consumption alone or in combination with resistance exercise. The 
study was parallel-designed and single-blinded, with participants randomized to receive either 
the placebo control (PL; n = 8) or phosphatidic acid treatment (PA, n = 8).  
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4.3.3 Preliminary Assessments 
Body mass and height: Participant body mass was recorded in loose clothing and without shoes 
to the nearest 0.1kg using a digital balance scale. Height was determined to the nearest 0.1cm 
using a stadiometer. 
Body composition: Following determination of body mass and height, participants underwent 
a dual energy x-ray absorptiometry scan (DXA) (Discovery DXA Systems, Hologic Inc., 
Bedford, MA) to determine whole-body and regional bone mineral density, fat- and fat-free 
mass. DXA scans were performed after a ~10 h overnight fast. Participants rested supine on the 
scanner in loose clothing with their feet positioned at shoulder width apart and held in place 
with micropore tape. Each scan took 7 min and was analysed by a trained DXA operator.  
Isotonic leg strength: Participant knee extensor one repetition maximum (1RM) strength was 
estimated in the dominant leg using a leg extension machine (VR-3, Medway, MA, USA) in 
order to determine the appropriate load of 75% 1RM for the subsequent experimental trial. 
Briefly, prior to exercise commencement, a baseline blood pressure measurement was obtained 
to ensure participants were normotensive (diastolic blood pressure 60-90 mmHg, systolic blood 
pressure 120-140 mmHg) to reduce the risk of adverse events during heavy-load, fatiguing RE. 
Following blood pressure assessment, participants initiated a self-selected 1-set warm-up after 
which the exercising load was gradually increased over subsequent sets until participants were 
unable to perform >10 repetitions. This final load was used to estimate knee extensor 1RM 
strength via the Brzycki equation (9). The increment in loading was based on subjective ratings 
of exercise intensity, which were monitored immediately after each lifting attempt using a 
modified Borg category-ratio scale (CR-10) (10). Each exercise set was separated by 2 min of 
passive rest. Strength assessments were led by a trained strength and conditioning specialist. 
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Dietary control: Participants were provided with a standardised meal the evening prior to the 
experimental trail. The meal contained ~787 kcal, comprised of ~19% protein (~37.5 g), ~46% 
carbohydrate (~90.7 g) and 35% fat (30.8 g). Participants were asked to abstain from alcohol 
and caffeine for 24 h prior to the experimental trial. Furthermore, participants were asked to 
refrain from strenuous exercise for 48 h prior to the experimental trial. 
 
4.3.4 Experimental Trial 
Following an overnight fast, participants returned to the SportExR laboratory at 0630 h 
following a ~10 h overnight fast. Upon arrival, a 21G cannula was inserted in an antecubital 
vein of both forearms. One cannula was used for frequent blood sampling, whilst the other was 
used to administer a stable isotope amino acid infusion. After obtaining a baseline blood 
sample, a primed continuous infusion of L-[ring-13C6] phenylalanine was initiated (prime: 2 
molkg-1; infusion: 0.05 molkg-1, Cambridge Isotope Laboratories, Andover, MA, USA). 
The contralateral arm was warmed to ~60C using an electric heating blanket to obtain 
arterialized blood samples at -180, -120, -60 and immediately prior to exercise, and at 20, 40, 
60, 90 ,120, 180, 240 and 300 min of post-exercise recovery. A total of 10 mL of arterialized 
blood was sampled at each time point and separated into ethylenediaminetetraacetic (EDTA) 
and serum separator vacutainers (BD, Oxford, UK). Blood samples were centrifuged for 10 min 
at 3000G and 4C. Plasma and serum were aliquoted and stored at -80C until further analyses. 
After ~150 min of stable isotope infusion, a muscle biopsy was obtained under local anaesthesia 
(1% lidocaine) from the quadriceps vastus lateralis of the non-dominant, non-exercised leg 
using the Bergström technique (4). Muscle biopsy tissue was quickly rinsed in ice-cold saline 
and freed from any visible blood, connective tissue and fat before being snap-frozen in liquid 
nitrogen and stored at -80C.  Immediately after biopsy obtainment, participants completed a 
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unilateral leg extension RE bout of the dominant leg consisting of two warm-up sets followed 
by 6 sets of 12 repetitions at 75% of their previously estimated 1RM, designed to elicit a rating 
of ~8-9 on the Borg CR-10 scale. Exercise sets were interspersed by 2 min of passive rest during 
which participants remained seated on the machine. Participants completed the exercise with a 
lifting-lowering cadence of ~1 sec without pause. Time-under-tension and Borg CR-10 rating 
were recorded after each exercise set. Following RE completion, participants consumed their 
respective PA or placebo control treatment over 1 h post-RE (described in detail below) and 
remained in a supine position for the remainder of the experimental trial. At 150 and 300 mins 
after starting treatment consumption, muscle biopsies were obtained from the non-exercised 
and exercised legs. Muscle biopsies were sampled ~2-3 cm from one another in a distal-to-
proximal orientation. An overview of the experimental trial is provided in Figure 4.1. 
 
Figure 4.1: Schematic overview of the experimental trial. PA; 750mg of phosphatidic acid-
enriched soybean phospholipid supplement, PL; 750mg of rice-flour placebo. 
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4.3.5 Treatment Administration 
Immediately and 1 h after RE completion participants consumed two 375 mg gelatine capsules 
(totalling 1500 mg over 1 h post-exercise) of either a rice-flour placebo control (PL) or 
phosphatidic acid-enriched soybean phospholipid supplement (PA; Mediator® 50P, 
ChemiNutra, Austin, US). Treatment capsules were visually identical and ingested with water. 
The phospholipid composition of PA was; 50-60% phosphatidic acid, 5-15% 
phosphatidylcholine, 5-15% phosphatidylethanolamine, 1-5% phosphatidylinositol, 1-5% lyso-
phosphatidylcholine, 1-5% N-acyl phosphatidyl ethanolamine. The PA source, dosing and 
ingestion pattern chosen herein was based on the recent work of others demonstrating that the 
same soy-derived PA product; i) robustly increases p70S6K signaling in cultured cells (34), ii) 
elevates muscle protein synthesis in rats when consumed acutely in a dose equivalent to 
1500mg for humans (38), iii) elevates circulating PA and lysophosphatidic acid concentrations 
in humans (43), and iv) enhances RE-induced lean body mass and strength increases in young 
males (26, 34).  
 
4.3.6 Blood Analyses 
Plasma amino acid enrichment and concentration 
Plasma [13C6] phenylalanine enrichment was determined by gas chromatography-mass 
spectrometry (GCMS; model 5973; Hewlett Packard, Palo Alto, CA, USA) by monitoring ions 
234/240. Briefly, 300 L of plasma was diluted 1:1 with acetic acid before being purified 
through cation-exchange columns and dried down overnight under nitrogen. The purified amino 
acids were then converted to their N-tert-butyldimethyl-silyl-N-methyltrifluoracetamide 
(MTBSTFA) derivative. Simultaneously, leucine and phenylalanine concentrations were 
measured by GCMS using the internal standard method. By adding a known amount of internal 
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standard (6 L) to 300 L of plasma, the amount of tracee was calculated. The internal 
standards were U-[13C6] leucine (ions 302/308) and U-[13C9–15N] phenylalanine (ions 336/346) 
added in a ratio of 100 μLml−1 of blood. 
 
4.3.7 Muscle Tissue Analyses 
Myofibrillar and muscle-free amino acid extraction 
The myofibrillar protein fraction and muscle free pool were extracted for the analysis of 13C6 
phenylalanine enrichment from ~30 mg of muscle tissue as previously described (2). Briefly, 
muscle tissue samples were homogenised in a 2 mL Eppendorf using clean sharp scissors. 
Homogenised samples were placed on a shaker (IKA, Vibrax, Germany) for 10 min at room 
temperature at 1500 rpm and subsequently centrifuged at 11000 g for 15 min at 4C. The 
supernatant containing the amino acid free pool (IC) was transferred to a clean Eppendorf and 
stored at -80C for further Western blot analyses, whilst the myofibrillar pellet washed twice 
through centrifugation at 11000 g for 15 min at 4C with 500 L homogenisation buffer. To 
separate the collagen fraction from the myofibrillar pellet, the pellet was incubated in 750 L 
of 0.3 M NaOH for 30 min at 30C, giving the sample a vortex mix at 15 and 30 min. The 
sample was then spun at 13000 rpm for 10 min at 4C and the supernatant transferred to a 4 mL 
glass collection tube. A 750 L volume of 0.3 M NaOH was then added to the pellet, 
centrifuged at 13000 rpm for 10 min at 4C and the supernatants combined. Myofibrillar 
proteins were then precipitated by adding 1 mL of 1 M PCA, which was centrifuged at 3200 
rpm for 20 min at 4C. The pellet was washed twice with 2 mL of 70% ethanol. The remaining 
myofibrillar pellet was hydrolysed at 110C overnight in 1 mL of 0.05 M HCl and 1 mL of 
activated Dowex 50W-X8 100-200 resin (Bio-Rad laboratories INC, USA). Constituent amino 
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acids of the myofibrillar fraction and IC free-pool were purified on cation-exchange columns 
by eluting with 2 M NH4OH and evaporating to dryness. Amino acids were then derivatised as 
their n-acetyl-n-propylester, and phenylalanine labelling determined by gas chromatography-
combustion-isotope mass spectrometry (Delta Plus XP, Thermofisher Scientific, Hemel 
Hempstead, UK). Due to limited sample availability, tracer enrichment in the intracellular pool 
was only analysed in a subset of participants (n=11) and yielded a tracer to tracee ratio of 4.37 
± 0.9%.  
Intramuscular signaling 
Western blot analyses were performed on the sarcoplasmic protein fraction obtained during 
myofibrillar protein isolation (described above). Sarcoplasmic protein content was determined 
by a DC protein assay before western blot aliquots of 2 μg protein per 1 μL were prepared in 
4x Laemmli sample buffer and sucrose lysis buffer and subsequently boiled for 5 min. Equal 
amounts of protein (30 μg) were loaded onto 10–15 % gels and separated by SDS-PAGE for 1 
h. Following electrophoresis, proteins were transferred onto a biotrace nitrocellulose membrane 
(Pall Laboratory, Portsmouth, U.K.) for 1 h at 100 V. Membranes were subsequently blocked 
in 5 % milk for 1 h and washed 3 times for 5 min in TBST before being incubated overnight at 
4C in following primary antibodies: Muscle Ring Finger protein 1 (MuRF1, sc-398608) 
purchased from Santa Cruz Biotechnology (Santa Cruz Biotechnology, Dallas, Texas, U.S.), 
phospho-p70S6K1 Thr389 (#9205), total 70 kDa S6 protein kinase (p70S6K1; #9202), 
phospho-eukaryotic initiation factor 4E binding protein (4E-BP1) Thr37/46 (#9459), total 4E-
BP1 (#9452), phospho-eukaryotic elongation factor 2 (eEF2) Thr56 (#2331), total eEF2 
(#2332), phospho-protein kinase B (Akt) Ser473 (#3787), total Akt (#9272) each purchased 
from Cell Signaling Technology (New England Biolabs (UK) Ltd, Hitchin, U.K.). Membranes 
were then washed 3 times for 5 min in TBST and incubated for 1 h in their respective secondary 
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antibody and washed again 3 times for 5 min in TBST. Protein quantification was achieved by 
incubating the membranes for 5 min in Immobilon Western chemiluminescent HRP substrate 
(Merck Millipore, Watford, UK) before being imaged using a G:BOX Chemi XT4 imager using 
GeneSys capture software (Syngene, Cambridge, U.K.). Bands were quantified using Image 
Studio Lite (Li-Cor, Lincoln, Nebraska, U.S.). 
 
4.3.8 Calculations 
MyoPS rates were calculated from 13C6 phenylalanine incorporation by using the standard 
precursor-product model: 
FSR (%h-1) =  Eb / Ep x 1 / t x 100  
Where  Eb is the difference in bound 13C6 phenylalanine enrichment between two biopsy 
samples, Ep is the mean plasma precursor enrichment and t is the time in min between muscle 
biopsy samples. Resting fasted MyoPS were calculated using the pre-infusion plasma 13C6 
phenylalanine enrichment as a proxy for basal muscle protein enrichment, a technique that has 
previously been validated in tracer naïve older individuals (12). 
Plasma leucine and phenylalanine concentrations were calculated using the internal standard 
method: 
Concentration (mmol/mL) = (Tracer amount / TTR) / Volume 
Where Tracer amount is the amount of internal tracer in mmol, TTR is the tracer to tracee ratio 
in the sample, and Volume is the amount of plasma sample in mL.  
 
4.3.9 Statistics 
Data analysis was performed using SPSS version 22 (IBM, Chicago, IL, USA). Anthropometric 
and exercise parameters were analysed using a one-way ANOVA. MyoPS rates, intracellular 
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signaling and insulin were analysed using a two-way, repeated measures ANOVA with one 
within (three levels; basal, early and late MyoPS) and one between factor (two levels; group). 
A Tukey’s HSD post hoc test was performed whenever a significant F ratio was found to 
determine specific differences. Significance was set at p < 0.05 for all analyses. All values are 
presented as means ± SD or SEM. 
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4.4 Results 
4.4.1 Anthropometric and Exercise Parameters 
There was no significant difference between groups for body mass, BMI, whole-body or 
regional FM and FFM or knee extension 1RM strength (Table 4.1). There was no significant 
difference in resistance exercise variables or perceived intensity (Borg CR-10) between PL and 
PA during the experimental trial (Table 4.1). 
 
Table 4.1. Participant anthropometric, strength and resistance training characteristics. 
 PL (n = 8) PA (n = 8) 
Age 69.4 ± 3.6 68.4 ± 1.8 
Body mass (kg) 73.9 ± 7.4 73.7 ± 8.9 
BMI (kgm-2) 23.1 ± 1.6 24.4 ± 2.1 
Whole-body FM (kg) 16.4 ± 2.9 19.4 ± 4.0 
Leg FM (kg) 5.2 ± 1.0 5.9 ± 1.5 
Whole-body FFM (kg) 53.6 ± 5.7 50.6 ± 5.6 
Leg FFM (kg) 17.1 ± 1.4 16.1 ± 1.9 
Knee extension 1RM (kg) 87.4 ± 18.3 79.4 ± 20.7 
Training volume (kg) 1918 ± 377 1725 ± 602 
Volume per set (kg) 320 ± 63 288 ± 100 
Time-under-tension total (sec) 183 ± 37 170 ± 66 
Time-under-tension per set (sec) 31 ± 6 28 ± 11 
Average load per set (kg) 26.9 ± 4.3 24.3 ± 8.2 
Average Borg CR-10 8.4 ± 1.4 7.1 ± 1.5 
 
Values are presented as means ± SD. BMI; body mass index, FM; fat-mass, FFM; fat-free mass, 
1RM; one-repetition maximum, Borg CR-10; Borg category-ratio scale. 
 
4.4.2 Plasma Amino Acid and Serum Insulin Concentrations 
Plasma leucine and phenylalanine concentrations did not differ between groups in the basal 
state or throughout the experimental trial (Figure 4.2A and 4.2B, respectively). Serum insulin 
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concentration decreased significantly below basal values by 90 min post-exercise cessation 
until 240 and 300 min in PL (P < 0.05) and PA (P < 0.05), respectively, with no differences 
between groups (Figure 4.2C). Plasma 13C6 phenylalanine enrichment significantly increased 
above basal values (-180 min) 60 min after initiation of the stable isotope tracer infusion and 
remained elevated for the duration of the trial in PL and PA (P < 0.001). Linear regression 
analysis revealed that the 13C6 phenylalanine enrichment slopes in both groups were not 
significantly different from zero, confirming the obtainment of an isotopic steady state (Figure 
4.2D).  
 
Figure 4.2: Plasma phenylalanine (A), leucine (B) and insulin concentration (C) and 13C6 
phenylalanine enrichment (D) in experimental trials. At t = 0 and 60 min, participants orally 
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ingested 750mg of PA or PL with water. ∗ indicates significantly different from basal fasting 
values (-180 min) for PL and PA. † indicates significantly different from basal fasting values 
for PA only. Values are means ± SEM. Significance was set at P < 0.05. 
 
4.4.3 Myofibrillar Protein Synthesis 
Temporal MyoPS rates in rested and exercised legs are presented in Figure 4.3A and 4.3B, 
respectively. Aggregate MyoPS rates in rested and exercised legs are presented in Figure 4.3C 
and 4.3D, respectively. In the rested leg, no significant within or between group differences 
were found for MyoPS rates in the basal state or over 0-150 min, 150-300 min and aggregate 
0-300 min. In the exercised leg, MyoPS rates over 150-300 min were significantly greater than 
basal values (P = 0.001) and 0-150 min (P = 0.019) in PL only, and were 40% greater than 
basal values over the aggregate 0-300 min in PL only (P = 0.023). In the exercised leg, there 
was a strong trend for greater MyoPS rates over 150-300 min in PL compared with PA (P = 
0.051). There was no significant temporal or aggregate change in MyoPS rates from basal 
values in rested or exercised legs in PA, although there was a trend for a reduction in MyoPS 
from basal values in the rested leg over 150-300 min in PA only (P = 0.053). There was a trend 
for MyoPS rates in the exercised leg between 150-300 min to be greater than corresponding 
values in the rested leg for PL only (P = 0.073).  
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Figure 4.3: Myofibrillar fractional synthesis rate (FSR) during basal postabsorptive conditions 
(prior to exercise and/or treatment administration) and over the 0-150 and 150-300 min post-
exercise recovery period in the resting leg (REST; A) and exercised leg (EX; B), and over the 
aggregate 0-300 min post-exercise recovery period in the resting leg (C) and exercised leg (D) 
after PA or PL ingestion. ∗ indicates significantly greater than basal state MyoPS rates in the 
same leg, † indicates significantly greater than MyoPS rates over 0-150 min in the same leg. 
Values are means ± SEM. Significance was set at P < 0.05. 
 
4.4.4 Intramuscular Signaling 
Phosphorylation of p70S6KThr389 increased by 13.6-fold above basal levels in the exercised leg 
at 300 min in PL (P = 0.02), and was 19.4-fold greater than corresponding values in the rested 
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leg (P = 0.02; Figure 4.4A). Phosphorylation of 4EBP1Thr37/46 increased by 2.7-fold and 1.9-
fold above basal (P = 0.01) and 150 min (P = 0.047) values, respectively, in the exercised leg 
at 300 min in PL. Phosphorylation of 4EBP1Thr37/46 at 300 min in the exercised leg for PL was 
greater than the rested leg at all time-points (P < 0.05; Figure 4.4B). AktSer473, MAPKSer44/42, 
eEF2Thr56 phosphorylation and MuRF1 protein did not change over time in rested or exercised 
legs or differ between groups at any time-point (Figure 4.4C-F).  
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Figure 4.4: Intracellular signaling phosphorylation of p70S6KThr389 (A), 4E-BP1Thr37/46 (B), 
AktSer473 (C), eEF2Thr56 (D), ERK1/2Thr202/Tyr204 (E) and MuRF1 protein (F) expressed as fold-
change from basal values at 150 and 300 min post-exercise in rested and exercised legs with 
PA and PL ingestion. ∗ indicates significantly greater than basal value, † indicates significantly 
greater than value at 150 min, # indicates significantly greater than PA at same time. Values 
are presented as means ± SEM. Significance was set at P < 0.05.  
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Figure 4.5: Representative western blot images 
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4.5 Discussion 
The present study is, to our knowledge, the first in vivo investigation of the effect of oral 
phosphatidic acid (PA) or placebo (PL) ingestion on resting and exercise-induced intramuscular 
signaling and MyoPS rates in healthy older individuals. In the exercised leg, MyoPS rates 
increased above basal values in late phase (150-300 min) of RE recovery for PL, but not PA. 
Similarly, RE increased intracellular anabolic signaling (p70S6K and 4E-BP1) at 300 min for 
PL only. In the rested leg, there was no alteration in MyoPS for PL, but a trend for a reduction 
in MyoPS rates below basal values between 150-300 min in PA. Thus, in contrast to our initial 
hypotheses, oral PA ingestion attenuated RE-induced stimulation of MyoPS and intracellular 
anabolic signaling in older males. Taken together, our acute findings suggest that PA provision 
may not be an effective means of augmenting the muscle remodelling response to RE training 
in older individuals. 
 
Resistance exercise (RE) provides a potent stimulus to increase MyoPS in both young (11) and 
older individuals (53). However, a blunted response to this anabolic stimulus has been observed 
in older individuals, that has been attributed to an inability to promptly activate mTORC1-
mediated signaling compared with the young (21, 35). This muscle anabolic resistance to RE 
likely explains the diminished adaptive response to long-term RE training in older compared 
with younger individuals (3, 23). Thus, interventions to maximize the MyoPS response to RE 
in older individuals are of great importance in combatting sarcopenia. In this regard, PA has 
been touted as a ‘nutraceutical’ with purported muscle anabolic properties (16, 44). 
 
Although studies in cell culture (34, 51) and animal models (38, 40, 55) have explored the 
mechanisms through which PA modulates protein translation, studies in human skeletal muscle 
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are scarce. Endogenous production and exogenous provision of PA phosphorylate mTORC1-
mediated proteins (i.e. p70S6K and 4E-BP1) and protein synthesis through distinct proximal 
pathways (19). Whilst endogenous PA (i.e. mechanical load-induced) binds directly to the 
FKB12 rapamycin biding domain on mTORC1 (54), exogenous PA provision is thought to 
activate mTORC1 through the ERK pathway (51). Furthermore, others have reported that 
prolonged PA supplementation (identical source and dosing strategy to that used herein) 
enhances RE training-induced increases in lean mass and strength in younger individuals (26, 
34). In a study by Hoffman et al, 16 resistance-trained men were either supplemented with 
750mg of PA or a placebo whilst undergoing an 8-week resistance training program. A likely 
benefit on strength improvements and very likely benefit on lean tissue gains were found for 
the PA treatment group (26). Whilst these results might favour the use of PA, caution is 
warranted. The timing of PA ingestion was not controlled, which might have led to participants 
ingesting the supplement either in the morning or in the evening. Although, to date, research 
investigating the timing of PA ingestion is non-existent, this aspect might likely impact PA’s 
anabolic potential. Furthermore, RE sessions were not supervised. Although participants were 
asked to keep a training log, actual training volume and load could not be verified. Finally, 8 
weeks of RE training is likely too short to reveal any significant differences between groups 
containing such small number of participants (placebo: n=9, PA: n=7) (29, 49). Research by 
Joy and colleagues (34) addressed some of the shortcomings in the above mentioned study (26) 
by supervising training sessions and controlling PA ingestion time. Joy et al. found superior 
increases in muscle cross sectional area and lean body mass when subjects were supplemented 
with PA compared with a placebo. These findings were supported by the upregulation of 
anabolic signaling in cell culture upon PA treatment. However, no in vivo signaling 
measurement were made. In order to investigate the separate and synergistic effects of distinct 
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PA-mediated signaling pathways on MyoPS in older individuals, we provided PA exogenously 
through oral ingestion, whilst mechanical contraction was used as a stimulus for endogenous 
PA production. Although we could not directly confirm that RE induced an increase in PA 
synthesis, others have demonstrated that ex vivo eccentric contractions elicit a sustained 
increase in PA in mouse EDL muscle (40). Surprisingly, exogenous oral PA ingestion alone 
tended to reduce MyoPS rates below basal values between 150-300 min, and completely 
blunted the RE-induced increase in intracellular anabolic signaling and MyoPS observed in PL 
between 150-300 min. Thus, given that inhibition of RE-induced mTORC1-mediated signaling 
via rapamycin impairs MPS in humans (17), the attenuated RE-induced p70S6K and 4E-BP1 
signaling response in PA offers a likely explanation for the absence of any RE-induced increase 
in MyoPS. 
 
The present findings of a potential interference effect of PA on RE-induced anabolic signaling 
and MyoPS are difficult to reconcile with previous in vitro evidence of the pro-anabolic effects 
of PA on mTORC1-mediated signaling (18, 34) and protein synthesis (38). However, indirect 
support for our findings can be gleaned from the recent work of Mobley and colleagues (38), 
who demonstrated that PA ingestion alone tended to stimulated MPS, but blunted the MPS 
response to whey protein ingestion. Despite the PA-induced attenuation of the MPS response 
to whey protein, the authors did not report an accompanying impairment in intramuscular 
anabolic signaling (38), indicating a degree of discordance between anabolic signaling and MPS 
responses in this experimental model compared with the present human study. Indeed, the 
capacity for maximal mTORC1-mediated signaling activity has been reported to exceed that 
required for peak MPS stimulation in rodents (15). Nonetheless, the specific mechanisms 
through which PA interferes with RE-induced MyoPS and potentially impairs basal-state 
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MyoPS in older individuals are intriguing. One possibility is that PA-derived production of 
diacylglycerol (DAG), catalysed by the enzyme phosphatidic acid phosphatase, may impair 
insulin signaling and blunt MyoPS rates in older individuals (13, 47). Although somewhat 
permissive for mechanical contraction-induced protein synthesis, distal components of the 
insulin signaling pathway (i.e. Akt) converge with mTORC1-mediated signaling (6). In the 
present study, we did not detect any change in Akt phosphorylation from basal values or 
difference between PL and PA, although we cannot rule out that insulin signaling proteins 
proximal to Akt may have been impaired in the presence of DAG production. 
 
In addition to blunting the intramuscular signaling and MyoPS response to RE in older 
individuals, exogenous oral PA provision surprisingly had no detectable effect on ERK1/2 
phosphorylation at rest or following RE in the present study. The ERK signaling pathway has 
been suggested as an important mechanistic link between exogenous PA provision and 
mTORC1-mediated signaling in vivo (51). However, PA-induced activation of ERK and thus 
mTORC1-mediated signaling hinges on the conversion of PA to lysophosphatidic acid (LPA) 
which may, in turn, depend on the presence of the converting enzyme, phospholipase A (PLA) 
(51). Thus, the absence of mTORC1-mediated signaling in response to exogenous oral PA 
ingestion suggests that this route of administration may not have altered LPA production. 
Unfortunately, we were unable to measure intramuscular PA, LPA, PLA and DAG 
concentrations due to technical limitations and tissue availability (40). However, the blunted 
intracellular anabolic signaling and MyoPS response to RE in older individuals following PA 
ingestion, suggests a degree of cross-talk between this nutrient compound and skeletal muscle.  
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It is well described that RE robustly increases MPS and, to a lesser extent, MPB (41, 45). 
Provision of amino acids in close proximity to RE further increases MPS and decreases MPB, 
enhancing overall net balance compared with fasted-state RE (5, 50). In order to delineate the 
specific effects of PA provision on MyoPS at rest and in response to RE, we chose to provide 
PA or PL alone, in the absence of amino acid provision. As expected, our results demonstrate 
a significant, albeit delayed, increase in MyoPS in PL between 150-300 min post-RE in older 
individuals. It is possible that the RE-induced increase in MyoPS in our experimental model 
might have been driven by concomitant elevations in MPB, in which the release of free amino 
acids from the muscle intracellular free-pool would be re-utilized for stimulation of MyoPS 
(52). Thus, we were interested to understand whether the blunted MyoPS response to RE in PA 
(and trend for a reduction in MyoPS rates in the rested leg) could be explained by an anti-
proteolytic effect which, theoretically, would potentially decrease the availability of circulating 
amino acids required for MyoPS. This rationale was based on earlier work from Jaafar et al. 
(31), in which overexpression of the PA precursor, phospholipase D1, in myotubes, negatively 
regulated the expression of factors involved in muscle proteolysis, including MuRF1, and 
prevented atrophy in the presence of TNF-α and dexamethasone. Given that MuRF1 expression 
has been shown to be upregulated after RE in older individuals (22) and was therefore measured 
in the present study as a proxy marker for proteolysis in the absence of direct in vivo MPB rates. 
However, we found no difference in MuRF1 protein over the post-exercise recovery period 
compared with basal values for PL and PA. In addition, we did not detect any differences 
between PA and PL in circulating amino acid or insulin concentrations that could support a role 
of PA in suppressing proteolysis. Taken together, our data refute the notion that PA-mediated 
inhibition on RE-induced proteolysis may explain the impairment in MyoPS rates, and instead 
suggest that PA-mediated anabolic blunting may underlie this response. However, given the 
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complexity of factors involved in muscle proteolysis, the potential for PA to modulate different 
intramuscular proteolytic pathways in response to RE in older individuals requires further 
exploration.  
 
In conclusion, we are the first to study the in vivo anabolic properties of acute oral PA ingestion 
in healthy older individuals. PA ingestion attenuated the RE-induced increase in MyoPS and 
tended to exert similar deleterious effects on resting MyoPS rates. Mechanistically, the 
attenuation of RE-induced MyoPS in PA was accompanied by impaired p70S6K and 4E-BP1 
phosphorylation. The precise cause of the apparent interference effect of PA on RE-induced 
muscle anabolism in older individuals remains to be fully elucidated, but may partly be 
attributed to PA-mediated DAG synthesis and impaired insulin signaling. Future research 
should address whether oral PA provision results in endogenous DAG production in aged 
skeletal muscle. Furthermore, given the reported enhancement in muscle remodelling in young 
individuals supplemented with PA during long-term RE training, potential age-related 
differences in the acute and chronic muscle anabolic response to PA provision should be 
probed. Furthermore, it is yet to be elucidated if a PA-loading phase is desirable to enhance its 
anabolic effect. Similar to creatine, a PA-loading phase might be necessary to gradually 
increase intramuscular PA concentrations (30). If this is the case, future studies should 
investigate the optimal length of, and PA dose to be administered during, the loading period. 
Dose-response studies need to shed light over the question what the optimal PA dose is to be 
administered either acutely or during a loading phase to elicit a maximal muscle anabolic or 
anti-catabolic response. Although speculative, our acute mechanistic data hint that long-term 
PA supplementation would not enhance, and may potentially impede, RE training-induced 
muscle remodelling in older individuals. 
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5.1 Introduction 
Since the introduction of the term “sarcopenia” by Irwin Rosenberg (50), research aimed at 
unravelling the underlying mechanisms of and potential countermeasures to this phenomenon 
has been forthcoming. Although significant progression has been made, much work still needs 
to be done to have a meaningful clinical impact, particularly in the context of the rapidly 
expanding ageing population (48).  
The mechanisms underlying sarcopenia are undoubtedly complex and multifactorial (46), but 
ultimately manifest in a negative net muscle protein balance, and hence muscle protein loss 
over time. This negative net protein balance appears to be primarily driven by a blunted 
response to pro-anabolic stimuli, such as protein nutrition (32) and exercise contraction (37). It 
has hence been suggested that older individuals would need to increase total exercise 
volume/workload and consume greater amounts of dietary protein throughout the day and on a 
meal-by-meal basis to restore the muscle anabolic response (36, 42). Furthermore, a shift in 
body composition towards relative fat mass gains is observed with ageing (14). Combined, 
muscle anabolic resistance in the face of increasing fat mass might lead to the development of 
sarcopenic-obesity (49); a condition leading to adverse metabolic health and frailty (38), posing 
monumental strains on health care costs (30). To date, we are yet to fully elucidate the 
mechanisms underpinning sarcopenia, obesity, and sarcopenic-obesity. These underlying 
factors are of utmost importance in order to develop successful strategies to counteract 
sarcopenia and sarcopenic-obesity. Therefore, the purpose of the present thesis was: 
 
I. To determine intake, pattern and source of dietary protein in healthy young and 
community dwelling older individuals 
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II. To investigate how old age per se, and the addition of obesity and physical inactivity 
affect the muscle anabolic response to moderate-dose protein ingestion. 
III. To determine the effectiveness of a novel nutraceutical, phosphatidic acid (PA), in 
enhancing rates of myofibrillar protein synthesis at rest and after exercise in healthy 
older individuals compared with a placebo. 
 
The present chapter will provide a brief summary of the key findings from the studies described 
in previous chapters of this thesis. Based on Chapter 2 we will discuss the daily protein intake, 
distribution, and source in older individuals, provide some rationale for alternative guidelines, 
and formulate directions for future research. Based on the observations made in Chapter 3 we 
will discuss how ageing, physical activity and obesity might play a role in the anabolic response 
to moderate-dose protein ingestion, and formulate directions for future research. Finally, we 
will discuss the findings of Chapter 4, and formulate recommendations for future research to 
outline whether there are any the potential muscle anabolic properties in phosphatidic acid. 
 
5.2 Protein Distribution in the Ageing Population 
Muscle anabolic resistance to protein nutrition is thought to be one of the primary mechanisms 
leading to age-related muscle loss (12), and reiterates the need for greater dietary protein intakes 
in older individuals to attenuate this muscle loss (66). Besides the ingested protein amount, the 
pattern of intake (39) and source (67) of dietary protein can influence the extent to which muscle 
protein synthesis (MPS) is stimulated. Therefore, in Chapter 2 of the present thesis, we 
assessed intake, pattern, and source of dietary protein in both healthy young and community 
dwelling older individuals upon completion of a 3-day weighed food diary. Our data 
demonstrate that old compared with young individuals consumed less overall dietary protein, 
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although the RDA (0.8 gkg-1day-1) was met by the majority of individuals in both groups. 
Furthermore, dietary protein intake throughout the day was unevenly distributed in both young 
and older individuals, meaning older individuals failed to reach the reported threshold 
requirement for maximal stimulation of MPS at breakfast and lunch (0.4 gkg-1). Ingested 
dietary protein sources were equivalent between young and old, with the exception that older 
individuals consumed less animal-derived protein at lunch compared with the young. 
 
5.2.1 The Importance of Protein Dose and Intake Pattern 
Recently, debate has arisen as to whether total dietary protein intake is more important than 
pattern of protein consumption to stimulate MPS and increase whole-body lean mass in older 
individuals (2, 34, 39). Current guidelines recommend daily dietary protein intakes of 0.8 gkg-
1day-1 to be adequate and meet the metabolic demand of this nutrient. Nevertheless, several 
research studies conducted over the past few years have demonstrated beneficial effects on 
muscle mass accretion when daily protein consumption is increased in older individuals (26). 
The results presented in Chapter 2 concerning total daily protein intake are in line with 
previous studies (9, 56), showing that the majority of older individuals meet the current RDA 
for protein intake. However, we observed a drastic decrease in the number of individuals 
reaching an alternative guideline 1.0 gkg-1day-1 (4). Furthermore, our data suggests that only 
1 in 10 older people ingested the amount of protein, as proposed by Moore et al (42), to 
maximally stimulate MPS within a given meal (0.4 gkg-1) 3 times over the time course of a 
single day. Based on this observation, it would be safe to assume that older individuals likely 
spend a significant proportion of the day in a relative protein deficient state, which would 
consequently lead to suboptimal MPS rates and, potentially, to skeletal muscle loss over time 
(63). Our findings support the position that meal-specific protein intake in older individuals is 
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suboptimal and is characterised by an uneven protein distribution throughout the day. 
Increasing protein intake on a meal-by-meal basis might be pivotal in mounting repeated, robust 
skeletal muscle anabolic responses in older individuals, whereas solely assessing total daily 
protein intake would not indicate if the maximal anabolic response within each meal has been 
achieved. 
 
It has been suggested recently that adult men and women consuming protein evenly across the 
day have superior 24 h MPS stimulation compared with those consuming uneven protein 
amounts throughout the day (39). The theory of an evenly distributed protein intake is based on 
the premise that a protein dose capable of maximally stimulating MPS is consumed at each 
meal. Therefore, studies that fail to provide this amount (0.24 and 0.4 gkg-1 in young and old, 
respectively) are unlikely to find an advantage of even over uneven protein distribution (2, 6). 
More recently, complementary acute and longitudinal studies were published, in which the 
effects of even and uneven protein intake patterns were probed in older individuals (34, 35). 
Although the protein dose provided with each meal in the evenly distributed group was between 
30-40g, this might not have been sufficient to fully stimulate MPS as no differences were 
observed in MPS between an even and uneven protein distribution (34). The threshold for 
maximal MPS stimulation, as demonstrated by Moore et al (42), is based on the ingestion of a 
“high-quality” protein. Since most meals in a Western diet consist of both animal- and plant-
derived proteins, varying degrees of protein quality will be consumed within a meal. Therefore, 
the actual protein amount to be consumed within a mixed meal might be greater than that 
determined by Moore et al (42). Indeed, the plasma aminoacidemia and leucinemia upon 
consumption of a mixed meal is lower compared with that observed after the ingestion of pure 
AA/EAA (47, 64). Therefore, older individuals might need to consume protein amounts 
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>0.4gkg-1meal-1, to maximally stimulate MPS. A further consideration is that increasing the 
levels of protein consumption beyond the RDA will result in greater insulinemia. Increased 
systemic insulin concentrations have been associated with anti-proteolytic effects. In young 
individuals, this insulin-mediated MPB inhibition has been shown to saturate (21), whilst older 
individuals show an impaired proteolytic response to increased insulin concentrations (60). 
These data reaffirm the need for higher protein intakes in older individuals with each main 
meal, especially in the context of mixed meal consumption. Although the study described in 
Chapter 2 did not measure MPS or MPB, we reaffirmed the observation of a suboptimal 
protein intake in older community dwelling individuals at breakfast and lunch. Future 
guidelines should emphasise the importance of consuming protein doses equal to, or exceeding, 
the threshold for maximal MPS stimulation proposed by Moore and co-workers (42) with each 
meal, regardless of the distribution pattern.  
 
5.2.2 Future Research 
To date, evidence supporting the superiority of evenly distributed protein intake across the day 
is inconclusive (34, 35, 39). Therefore, future investigations should explore the potential of 
consuming protein doses beyond those shown to saturate MPS, in order to elucidate when and 
whether a mixed meal is able to fully stimulate and inhibit MPS and MPB, respectively, in older 
individuals. Besides protein consumption, exercise has been deemed a potent driver of MPS 
via increasing the anabolic effect of nutrient intake (57). Implementing an exercise training 
regimen alongside a tailored protein nutrition intervention might therefore increase the muscle 
–specific and whole-body anabolic responses to protect against sarcopenia. Finally, optimizing 
protein intake in institutionalised and/or hospitalised populations is of pivotal importance, as 
malnutrition is often observed in these clinical settings (33, 40).  
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5.3 Anabolic Resistance in an Aged and Obese Population 
Worldwide, obesity rates have reached an all-time high (59). Whilst being associated with 
plethora of comorbidities (45, 53, 59), less is known on how obesity might affect the 
progression of sarcopenia (44, 68). Physical activity is an important locus of control in the 
regulation of skeletal muscle mass in both young and older individuals, with increased physical 
activity levels stimulating MPS (36), and decreased physical activity levels blunting MPS (7). 
Therefore, in Chapter 3 of the present thesis, we aimed to broaden our knowledge on the 
complex relationship between ageing, physical activity and obesity with postabsorptive and 
postprandial MPS rates. Our results show that the postprandial MyoPS responses to ingestion 
of a moderate protein dose was robust in young lean (YL), more modest in old lean (OL) and 
non-existent in old obese (OO) individuals. No correlations were found between any of the 
intramyocellular lipid (IMCL) characteristics and MyoPS in younger and older individuals. 
However, average daily step count and leg fat mass were significantly correlated with MyoPS 
in older individuals. 
 
5.3.1 Lipid Induced Anabolic Resistance 
Ageing is associated with a shift in body composition towards an increase in relative fat mass 
and ectopic fat deposition (11, 14). Elevated IMCL content has been observed in insulin 
resistant obese Type II diabetic individuals (43) and has been associated with impaired 
myofibre contraction in older individuals (11). Furthermore, obesity has been associated with 
decreased postprandial MPS in older individuals (44) and ectopic fat deposition contributes to 
anabolic resistance in old sarcopenic-obese rats (54). These data seem to support an obesity-
induced blunting of postprandial MyoPS due to IMCL accumulation. However, we were unable 
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to find associations between any of the fibre-specific IMCL properties and MyoPS rates in both 
young and older individuals, despite two-fold greater IMCL content in Type II fibres of OO 
compared with OL and YL. When examining Fibre Type I IMCL content similar results were 
found between YL and OL. These rather peculiar findings might be explained by a phenomenon 
referred to as the “athlete’s paradox”, or a state of increased IMCL content in endurance trained 
athletes (58). Although similar at first, the increased IMCL content in endurance trained athletes 
serves very distinct functions to that observed in obese individuals. Endurance trained 
individuals will most likely benefit from these intramuscular lipid droplets as a fuel substrate, 
and could hence be seen as an evident adaptation to endurance training (55). The intracellular 
localisation of these lipid droplets in trained individuals will consequentially lie in close 
proximity to mitochondria and will display high turnover rates (55). In contrast are the elevated 
IMCL levels in obese individuals. Due to increased levels of physical inactivity, the lipid 
droplets will likely not be readily used as a fuel and hence not co-localise closely with 
mitochondria. Therefore, the turnover rate of lipid droplets in obese inactive individuals will be 
slow compared with highly active individuals (58). This IMCL accumulation in obese 
individuals has been associated with insulin resistance and thought to have a negative impact 
on metabolic health (11, 20). Measurements of IMCL localisation and turnover rate were 
beyond the scope of the study presented in Chapter 3. Assessing these characteristics would 
shed light on potential mechanisms through which obesity and IMCL accumulation may 
adversely affect skeletal muscle proteostasis in older individuals. Furthermore, investigating 
the potentially adverse effects of different lipid specifies, such as diacylglycerol and ceramides, 
on muscle protein turnover might expand our knowledge on the mechanisms of obesity-induced 
muscle anabolic resistance. Although we were unable to detect any association between IMCL 
content and the observed decreases in MyoPS in OO, significant correlations between insulin 
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sensitivity and Fibre type I IMCL content, and between leg fat mas and MyoPS were found. 
These observations, although indirect, provide some support for the obesity-induced blunting 
of postprandial MyoPS rates in older individuals. 
 
5.3.2 The Ageing-Obesity Paradox 
Previous research has suggested a protective effect of obesity on skeletal muscle mass (28), and 
has controversially been suggested as potentially beneficial in the battle against sarcopenia. In 
Chapter 3 of this thesis, we found that skeletal muscle mass, and fibre Type I and Type II CSA 
were somewhat protected in OO compared with OL. These results are supportive of the 
existence of the “ageing-obesity paradox”. Nevertheless, we observed a blunted MyoPS upon 
consumption of moderate-dose protein ingestion in OO compared with OL. Taken together, 
these observations beg the question, is obesity detrimental to the skeletal muscle anabolism, 
and, more importantly, when any potential deleterious effect of obesity might occur? It has been 
widely accepted that, with increasing body mass, absolute skeletal muscle mass increases (29). 
Consequentially, obese individuals most likely have increased absolute skeletal muscle mass 
over normal weight individuals, and are therefore considered to have a head start when it comes 
to being protected against sarcopenia. On the other hand, obesity is associated with increased 
muscle adipose tissue infiltration (11), which will lead to insulin resistance (52) and an impaired 
MPS response to anabolic stimuli (44). Based on our observations and those of others, we 
postulated the existence of an ageing-obesity ‘threshold’ beyond which, obesity-induced 
muscle anabolic resistance results in a precipitous, rapid decline in muscle mass. This threshold 
is likely based on muscle quality rather than absolute levels of skeletal muscle mass. For 
example, this could be determined by the ratio between leg fat and fat-free mass. Even though 
in our study absolute skeletal muscle mass and fibre CSA were protected in OO, the muscle 
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anabolic response to a protein feed was severely blunted. This might indicate that the OO 
included in our study have just passed this muscle quality threshold value, and will suffer severe 
muscle loss (and incidence of metabolic disease) in the foreseeable future. Indeed, calculating 
the leg FM:FFM ratio results in 0.58, 0.44 and 0.42 in OO, OL and YL individuals, respectively, 
and showed a strong correlational trend with MyoPS in older individuals (r2 = 0.22, P = 0.056). 
Taken together, our observations support the hypothesis of a “muscle quality threshold”, 
beyond which accelerated muscle loss occurs (Figure 5.1). Preserving muscle quality with 
ageing is therefore of utmost importance to conserve a healthy anabolic response. 
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Figure 
5.1.: 
Hypothetical relationship between muscle quality and rate of muscle accretion or loss with advancing age.  The dotted line represents the muscle 
quality threshold. Arrows represent factors that might influence muscle quality. The red line represents a decreased muscle quality. The green 
line is representative of muscle quality maintenance. The yellow line depicts the normal chronological ageing process. 
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5.3.3 The Role of Physical Activity 
Resistance and endurance exercise have the ability to robustly increase MyoPS (61). In 
Chapter 3 step count was significantly elevated in YL and OL compared with OO, and 
significantly correlated with MyoPS in older individuals. However, no correlations were found 
between any of the physical activity intensity levels and MyoPS. These results might advocate 
the importance of time spent being active rather than the actual physical activity intensity. This 
hypothesis might seem to contradict recent studies advocating the positive effects of high 
intensity interval training (HIIT) on metabolic health (19). However, in Chapter 3 we used 
accelerometry to determine physical activity levels based on metabolic equivalent (MET) cut-
off values. A MET value of 1 is defined as the oxygen consumption rate at rest or sitting and 
equals 3.5 mLkg body mass-1min-1. However, i) relative maximal oxygen consumption 
(VO2max) declines with advancing age (22), and ii) whilst absolute VO2max does not differ 
between sedentary non-obese and obese individuals, relative VO2max values will decrease 
significantly in obese individuals (8). Given the above information, the actual physical activity 
intensity at a given MET value will depend on age, VO2max, and body mass. Therefore, the MET 
cut off value for vigorous exercise (a MET value of 7 in our study), will likely have been 
perceived as easier by YL and OL compared with OO. Based on this information, even though 
we did not find any differences in accelerometry-derived physical activity levels between 
groups, obese old individuals might have worked relatively harder at each physical activity 
intensity level. This would support our theory of advocating the importance of time spent being 
active rather than physical activity intensity per se. Therefore, obese older individuals, for 
whom intense physical activity might not even be feasible, could potentially benefit from 
merely increasing physical activity time rather than intensity. 
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5.3.4 Future Research 
Future research should further investigate how physical activity interventions in (older) obese 
individuals might alter muscle quality and lead to an improved muscle anabolic response. 
Furthermore, investigating whether muscle quality is preserved in physically active (older) 
obese individuals might shed light on whether lifelong exercise would be protective against 
sarcopenia in normal weight and obese older individuals. Finally, further exploration of the role 
of IMCL in obesity-induced muscle anabolic resistance and sarcopenia is pivotal. Specifically, 
investigating the co-localisation of lipid droplets and mitochondria, IMCL turnover rate via 
isotopic measurement methods and the role of specific lipid species could expand our 
knowledge on the underlying mechanisms of sarcopenic-obesity. 
 
5.4 Phosphatidic Acid as a Countermeasure to Age-Related Muscle Anabolic Resistance 
Recently the search for novel nutraceutical compounds to enhance musculoskeletal health 
indices has increased exponentially (13). Phosphatidic acid (PA) has recently reported to 
increase intracellular anabolic signaling in cell culture and animal models (3, 16, 25), and 
enhance muscle mass and strength increases when supplemented over time in young individuals 
(23, 24, 31). However, in vivo human research investigating the mechanisms behind the 
potential beneficial effects of oral PA ingestion are lacking. Furthermore, it is unknown if the 
reported beneficial effects in younger individuals translate to an older population. Therefore, 
the study presented in Chapter 4 of the current thesis investigated the effects of acute oral PA 
or placebo (PL) ingestion on resting and exercise-induced intramuscular signaling and MyoPS 
rates. We found increased MyoPS in PL, but not PA, following resistance exercise. 
Furthermore, anabolic signaling was increased in PL only. These results suggest a potential 
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inhibitory effect of acute PA provision on the muscle anabolic response to RE in older 
individuals. 
 
5.4.1 The Phosphatidic Acid Interference Effect 
Increasing or maintaining muscle mass is of primordial importance with ageing. Resistance 
exercise (RE) is regarded as one of the most potent stimuli able to fulfil this objective. Whereas 
healthy young individuals show a robust increase in MPS upon resistance exercise, this anabolic 
response is somewhat negated in older individuals (37), and has been associated with impaired 
intramuscular anabolic signaling (17). Following investigations in cell culture and rodents, PA, 
shown to upregulate intracellular anabolic signaling, could pose a viable strategy to enhance 
the MyoPS response to RE. In Chapter 4, we examined the mechanistic effects of acute oral 
PA supplementation and found a blunted anabolic response to oral PA ingestion compared with 
PL. Reconciling these findings with previous in vitro studies demonstrating a pro-anabolic 
response upon PA treatment (15, 31) is difficult. To date research is still to elucidate how oral 
PA provision in humans might modulate intramuscular anabolic signaling. One possible 
explanation may be found in the intracellular production of diacylglycerol (DAG), catalysed 
via phosphatidic acid phosphatase (10). Increased intracellular concentrations of DAG might 
play a role in the insulin resistance of human muscle, and could hence impair MyoPS (1). 
However, we did not observe any differences between groups in plasma insulin concentrations 
and Akt phosphorylation. This could imply that increased DAG concentrations might impair 
insulin signaling proximal to Akt. However, we did not assess intracellular DAG and 
phosphatidic acid phosphatase content due to insufficient tissue availability. Measuring the 
concentration of these lipids and enzymes in future research might shed light on possible 
mechanisms through which PA might impair intracellular signaling. Moreover, no study to date 
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has reported intracellular lipid concentrations or availability upon PA supplementation. 
Designing methods to measure intracellular PA concentrations would inform us on its 
bioavailability (if any at all), and might give us valuable information on what an optimal dosage 
could be to provoke potential muscle anabolic effects. Additionally, methodological differences 
between previous studies and our work, might explain some of the discrepancies. Whereas 
previous research mainly investigated the effects of PA in cells or rodents (31, 41, 62), we 
investigated the mechanistic effects of PA provision in vivo in humans. Translating findings 
from ex vivo or animal studies into a human model is not always accurate and might yield 
different outcomes (51). Therefore, future research should further investigate the effects of 
acute or chronic PA supplementation in older individuals to expand our understanding on how 
PA could act as an anabolic stimulus.  
 
5.4.2 Anti-Catabolic Properties of Phosphatidic Acid 
Resistance exercise increases MPS and MPB, and in the absence of protein nutrition, results in 
a negative net protein balance (5). In order to examine the sole effects instigated by PA, we 
chose not to provide AA in close proximity to the RE bout. As expected, in PL, MyoPS 
increased in the late phase (150-300 min) of RE recovery. This stimulation could be explained 
by elevated MPB rates upon RE completion, resulting in increased free intracellular AA 
concentrations, which in turn could be re-utilised as building blocks for MPS (63). Based on 
the theorem of an increased MPB after RE, we hypothesised that the observed decrease in 
MyoPS with oral PA ingestion might have been the result of decreased MPB rates. This would 
cause free intracellular AA concentrations to decrease, and hence inhibit MPS rates. Support 
for this hypothesis was found in a study by Jaafar et al (27), allocating anti-proteolytic 
characteristics to phospholipase D1 (a PA precursor). In this study, PLD1 overexpression 
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prevented myotube-atrophy in the presence of TNF-α, and was characterized by a decrease in 
MuRF1 expression. Based on these results, and evidence of increased MuRF1 expression after 
RE (18), we decided to examine MuRF1 concentration in our study. However, we failed to 
observe any difference in the expression of MuRF1 between PA and PL, and hence concluded 
that the blunted MyoPS upon PA ingestion was most likely due to decreased anabolic signaling. 
Nevertheless, we acknowledge the complexity of factors involved in the MPB process. Ideally, 
future studies should measure MPB upon PA supplementation via isotope tracer techniques 
(65). Furthermore, measuring additional ubiquitin proteins might shed more light on the 
possible anti-catabolic characteristics of PA. As we decided not to provide AA in conjunction 
with PA, future research should explore if AA feeding could rescue the observed decrease in 
MyoPS in older individuals, as AA appear to signal to mTORC1 through divergent proximal 
pathways to exogenous PA. Based on our findings, PA might not be a viable strategy to 
counteract sarcopenia as it potentially blunts intramuscular anabolic signaling in healthy older 
individuals.  
 
5.4.3 Future Research 
Despite our results suggesting an inhibited muscle anabolic response upon acute oral PA 
ingestion in healthy older individuals, it would be presumptuous to conclude PA 
supplementation is ominous for muscle accretion. Future research should investigate whether a 
PA loading phase might be necessary to elicit its full potential as an anabolic or anti-catabolic 
stimulus. Furthermore, studies should investigate the acute and longitudinal effects of 
combined PA and protein supplementation in both young and older individuals. Finally, our 
study implemented a PA dosing strategy based on previous research. However, to date no dose-
response study has investigated what the optimal supplementation dosage of PA would be. 
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5.5 Conclusions 
In this thesis, we have explored some the potential causes, mechanisms of and countermeasures 
to age-related muscle anabolic resistance and sarcopenia. We observed a sub-optimal dietary 
protein intake pattern in healthy older community dwelling individuals compared with the 
young, even though the majority consumed sufficient amounts of daily dietary protein 
according to RDA guidelines. Furthermore, we did not find any difference in protein source 
consumption between young and old, except at lunch where older individuals consumed greater 
amounts of bread, a “lower-quality” plant-based protein. 
In response to moderate-dose protein ingestion, we observed a blunted 4 h postprandial MyoPS 
response in obese older individuals compared with young lean and older lean individuals. 
Although we did not find an association between any of the IMCL characteristics and change 
in postprandial MyoPS rates, step count and leg fat mass did significantly correlate with 
postprandial MyoPS in older individuals. 
Finally, we investigated if oral ingestion of the purported nutraceutical, PA, could acutely 
modulate MyoPS in healthy older individuals at rest and following resistance exercise. We 
observed a blunted MyoPS response, both at rest and after resistance exercise, with acute PA 
provision, which was supported by an impaired intramuscular anabolic signaling. 
In the present thesis, we explored the mechanisms of and countermeasures to age-related 
sarcopenia. We observed a suboptimal pattern of protein intake in older individuals, and 
demonstrated the detrimental effects of obesity in combination with physical inactivity on the 
muscle anabolic response to protein feeding. Finally, we were the first to establish the 
mechanisms underlying the potential anabolic properties of PA as a countermeasure to 
sarcopenia. 
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CHAPTER 6 
APPENDICES 
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6.1 Methods for GCMS and GC-C-IRMS 
Skeletal muscle mass is constantly being synthesized and degraded (5). Any observed changes 
in whole-body muscle mass are therefore the consequence of alterations in muscle protein 
synthesis (MPS) or muscle protein breakdown (MPB). In vivo measurement of alterations in 
MPS and MPB is best performed using stable, non-radioactive isotope tracers (4).These tracers 
are intravenously introduced into the circulation, from where they are taken up by muscle cells 
into the intracellular pool and subsequently integrated in de novo skeletal muscle (2). Using the 
Bergström needle biopsy technique, skeletal muscle is sampled at different time points. This 
technique results in the obtainment of muscle sample sizes ranging from ~50-150mg (1). 
Muscle biopsy samples are subsequently used to determine stable isotope tracer incorporation. 
Fractional or total muscle protein synthesis rates are then calculated by establishing the 
difference in isotope tracer incorporation over time (7). 
 
In Chapter 3 of this thesis we investigated the myofibrillar protein synthesis response to a sub-
optimal dose of protein in young lean, older lean and older obese individuals. Extraction of 
myofibrillar protein fractions was based on the University of Nottingham-Derby protocol. 
Although, minor alterations were made and are noted in bold, italic in parentheses. This 
method uses tissue homogenisation and centrifugation to separate the different protein 
fractions. Chapter 4 of the thesis investigated the myofibrillar protein at rest and after exercise 
in combination with the ingestion of a phosphatidic acid supplement or placebo. The procedure 
for myofibrillar protein extraction was processed according to the University of Nottingham-
Derby protocol. Minor alterations between the specific isolation protocol in each of these 
chapters were implemented and In both chapters, plasma 13C6 Phenylalanine enrichment and 
plasma Phenylalanine and Leucine concentration were measured using the internal standard 
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method (7). Specifically, by adding a known amount of stable isotope tracer to an unknown 
amount of tracee, one can calculate the concentration by determining the tracer to tracee ratio, 
resulting in following formula (7): 
Concentration = (Tracer amount/TTR)/Volume 
 
6.1.1 Method of muscle myofibrillar protein isolation. 
Method Preparation and Supplies 
• Skeletal muscle tissue required: 20-30mg 
• 4mL black screw top glass vials 
• Scissors to divide muscle on N2 
• Plastic weighing boats to weigh muscle 
• Plastic 1.5mL eppendorfs 
• Pipette tips (10L, 200L, 1000L, 5mL) 
• Plastic columns with filter disc (biorad) 
• Auto-sampler glass vials with inserts and screw tops 
• Polystyrene box to hold liquid N2 
 
Reagent Preparation 
Homogenisation buffer pH 7.5 
Chemical FW Final 
Concentration 
100mls 
Tris-HCL 157.6 50mM 0.788g 
EDTA 372.2 1mM 0.0372g 
EGTA 380.4 1mM 0.0380g 
Β-Glycerophosphate 216.0 10mM 0.216g 
NaF 41.99 50mM 0.2g 
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This makes a stock solution, of which 10mL is extracted. A Protease Inhibitor Tablet EDTA-
free (Roche No. 05892791001) and 25L of a 200mL sodium orthovanadate stock solution is 
added. 
 
Preparation of Sodium Orthovanadate 
• Prepare Sodium orthovanadate to 200mM with ddH20 
• Adjust pH to 10 with 1M NaOH or 1M HCl. At pH 10, solution will be yellow in colour. 
• Boil solution until it turns colourless, this takes ~10 minutes. 
• Allow solution to cool to room temp. 
• Readjust pH to 10 and repeat steps 3 and 4 until solution remains colourless and pH 
stabilizes at 10. 
• Store aliquots at -20oC. 
 
Sample Preparation Prior to Isolation 
• Fill polystyrene box with liquid N2, weigh the weighing boat before placing it in N2.  
• Take muscle sample, which is store in a plastic screw top cryovial, out of the dewar and 
tip it onto the weighing boat. 
• Weigh sample and adjust its weight on N2 using scissors if it is not between 20-30mg. 
When not weighing the sample, keep muscle frozen on N2. 
• Store sample to be used for protein isolation in clean 1.5mL eppendorf with pierced lid. 
• Store any remaining tissue in the old cryovial for later use. 
• Add 10 uL of ice-cold homogenisation buffer per mg of tissue, rapidly homogenise 
tissue using clean sharp scissors (wash scissors in Decon 90, ddH2O and then wipe with 
100% ethanol). If a more dilute/concentrated protein extraction sample is required, then 
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the buffer volume can be altered accordingly. Keep samples on ice until all samples 
have been homogenised. 
• Place samples on Vibrax shaker for 10 minutes at room temperature at speed 1000-1500 
rpm (making sure the samples are well mixed, speeds towards 1500 rpm might be 
required). 
• Centrifuge samples at 11,000 g at 4C for 15 min to pellet the myofibrillar, collagen 
and mitochondrial fractions. Transfer the supernatant to a clean eppendorf for protein 
quantitation (keep on ice at all times). Keep myofibrillar pellet on ice! 
• Wash myofibrillar pellet twice. For each wash use 500uL of homogenisation buffer and 
centrifuge at 11,000g at 4C for 10 min. Discard after both washes. This step makes 
sure any excess sarcoplasmic fraction is removed. 
 
Separation of Myofibrillar Protein Fractions 
• Add 1000L of 0.3N NaOH to the myofibrillar pellet and vortex to mix. Incubate in a 
water bath (or heating block) at 37C for 30min. Vortex mix at 15 and 30 minutes. 
(Heating block is set at 50C and sample vortex mixed every 10 min) 
• Centrifuge samples at 13000 rpm at 4C for 20 minutes. Transfer the solubilised 
myofibrillar supernatant to a clean boiling tube. 
• To the pellet add 500L of 0.3N NaOH and vortex to mix. Centrifuge at 13000 at 4C 
for 20 minutes. Remove and combine supernatants. 
• To the supernatant (which contains the myofibrillar fraction) add 1mL of 1M PCA to 
precipitate the protein and vortex to mix. Centrifuge at 3200 rpm at 4C for 20 minutes. 
Discard the supernatant. 
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• Myofibrillar pellet: Wash the pellet from step 5 twice with 2mL of 70% ethanol, 
centrifuge at 3200 rpm at 4C for 15 min. Discard supernatant using a fine tip Pasteur 
pipette. 
• Protein hydrolysis of both fractions. Re-suspend pellets in 0.1N HCl and then add 1mL 
of Dowex slurry. Cap and incubate the resulting sample at 110C overnight for 
approximately 16 hours. (Protein hydrolysis is performed by adding 2mL of 0.5N HCl 
and 1mL Dowex slurry) 
• Remove the sample from the oven, if it has dried out add 2mL of 0.05N HCl and re-
incubate the tube for 2 hours at 110C. Allow sample to cool. To continue follow SOP 
for isolation of AA using Dowex H+ resin. 
 
Baseline Plasma Protein Bound 13C6 Phenylalanine 
• Spin plasma at 4C for 5 min at 11.000g 
• Aliquot 50L in new eppendorf, add 200L of 100% ethanol 
• Vortex and put in fridge for 10 min. 
• Spin plasma at 4C for 5 min at 11.000g 
• Discard supernatant, add 1mL of ethanol, spin at 4C for 5 min at 11.000g  twice 
• Hydrolyze pellet overnight in 1mL of 0.1N with 1mL of activated dowex resin. 
• Hydrolyzed substrate can now be treated similar to myofibrillar fraction. Start at column 
procedure 
 
6.1.2 Intracellular [13C6] Phenylalanine Enrichment from Sarcoplasmic Fraction 
• Take 100μl of sarcoplasmic fraction from each muscle sample. For the basal value, take 
50μl of basal plasma. 
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• Add 20μl of 1N PCA and 2μl of D2 Phenylalanine (20μg/mL internal standard). 
• Vortex samples, place samples in fridge at 4°C for 10 min. Centrifuge for 10 min at 
13.000rpm. 
• Bring samples to a neutral pH. Use liquid universal indicator to check pH. KOH/PCA 
can be used to adjust pH. 
• Add 10μl of urease for 20 min at room temperature. 
• Fractions are ready to be treated as myofibrillar fractions. Start at column procedure. 
 
Isolation of Amino Acids 
• Columns with filter discs are prepared and 2mL of dowex slurry is added to the column 
or 1mL for plasma and intracellular AA isolation (volumes in brackets). 
• Wash the column with 6mL (4mL for IC) of 2N NH4OH. Flow may need to be  
• initiated using a 5mL pipette to remove airlock. Use a repeater pipette. 
• Neutralise the NH4OH by adding 9mL (6mL) distilled water.  
• Prime the columns with 6mL (4mL) of 1N HCl. The columns are then prepared for the 
sample addition. 
• The samples can now be added to the columns (poor it). Add 3x 0.5mL of 1N HCl to 
rinse the sample tube out. Make sure to remove as much of the Dowex as possible. 
• Add 1mL of 1N HCl to the columns and when the liquid has dripped through add a 
further 1mL. 
 
N acetyl, n-propyl ester (NAP) Derivatisation. 
• The AA form the dowex columns should have been eluted in 3mL of NH4OH. These 
samples need reducing to at least 1mL by evaporation under nitrogen at 90C. 
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• Aliquot the sample into auto-sampler vials labelled with permanent marker and cover 
with cellotape or printed label and completely dry at 70C under nitrogen in turbovap. 
• In the fume hood add 200L propyl acetate and 100uL BF3:Propanol (14%). Cap and 
vortex to mix the samples and heat at 110C for 30 mins (in oven). Place vials in an 
appropriate sample tray, i.e. heat resistant, and remove from oven using heat resistant 
gloves and allow samples to cool. 
• De-cap the tubes and dry completely in the turbovap with nitrogen at 70C (approx. 10-
15 min). 
• In the fume hood add 100uL BF3:Propanol (14%) and dry in the turbovap with nitrogen 
at 70C (approx. 10-15min). 
• In the fume hood add 50L acetonitrile and 25L 1,4 dioxane to the dried sample. 
(Vortex to mix). 
• Add 37.5L triethylamine then add 22.5L acetic anhydride, cap and vortex. Heat in 
oven at 55C for 15 min. Allow samples to cool. 
• Uncap the tubes and transfer to 1.5mL eppendorf tubes. Add 50 L chloroform Add 
150 L 0.001M NaHCO3 and tap tubes to mix. Two layers should from quickly in the 
eppendorf. 
• Remove the upper layer with a 200mL pipette and discard. Ensure that you have 
completely removed the top layer, including the small liquid bubble that remains on the 
top. 
• Add a molecular sieve to each tube and leave for 2 min to absorb any remaining aqueous 
layer. 
• Transfer to auto-sampler vials with insert and cap (top up with 50L chloroform if the 
sample is likely to be too concentrated). 
 219 
6.1.3 Analysis of [13C6] Phenylalanine Enrichment by Gas Chromatography-Combustion-
Isotope Ratio Mass Spectrometry 
 
Establish: 13C6 Phenylalanine in myofibrillar fractions. 
 
Rate (Cmin-1)            10Cmin-1           1Cmin-1             20Cmin-1 
Temperature (C)  110C          235C           242C          280C 
Time (min)  1.0’   3.0’   2.0’   8.0’ 
 
• GC-C-IRMS: Thermo DeltaplusX MS, Thermo Trace GC ultra, Thermo GC 
combustion III, Thermo AS2000 auto-sampler 
• Column: Delta’s (column Agilent DB1701 30M x 0.25 mm x 1.0 µm). 
• Inlet method: Temp 250°C injection volumes of 0.2-2.0µl ran split less at 1.4ml/min 
with constant purge 
 
6.1.4 Extraction of Free Plasma Amino Acid  
Method Preparation and Supplies 
Plasma needed: 300μl 
Reagents needed: 
• 70% Ethanol (EtOH) 
• 1N HCl 
• 2N NH4OH 
• MTBSFTA (N-tert-butyldimethyl-silyl-N-methyltrifluoracetamide, 394882 
ALDRICH) 
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• Acetonitrile (271004 SIGMA-ALDRICH)  
• Activated AG 50W-X8 Resin, 100-200 mesh hydrogen form 
Supplies needed: 
• 1.5mL eppendorf tube 
• 4mL screw top vial 
• Glass auto-sampler vials, vial inserts, screw caps 
• Heating block with N2 to dry samples 
• Plastic columns with filter disc (biorad) 
 
Plasma 13C6 Phenylalanine Enrichment and AA Concentration from Plasma 
Sample Preparation 
• Take samples and internal standard out of the freezer and defrost  
• Label new eppendorfs and weigh eppendorfs 
• Vortex samples and internal standard once defrosted 
• Centrifuge samples (3000rpm, 5 min, 4°C)  
• Transfer 300µl of sample to new eppendorf – re-weigh eppendorf – record weight 
• Add 6µl of internal standard to sample, re-weigh eppendorf  
• Add 300µl of acetic acid (1:1 dilution)  
 
Column procedure 
• Rinse columns with ddH2O  
• Fill columns with ~ 3.5mL activated resin (up to second line) 
• Rinse the columns 2 x 3mL HCl (1N) (each time letting it drain through) 
• Vortex samples 
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• Place prepared sample on the column with Pasteur pipette, add 1ml ddH2O to sample 
tube to rinse 
• Add 3ml HCl 1N to the column  
• Rinse column 9 times with 3mL ddH2O (or until neutral, check using pH paper)  
• Put column on glass tube and add 3mL NH4OH, collect and test pH 
• If not alkaline add 1mL NH4OH at a time 
• Add 3mL ddH2O 
• Vortex screw top tube 
• Place tubes with the liquid under N2 until dry  
 
N-tert-butyldimethylsilyl- N-methyltrifluoroacetamide (MTBSTFA) Plasma Derivatisation 
• Dissolve the dried sample or standard in 50µL acetonitrile and 50µL MTBSTFA 
• Place the tubes for 1 hour at 70°C in the heating block (with caps)  
• Centrifuge (3000rpm, 5 mins, 25°C) 
• Transfer into auto-sampler vials 
 
6.1.5 Analysis of Free Plasma [13C6] Phenylalanine Enrichment by Gas Chromatography 
Mass Spectrometry 
 
Establish: Free plasma 13C6 Phenylalanine in myofibrillar fractions and AA concentrations. 
 
Rate (Cmin-1)            10Cmin-1           30Cmin-1             50Cmin-1 
Temperature (C)  100C          170C           235C          250C 
Time (min)  0.5’   1.5’   1.0’   6.0’ 
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Column: Capillary column, Agilent 19091J-433, 30m x 250µm x 0.25µm 
Inlet method: 
• Mode: Split, with 25:1 split ratio 
• Split flow: 62.4mL/min; Total flow: 67.7mL/min 
• Gas type: Helium 
 
6.2 Method for Lipid Droplet Staining Using Bodipy (493/503) 
Triacylglycerol (TAG) is most often stored in white adipose tissue. Once stored within the 
organelle it is then referred to as a neutral lipid droplet (LD).  However, under specific 
conditions, such as obesity, TAG can be stored in tissues other than white adipose tissue (3, 6). 
The accumulation of TAG in these non-adipose depots is referred to as ectopic fat. In Chapter 
3 of the present study we examined LD accumulation within the muscle cells of young lean, 
old lean and old obese individuals. Two prominent measurement methods to quantify 
intramuscular LD have been used in previous literature; Oil Red O (ORO) and Bodipy 
(493/503). Whilst ORO is a powerful tool to quantify intramuscular LD, it has some 
disadvantages such as a short shelf-life and difficulties getting it into solution. Therefore, we 
decided to image intramuscular lipid droplets using Bodipy (493/503), which has a longer shelf 
life and dissolves easily into solution (6). The Bodipy (493/503) dye has previously been shown 
a successful method to quantify lipid droplets and allows the simultaneous use of other stains 
(e.g. myosin heavy chain and cell border) (6). 
 
6.2.1 Method Preparation and Supplies 
• Pipette tips (10L, 200L, 1000L, 5mL) 
• Glass/plastic holder for slides 
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• Plastic box with lid to incubate slides 
• Make up 3.7% formaldehyde, dilute with dH2O. 
• Make up primary antibody: 25uL per section+ spare. You need a 1:25 solution using 
5% NGS. For 1 section, you need 1uL primary antibody and 24uL of 5% NGS. Dilute 
with 1x PBS. 
• Secondary antibody: 1:150 dilute, in 1x PBS. 25uL per section + spare is needed 
• WGA solution 1:100 dilute 1uL of stock solution into 99uL of 1x PBS. 25uL per 
section + spare is needed 
• Bodipy solution is 1:50 dilute 1uL of stock solution into 49uL of 1x PBS. 25uL per 
section + spare is needed 
 
6.2.2 Staining protocol 
Four to six muscle sections are put on a slide. With a glycerol containing pen, draw around the 
sections. This prevents any antibodies or solutions to drip of the glass slide containing the 
sections. Once the sections are on the slide, sections are fixed for 1h in 3.7% formaldehyde, 
whilst put on a rocker at low speeds (±50 rpm). Upon fixing the section, the slides are washed 
3 times for 30 seconds in ddH2O, incubated for 5 min in 0.5% triton-100 in (diluted in 1x PBS), 
and washed 3 times for 5 min in 1x PBS. Sections are consequently incubated for 2 h in the 
myosin heavy chain primary antibody (DSHB laboratories, University of Iowa, US). Primary 
antibody is diluted 1:25 in 5% normal goat serum (diluted in 1x PBS). Thereafter, sections are 
washed 3 times for 5 min in 1xPBS, and incubated for 30 min in the secondary antibody (diluted 
1:150, goat anti mouse IgM 594, Thermofisher, A21044). Upon incubation sections are washed 
3x for 5min in 1xPBS and incubated in WGA350 (Wheat Germ Agglutinin, Alexa Fluor 350 
Conjugate, Thermofisher, W11263) for 30 min (1:100 diluted in 1x PBS). Sections are then 
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washed 2x for 2-3 min in 1x PBS, and incubated for 10 min in Bodipy493/503 (Thermofisher, 
D3922) diluted 1:50. The bodipy solution is light sensitive, extra care needs to be taken when 
incubating (keep away from light). Sections are then washes 3 times 3 min in 1x PBS. Finally 
cover slides are mounted in mowiol. 
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